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Abstract 
Background 
Amyloidosis is a very rare disorder of protein misfolding characterised by the deposition of 
certain proteins in an abnormal fibrillary form within the extracellular space, which disrupts 
the normal structure and function of organs throughout the body. Amyloid deposition may 
be systemic or localised, though there have been few systematic clinical studies of the latter. 
Treatment depends on the respective amyloid fibril type, and comprises chemotherapy 
regimens derived from myeloma for the most prevalent systemic monoclonal 
immunoglobulin light chain (AL) type. The clinical features of systemic AL amyloidosis are 
protean, commonly including a variety of poorly understood coagulation abnormalities and 
fatigue symptoms of uncertain cause. Measurement of serum free light chains (FLC) has 
been a very important advance in guiding treatment of systemic AL amyloidosis. Novel 
treatment approaches include the serum amyloid P component (SAP) depleting drug ((R)-
1-[6-[(R)-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl] pyrrolidine-2 carboxylic acid which has 
shown promise in a pilot study in patients with hereditary fibrinogen amyloidosis. 
Aims 
The hypothesis of this thesis was to explore the diagnostic investigations, categories 
including localised amyloidosis and prognosis and management of certain types of 
amyloidosis. To compare the performance of two commercially available serum free light 
chain assays and study the prognostic utility of each in systemic AL amyloidosis. To 
investigate the underlying bleeding and coagulation abnormalities, associated prognostic 
implications, endothelial dysfunction and implications for the possibility of light chain toxicity. 
To explore the sleep disordered breathing morbidity in amyloidosis. To investigate the 
incidence, patient characteristics and survival outcomes in patients with localised AL 
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amyloidosis. To explore a subgroup of localised amyloidosis: tracheobronchial and laryngeal 
amyloidosis from a clinical and proteomic perspective. To examine two types of treatment 
in systemic amyloidosis: the use of lenalidomide based chemotherapy with prior use of 
Thalidomide/Bortezomib treatment in systemic AL amyloidosis and CPHPC treatment. 
Results and conclusions 
Both FreeliteTM and N Latex assays have high sensitivity for detecting abnormal FLC in 
patients with systemic light chain amyloidosis, showing an excellent correlation between the 
assays for identifying the abnormal light chain subtype but with discordance in the absolute 
values.  
Coagulation abnormalities in systemic AL amyloidosis were frequent and included the 
following abnormalities: elevated concentration of fibrinogen in 42 (56.8%), elevated FVIII 
67 (90.5%) and vWF Ag 67 (90.5%). Kaplan Meier estimates showed that vWF Ag (p=0.039) 
and FVIII (p=0.01) thresholds greater than 280IU associated with a significant survival 
disadvantage. A fall in the vWF Ag levels following chemotherapy in those achieving a clonal 
response suggests potential light chain toxicity implications. Albumin concentration lower 
than 25g/L correlated with coagulation factors which are prothrombotic, implying that 
anticoagulation may be an important consideration in newly diagnosed systemic AL. Thus 
these findings suggest the potential prognostic utility of vWF Ag levels and thrombotic risks 
associated with newly diagnosed systemic AL patients. 
Recurrent overnight oxygen desaturations proved to be frequent in patients with cardiac 
and/or soft tissue amyloidosis, although the occurrence of sleep disordered breathing (SDB) 
needs confirmation with formal polysomnography. Patients with poor right heart ventricular 
systolic function score high with SDB questionnaires, which was associated with adverse 
outcome in newly diagnosed cardiac AL amyloidosis. 
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Localised AL amyloidosis is a very different disease from systemic AL amyloidosis, with a 
far superior prognosis. Local surgical resection is adequate in most patients with localised 
amyloidosis in whom treatment is needed, and radiotherapy can have a useful role in some 
patients whose disease cannot be controlled by local measures.  Progression to systemic 
AL amyloidosis is extremely rare except among patients with lymph node involvement.  
Patients with lymph node involvement and those with isotypic specific circulating free light 
chains warrant closer follow up for development of systemic amyloidosis. Most patients with 
localised AL have excellent long term outcomes.  
Laryngeal and tracheobronchial amyloidosis is a subtype of localised amyloidosis, in which 
hoarseness and dyspnoea are the predominant symptoms, the 2 year OS 93% and 90% 
respectively. Proteomic analysis of amyloid dissected from biopsies showed the presence 
of the amyloid signature proteins, apolipoprotein A1 (in greater amounts protein) and insulin-
like growth factor binding protein complex in all samples compared with patients with 
systemic AL or transthyretin amyloidosis. Of interest, apolipoprotein A1 has been described 
within the respiratory tract and insulin growth factor has been postulated to play a role in 
inflammation, which may be relevant with respect to the pathogenesis and effects of airways 
amyloidosis.  
Lenalidomide and dexamethasone combination treatment following prior proteasome 
inhibitor based therapy produced an overall haematologic response rate of 61%, including 
20% complete responses. Renal responses among patients who received prolonged 
treatment were surprisingly frequent; twenty one out of 38 (55%) evaluable patients 
achieved a renal response (40% on an ITT basis) – 7 (18%) at 6 months, 7 (18%) at 12 
months and an additional 7 (18%) patients at 18 months by long term follow up. This raises 
the possibility that immunomodulatory effects of lenalidomide therapy might enhance the 
otherwise slow natural regression of amyloid deposits. 
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CPHPC depletes circulating Serum amyloid P (SAP) component as a treatment for systemic 
amyloidosis.1 Our study of 10 patients suggested a significant reduction in the natural 
progression of renal decline and renal survival along with an excellent safety profile; this 
was supported by our QoL assessments using SFv36 questionnaires. 
The work in this thesis has thus contributed to improved characterisation and clinical 
management of various types of amyloidosis, and has identified several avenues of therapy 
that merit further investigation in larger populations and randomised clinical trials. 
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Figures 
Figure 1.1: Pathogenesis and presentation of AL amyloidosis: Direct deposition of amyloid 
fibrils lead to the typical clinical features depicted: peri-orbital bruising; macroglossia with 
indentation of teeth marks of the tongue; nail dystrophy; lower limb oedema with nephrotic 
syndrome; soft tissue infiltration of hands bilaterally; ECG showing small QRS complexes 
and late gadolinium enhancement of cardiac MRI. The pre-fibrillar light chain aggregates 
(and possibly the misfolded light chains) can have direct tissue toxicity. Cardiac toxicity of 
light chains appears to be a significant contributor to myocardial dysfunction seen in AL 
amyloidosis.  This may also be the reason for rapid improvement in NT-proBNP which 
parallels a haematological response to therapy often without any evidence of structural 
cardiac improvement but correlating with clinical improvement in the patients’ cardiac 
symptoms.  
Figure 1.2: Confirming the diagnosis and fibril typing in a patient with AL amyloidosis due 
to underlying kappa light chain secreting plasma cell dyscrasia.  Congo red staining 
demonstrates characteristic staining and apple green birefringence under cross polarised 
light.  Immunostaining with antibodies to kappa light chains is positive and there is no 
staining with antibodies to lambda or transthyretin (or SAA (not shown)  Proteomic analysis 
of the amyloidotic tissue shows presence of kappa light chains in addition to other proteins 
known to be present in amyloid fibrils (blue box).  Also note the presence of keratin which a 
common contaminant from the operators skin showing the need for meticulous specimen 
preparation to avoid false positive results. 
Figure 1.3: Radionuclide imaging in amyloidosis: 123I labelled serum amyloid P component 
scintigraphy showing uptake in the spleen and liver in a patient with AL amyloidosis (left).  
The middle panel shows low grade cardiac uptake of 99mTc-DPD in a patient with AL 
  
- 24 - 
amyloidosis compared with marked cardiac uptake of 99mTc-DPD in a patient with wild type 
transthyretin (senile cardiac) amyloidosis (right panel). 
Figure 1.4: Overall survival in AL amyloidosis stratified by haematological response in 
patients treated with high dose melphalan and autologous stem cell transplantation in a 
landmark analysis of 140 patients showing superior OS in those achieving a CR and vGPR 
(median OS not reached; no significant difference between the groups p=0.13) versus those 
achieving a PR and NR (median OS 77 and 50 months respectively; with no significant 
difference; p=0.39).2 (A); oral melphalan dexamethasone3 (B); dose adapted 
cyclophosphamide-thalidomide-dexamethasone in 202 patients with the median OS 42 
months; not reached at 60 months in patients achieving a CR; 50 months and 33 months for 
those achieving a PR and non-responders respectively4 (C).  The survival is best in patients 
who achieve complete or very good partial response with either treatment modality.  Note: 
These survival curves describe different cohorts of patients with varying selection criteria 
and are not directly comparable to each other.   NR, no response; PR, partial response; 
VGPR, very good partial response; CR, complete response, dFLC; difference in involved 
and uninvolved free light chains. 
Figure 1.5: Therapy algorithm for treatment for immunoglobulin light chain (AL) amyloidosis. 
Reassessment post 3 cycles of chemotherapy should be undertaken to optimise 
haematologic response according to consensus criteria. 
Figure 3.1: Comparison of FreeliteTM and N Latex assays with respective kappa (A) and 
lambda (B) values. 
Figure 3.2: Scatter plots of  N Latex and FreeliteTM free light chain assays for (A) kappa N 
Latex (n=91) and FreeliteTM (n=91) and (B) lambda N latex (n=90) and FreeliteTM (n=90) and 
(C) kappa/lambda ratio (n=90) illustrating the concordance of both free light chain assays. 
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Figure 3.3A and 3.3B: Difference in involved and uninvolved free light chain (dFLC) 
response in patients with evaluable disease. (A) Percentage of evaluable patients assessed 
at 2, 4 and 6 months according to haematologic response including no response (NR), 
partial response (PR), very good partial response (VGPR) and complete response (CR) with 
(B) illustrated the differences of the abnormal kappa/lambda ratio at set intervals between 
the FreeliteTM and N Latex assay. 
Figure 4.1A and 4.1B: Scatter plots comparing FVIII and vWF:Ag levels in all patient groups 
respectively. 
Figure 4.1C: Significant coagulation factors dependant on the albumin less than 25g/L in 
comparison to greater than or equal to 25g/L. 
Figure 4.2A and 4.2B: Overall survival stratified according to vWF:Ag and FVIII>280IU/L 
respectively. 
Figure 4.2C: Overall survival stratified according to a dFLC >180mg/L. 
Figure 4.3: A larger amyloid load by 123I SAP scintigraphy showing a trend to greater 
bleeding symptoms (Mann Whitney t-test, p=0.076) 
Figure 4.4A and 4.4B and 4.4C: Pre and post chemotherapy comparison of vWF:Ag (4A) 
and FVIII (4B), and vWF:Ag according to haematologic response (4C). 
Figure 5.1: Study Population. A total of 72 patients initially recruited, with proven cardiac 
and/or macroglossia amyloid. Specifically transthyretin (n=17), cardiac light chain 
amyloidosis (n=25), cardiac and macroglossia light chain amyloidosis (n=16) and patients 
with light chain amyloidosis with solely macroglossia (n=14). 
Figure 5.2A and 5.2B: Overnight oximetry tracing of 2 patient with cardiac amyloidosis 
showing oxygen saturations (red tracing) and pulse variability (blue tracing). A normal 
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oximetry tracing is illustrated in Figure 1B, with the mean SpO2 of 94.6% and 3% ODI of 3.6 
events per hour. Figure 1C illustrates grossly abnormal oximetry findings with the mean 
SpO2 of 96% and 3% ODI of 46 events per hour.  
Figure 5.3A and 5.3B: Relationship of 4%ODI and heart rate change greater than 6bpm in 
different types of amyloid respectively. This illustrates that cardiac AL patients experience 
the highest number of oxygen desaturations and have reduced heart rate variability. 
Figure 5.3C and 5.3D: STOP BANG questionnaire and ESS questionnaires in different 
amyloid groups respectively, showing evident elements of obstructive sleep apnoea and 
central sleep apnoea in these different groups. There is a relative lower risk of obstructive 
sleep apnoea and high risk of central sleep apnoea in cardiac AL patients 
Figure 5.4: Relationship between 4%ODI and NYHA class symptoms in AL patients, 
showing a statistical trend in NYHA class I and III patients (p=0.05). 
Figure 5.5: Kaplan Meier curves illustrating the (A) overall survival categorised by the type 
of amyloidosis: including cardiac AL (blue line), soft tissue involvement with macroglossia 
(green line) and ATTR (yellow line); (B) overall survival comparing newly diagnosed cardiac 
AL (green line) and previously treated cardiac AL patients (blue line) (C) overall survival risk 
stratified on the 4%ODI frequency, with 4%ODI<10 (blue line), 4%ODI 10-15 (green line) 
and 4%ODI >15 (yellow line) in patients diagnosed cardiac AL patients. 
Figure 6.1A: Progression to systemic AL amyloidosis or need for therapy. A flow chart 
illustrating the patient flow, outcomes, treatment and progression to systemic AL in all 606 
patients described in the series. Light blue denotes patients in the study, with the dark blue 
showing additional information regarding the immunohistochemistry.  
Figure 6.1B: Overall distribution of localised amyloidosis by site of amyloid deposition.   
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Figure 6.2: A clinical spectrum of showing localised amyloidosis: (A) 123I labelled SPECT/CT 
showing a localised amyloidoma in the parieto-temporal region in a patient presenting with 
unexplained visual problems; (B) F-18 PET/CT scan in a patient with cutaneous amyloidosis 
showing multiple subcutaneous areas of FDG avidity at sites of amyloid deposition; (C) 
Bronchoscopy in a patient with tracheobronchial amyloidosis showing nodular amyloid 
deposits in the tracheo-bronchial tree; (D) A large cutaneous amyloid deposit in the scalp; 
(E) An enlarged axillary node in an elderly patient with localised lymph node amyloidosis; 
(F) and (G) A left iliosacral lesion in a patient with isolated localised bone amyloidosis 
showing marked uptake the lesion with 123I labelled SPECT-CT (F) which has completely 
disappeared at six months after completion of local radiotherapy with no 123I uptake at the 
site of the lesion and some sclerosis (G).  
Figure 6.3A: Kaplan-Meier curve with overall survival in all patients with localised 
amyloidosis. 
Figure 6.3B: Kaplan Meier curve illustrating difference between patients diagnosed with 
systemic AL amyloidosis (blue) and localised AL amyloidosis (green). The median survival 
of patients with localised AL amyloidosis has not been reached compared to a median of 
1.6 years for patients with systemic AL diagnosed over the same time period.  
Figure 6.3C: Kaplan-Meier curve illustrating the overall survival in all patients with localised 
Amyloidosis divided into 5 year intervals (except 1980-1995 (as there were smaller patient 
numbers)).  The number of patients in each group was 1980-1995 – 4% (24/606) 
during1980-1985, 3.8% (23/606) during 1986-1990, 6.5% (40/606) during 1991-1995, 
12.9% (78/606) during 1996-2000, 21.8% (132/606) during 2001-2005 and 51% (309/606) 
during 2006-2011. 
Figure 7.1A: Isolation of amyloid under bright field and (B) the TRITC filter.  
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Figure 7.1C and 7.1D: Demarcation of the areas of amyloid to be dissected under TRITC 
filter (C) and (D) under bright field. 
Figure 7.1E: Tissue under bright field post dissecting the amyloid tissue. 
Figure 7.1F: The dissected piece of tissue for proteomic analysis. 
Figure 7.1G: Congo red staining of tissue 
Figure 7.1H: Apple green birefringence of the tissue. 
Figure 7.2A: Presenting symptoms in the laryngeal cohort. 
Figure 7.2B: Presenting clinical symptoms in the tracheobronchial cohort. 
Figure 7.3: Kaplan Meier curve comparing overall survival in patients diagnosed with 
laryngeal amyloidosis with tracheobronchial amyloidosis, although not statistically significant 
(p 0.66), the curves show a clear difference in the time course in each disease following 
approximately 75 months. 
Figure 7.4: Proteomic analysis of a micro-dissected amyloidotic area showing the presence 
of the “amyloid signature proteins, along with light chains, 3 insulin growth factor (IGF) 
binding protein complex and other proteins. 
Figure 7.5: Protein sequence showing a repeating peptide sequence in patients with 
localised laryngeal and tracheobronchial amyloidosis by proteomic analysis. 
Figure 8.1A: Kaplan Meier estimated overall survival on an intention to treat basis.  The 
median overall survival has not been reached.   
Figure 8.1B: Kaplan Meier estimates of progression free survival. The median progression 
free survival was 44.5 months.  
  
- 29 - 
Figure 8.1C: Overall Survival stratified by the dFLC response achieved.  Patients achieving 
a partial dFLC response or greater (solid line) had a significantly better overall survival than 
those who did not achieve a dFLC response (dashed line) 
Figure 8.1D: Overall Survival stratified by the monoclonal protein response.  There was no 
significant impact of an isolated monoclonal protein response on survival (patients achieving 
a partial haematological response or greater (solid line) and no response (dashed line)). 
Figure 9.1A: The natural history of estimated glomerular filtration rate (eGFR) in hereditary 
fibrinogen amyloidosis patients treated with CPHPC (solid lines) and CKD matched controls 
(dashed lines). 
Figure 9.1B: Natural history of creatinine in hereditary fibrinogen amyloidosis patients 
treated with CPHPC (solid lines) and CKD matched controls (dashed lines). 
Figure 9.1D: Renal survival in patients receiving CPHPC (solid line) was significantly better 
(p<0.0001) than CKD matched controls (dashed line). 
Fig 9.1E: Natural history of the creatinine pre CPHPC treatment in a select group of patients. 
Figure 9.2: Recordings of VAS scores in 9 patients treated with CPHPC showing a 
progressive decline in joint pain whilst patients were on treatment. 
Figure 9.3A: Patient 1 with (β2M) amyloidosis illustrating a pictorial image of the recorded 
VAS scores at baseline and following 12 months of treatment with CPHPC. 
Figure 9.3B: Patient 2 with (β2M) amyloidosis illustrating a pictorial image of the recorded 
VAS scores at baseline and following 12 months of treatment with CPHPC. 
Figure 9.3C: Patient 3 with (β2M) amyloidosis illustrating a pictorial image of the recorded 
VAS scores at baseline and following 12 months of treatment with CPHPC. 
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Figure 9.4A and 9.4B: illustrate the coronal images of a PET/CT with increased metabolic 
activity in the thickened soft tissue surrounding both shoulders and hip joints at baseline (A) 
and 12 months post treatment respectively (B). 
Figure 9.5: Baseline QoL for AFib and DRA patients. 
Figure 9.6A and 9.6B: QoL at 6 and 12 months in DRA patients. 
Figure 9.7A, 9.7B and 9.7C: QoL at 6, 12 and 24 months in AFib patients with a good 
eGFR. 
Figure 9.8A, 9.8B and 9.8C: QoL at 6, 12 and 24 months in AFib patients with a poor eGFR. 
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Chapter One:  Introduction 
 
This chapter is written in the context of my publication: Update on treatment of light 
chain amyloidosis. Shameem Mahmood, Giovanni Palladini, Vaishali Sanchorawala, 
Ashutosh Wechalekar. Haematologica. 2014, 99: 209-221, copyright permission obtained 
from Haematologica office for use in my thesis. 
 
Amyloidosis is a rare systemic disorder characterised by misfolding of aberrant precursor 
proteins causing formation of unstable auto aggregates leading to amyloid fibril formation in 
a predominant β-pleated sheet structure.5 These fibrils are deposited in different organs, 
progressively affecting the organ’s architecture and function.6 The unstable protein may be 
hereditary or acquired, with 25 different proteins to form amyloid fibrils,7 The most common 
organs involved include the heart, kidneys, liver, gastrointestinal tract, autonomic and 
peripheral nervous system. Amyloidosis varies in its disease phenotype with a clear 
differentiation between a localised deposit of amyloid such as in localised amyloidosis and 
systemic amyloidosis, the latter depending on the underlying fibril type, organ involved and 
extent of amyloid deposition. 
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Amyloid proteins and fibrillogenesis 
Early studies show that a vital part of the process of protein fibrillogenesis is partial unfolding 
of the protein.8 Accelerated fibrillation in protein deposition diseases are associated with 
certain mutations, and allow destabilisation of the native structure, resulting in an increased 
quantity of steady-state concentration of partially folded conformers. Transthyretin in 
solution has been shown to undergo dissociation to a monomer influenced by the 
temperature, pH, ionic strength and protein concentration. Amyloid fibril formation related to 
some TTR variants may be triggered by tetramer dissociation to a compact non-native 
monomer with low conformational stability.9 The structure of the monomer may form a 
partially unfolded monomeric structure and soluble aggregates. Variable domains have 
been implicated in systemic AL amyloidosis, with initial hypothesis suggesting that 
proteolysis occurred. Light chains are susceptible to aggregation due to a number of factors: 
(1) certain somatic mutations are thought to de-stabilise the protein and hence favour the 
formation of amyloid fibrils, (2) reduced thermodynamic stability and (3) the cellular 
environment. Structural experiments have shown that most variable domains from AL 
amyloidosis patients form crystals as monomers or dimers with the beta-pleated sheet. 
Oxidative stress is also important, having been associated with amyloid fibril deposits and 
cell death.10 Internalisation studies have shown that immunoglobulin light chains initially 
internalise into the cardiomyocytes by migrating into the lysosomal compartments. Little is 
known as to the underlying reason why certain organs are affected with these dynamic 
amyloid deposits resulting in impairment of the affected organ,11 even with slight variations 
within family members affected by the same hereditary variant protein. Previous 
experiments have shown that development of systemic AA amyloidosis occurs when a 
mouse is injected with protein from an AA amyloidosis mouse with an inflammatory 
precipitant.12 This raises the hypothesis which proposes that once amyloid fibrils deposit in 
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a tissue, a particular template or backbone is formed. The ongoing deposition of further 
precursor proteins allowing further amyloid deposits to be laid down within this template.  
Regression of amyloid deposits is less well understood, with earlier studies showing that 
this process is partly macrophage driven. Macrophage experiments in murine models have 
shown the complete degradation of Aβ amyloid fibrils in vitro.13, 14 It has been postulated 
that these macrophages infiltrating the amyloid deposits consequently result in the formation 
of multinucleated giant cells, encircling the amyloid prior to engulfing the amyloid deposit. 
Initial studies have explored this concept proposing that the clearance of amyloid may be 
antibody mediated,15 with antibody-amyloid specific administration successful in reducing 
the amyloid load in those diagnosed with Alzheimer’s disease16 or systemic AL.17 One 
method of translating this concept visually is by use of I123SAP scintigraphy, whereby the 
amyloid load may be assessed. It is variable as to which patients achieve amyloid regression 
by this technique independent of the clonal or inflammatory suppression attained – with 
clearly many factors which contribute to this phenomenon. 
Epidemiology 
Amyloidosis is a very rare condition, with the initial incidence based on deaths/post-mortem 
information, initially quoted as 4.5/100000018 and an estimated 500 new cases seen at the 
National Amyloidosis Centre each year. The subtle symptoms often masked as other 
medical conditions are likely to underestimate this condition. Multiple myeloma patients may 
have incidental amyloid deposits with no organ dysfunction in 38% of cases,19 with organ 
dysfunction present in 3-7% of patients.20 The incidence of systemic AA amyloidosis 
typically depends on the underlying inflammatory condition, with the prevalence increasing 
from 18% to 30% at post-mortem.21 The incidence of hereditary amyloidosis varies greatly 
between countries and remains little studied. Familial Amyloid Polyneuropathy varies 
between countries with different mutation variants prevalent in different locations, with the 
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most common FAP variant in the UK and Ireland the T60A variant.22 Earlier studies have 
estimated the V122I variant present in 3-4% of the Afro-Caribbean population, clinically 
similar to the wild type variant ATTRwt.23, 24 
Types of amyloidosis 
Localised amyloidosis 
Localised AL amyloidosis is characterised by amyloid deposits at a single site (commonly: 
bladder, skin, larynx, lung) due to local production of light chains and no evidence of 
systemic involvement. It has excellent prognosis with generally no need for systemic 
therapy.25 We will elaborate more on this type of amyloidosis in chapter 7. 
Systemic amyloidosis 
This group comprises of systemic light chain (AL) amyloidosis, systemic amyloid A (AA) 
amyloidosis, senile systemic amyloidosis (ATTRwt) and dialysis related amyloidosis (DRA). 
Systemic light chain (AL) amyloidosis is the most common type; in which the amyloidogenic 
protein is a monoclonal light chain secreted by a underlying clonal plasma cell (or rarely B 
lymphoid) dyscrasia.6 Other hereditary amyloidoses are due to amyloidogenic mutations in 
fibrinogen, Apolipoprotein A1 and A2, lysozyme and Gelsolin genes. AA amyloidosis occurs 
due to deposition of serum amyloid A protein (an acute phase protein) in a spectrum of 
disorders causing prolonged inflammation and treatment focuses upon reducing that 
inflammatory drive. Table 1.1 illustrates the common types of systemic amyloidosis.26 
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Table 1.1: Common types of systemic amyloidosis27 
Type Abbreviatio
n 
Precursor 
Protein 
Site of 
Synthesi
s 
Clinical 
Symptoms (in 
order of 
frequency of 
organ 
involvement) 
Specific 
Treatment 
Immunoglobulin 
Light Chain 
Amyloidosis 
AL Monoclonal 
Light chain 
Bone 
marrow 
plasma 
cells or B 
cell clone 
Renal, cardiac,  
PNS/ANS, GI, 
soft tissue 
Chemotherapy,  
ASCT, organ 
transplant 
Senile Systemic 
Amyloidosis 
SSA 
(ATTR – 
wild 
Type) 
Wild type 
transthyretin 
Liver  Cardiac, carpal  
tunnel 
syndrome 
Supportive 
(optimal CHF 
control), 
Doxycycline*, 
Diflunisal* 
Hereditary 
transthyretin 
Amyloidosis 
ATTR - 
mutation 
Greater than 
100 variant 
mutations 
Liver  PNS/ANS, 
cardiac, 
vitreous  
Involvement, 
leptomeninges 
Liver 
transplantation 
(V30M 
mutation), 
supportive 
(cardiac and 
symptomatic 
PNS/ANS) 
Diflunisal*, 
Tafamidis* 
Systemic AA SAA Serum 
amyloid A 
Liver Renal, GI, liver Suppression of 
Inflammatory 
disorder 
Eprodisate*  
Fibrinogen 
Amyloidosis 
AFib Fibrinogen α 
chain 
Liver Renal, liver Renal 
replacement 
Therapy, renal 
(&/or liver) 
transplant 
Apolipoprotein 
A1 
AApoA1 Apolipoprotei
n  
A1 
Liver, 
intestine 
Renal, liver, 
cardiac, larynx  
organ 
transplantation 
Supportive.  
AL, light chain amyloidosis; SSA, senile systemic amyloidosis, ATTR, amyloidogenic 
transthyretin mutations; SAA, systemic amyloidosis A, AFib, fibrinogen amyloidosis; 
AApoA1, Apolipoprotein A1, PNS, peripheral nervous system; ANS, autonomic nervous 
system; GI, gastro-intestinal; ASCT, autologous stem cell transplant; CHF, congestive heart 
failure * denotes treatments currently in clinical trials 
 
  
 CHAPTER ONE 
 
- 38 - 
Systemic AA amyloidosis 
The amyloid fibrils in systemic AA amyloidosis arise from serum amyloid A protein in the 
context of an underlying inflammatory condition. The most common inflammatory 
arthropathies account for 50% in the Western world, whereas in the developing world the 
majority of cases are secondary to infection. Hereditary periodic fever syndromes are 
associated with increased inflammatory stimulus and hence the risk of systemic AA 
amyloidosis. Table 1.2 describes the majority of inflammatory conditions.28 There are many 
contributing factors which remain unexplained as to why AA amyloidosis and the production 
of variable levels of SAA occur in this disease, with genetic polymorphisms possibly 
contributing to this phenomenon.29 
We recognise that systemic AA amyloidosis typically affects the kidneys in over 95% of 
patients, clinically presenting with proteinuria in approximately 10% of patients in end stage 
renal failure (ESRF) at diagnosis. Other organs involved can include the spleen (often seen 
by 123I SAP scintigraphy, adrenal glands, liver and gastrointestinal involvement, with less 
dysfunction of these organs.28 Approximately one third of patients will progress to ESRF 
with the risk of renal decline very much dependent on the underlying inflammatory disorder 
and treatment options, in recent years including newer biological agents. Renal 
transplantation has been performed in selected patients with excellent outcomes.30 
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Table 1.2: Conditions associated with underlying systemic AA amyloidosis28 
 
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Inflammatory Arthritis 
Adult Still’s Disease 
Ankylosing Spondylitis 
Juvenile Idiopathic Arthritis 
Psoriatic Arthropathies 
Reiter’s Syndrome 
Rheumatoid Arthritis 
Gout 
 
Chronic Infections 
Bronchiectasis 
Chronic Cutaneous Ulcers 
Chronic Pyelonephritis 
Leprosy 
Osteomyelitis 
Q Fever 
Sub-acute Bacterial Endocarditis  
Tuberculosis 
Whipples Disease 
 
Immunodeficiency States 
Common Variable 
Immunodeficiency 
Cyclic Neutropenia 
Hyperimmunoglobulin M Syndrome 
Hypogammaglobulinaemia 
HIV/Aids 
 
Other Conditions Predisposing To 
Chronic Infections 
Cystic Fibrosis 
Epidermolysis Bullosa 
Injected Drug Abuse 
Jejuno-Ileal Bypass 
Kartagener’s Syndrome 
Paraplegia 
Sickle Cell Anaemia 
 
 
Hereditary Periodic Fevers 
Cryopyrin associated periodic fever 
syndrome (CAPS) 
Familial Mediterranean fever (FMF) 
Mevalonate Kinase Deficiency (MKD 
or HIDS) 
TNF receptor associated periodic 
syndrome (TRAPS) 
 
Inflammatory Bowel Disease 
Crohn’s disease 
Ulcerative colitis 
 
Neoplasia 
Adenocarcinoma of the lung, gut, 
urogenital tract 
Basal cell carcinoma 
Carcinoid tumour 
Castleman’s disease 
Gastrointestinal stromal tumour 
Hairy cell leukaemia 
Hepatic adenoma 
Hodgkin’s disease 
Mesothelioma 
Renal cell carcinoma 
Sarcoma 
 
Systemic Vasculitis 
Behcet’s disease 
Giant cell arteritis 
Polyarteritis nodosa 
Polymyalgia rheumatic 
Systemic lupus erythematosis 
Takayasu's arteritis 
 
Additional 
Atrial myxoma 
Inflammatory abdominal aortic 
aneurysm 
Retroperitoneal fibrosis 
Sarcoidosis 
Sinus histiocytosis with massive 
lymphadenopathy 
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Dialysis related amyloidosis 
This condition may arise secondary to long term dialysis with the underlying fibril β-
microglobulin (β2M). This molecule is typically filtered via the kidneys, specifically the 
glomerulus and resorbed by the proximal tubular cells.31, 32 The majority of patients present 
clinically following a period of 10 years on dialysis with symptoms of carpal tunnel syndrome, 
spondyloarthropathies, arthralgia, subchondral bone cysts and fractures. The incidence of 
DRA is lower with higher flux dialysis membranes with renal transplantation the only means 
of reducing the former clinical symptoms.33 
Wild type transthyretin amyloidosis, senile systemic amyloidosis 
Amyloidosis caused by deposition of misfolded transthyretin (ATTR) is the next most 
common, either hereditary (due to amyloidogenic ATTR mutations) or a disease of aging; 
due to wild type ATTR deposition (senile systemic amyloidosis), with the fibril wild type 
transthyretin.34 The latter is typically seen in older men, with the majority describing previous 
Carpal Tunnel symptoms. Amyloid deposits with this fibril type can occur in the heart, and 
found in 25% of autopsy findings in those older than 80 years of age,35 with deposits also 
found in other tissues including the bladder, gastro-intestinal tract and soft tissue.36 Cardiac 
manifestations of this disease are typically demonstrated by echocardiography and cardiac 
MRI and tissue proof the ultimate test with wild type transthyretin gene sequencing. There 
is limited data as to the natural progression of this disease, typically slower with the mainstay 
of treatment centred on optimisation of heart failure treatment. 
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Hereditary Transthyretin amyloidosis 
Hereditary Transthyretin amyloidosis accounts for the majority of hereditary amyloidosis with 
100 mutations; with clinical presentation with progressive autonomic or peripheral 
neuropathy. Cardiac involvement is present in the majority of patients, with other tissue 
involvement including vitreous, gastrointestinal and less frequently the central nervous 
system usually in the third decade; with variability due to the mutation involved.37-39  
Transthyretin is produced in the liver in 95% of patients, with the rest produced in the choroid 
plexus and retina.40 The most prevalent transthyretin mutation involves the substitution of 
methionine for valine at position 30 (ATTRV30M). Clinical presentation is usually with an 
ascending sensorimotor peripheral neuropathy, with cardiac involvement rare. The age of 
onset occurs by the age of 30-40 years in the Portuguese, and presents approximately 20 
years later in the Swedish one. Whilst the most common variant in the UK and Ireland is 
T60A; clinical presentation including autonomic neuropathy and cardiac involvement by the 
age of 50 years.22, 41 Another transthyretin variant present in the Afro-Caribbean population 
(3-4%) is V122I variant with clinical cardiac disease after the age of 60 years.24 Evaluation 
of family members at risk is also an issue, with genetic counselling important. 
Orthotopic liver transplantation (OLT) was used initially in the 1990s with the premise that 
the mutant TTR is produced in the liver.41, 42 Symptoms of peripheral neuropathy improved 
when chosen earlier in the time course of the disease, with criteria such as age less than 60 
years, limited polyneuropathy or autonomic neuropathy, no significant renal or cardiac 
dysfunction important.43 However the mortality for this procedure is high.41, 44 There are 
newer anti-amyloid therapies, targeting stabilisation of the soluble TTR in the blood and 
inhibiting its production through silencing RNA and anti-sense oligonucleotide approaches. 
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Hereditary Aα-chain fibrinogen amyloidosis (AFib) 
Hereditary fibrinogen amyloidosis accounts for the most common cause of renal amyloidosis 
first described in 1993, with a variable penetrance and no family history described.45 There 
are 9 reported variants with E526V the most common.46 Clinical presentation is with 
proteinuria, hypertension and renal impairment at the age of 60 years and ESRF usually 
within 5 years from diagnosis. The renal biopsy shows a characteristic abundant glomerular 
amyloid infiltration with almost complete obliteration of the normal architecture but little or 
no vascular or interstitial deposits.47 
Combined renal and liver transplantation has been a treatment option for a selected cohort 
of patients, given the amyloidogenic protein is produced exclusively by the liver. The long 
term outcomes have been excellent but this procedure carries a high mortality risk.48  Renal 
transplantation is another option with the median graft survival 7 years with recurrent 
amyloid deposits typically the cause for further renal decline.47 
Hereditary apolipoprotein A1 amyloidosis (AApoA1) 
Apolipoprotein A1 is an HDL important in the role of cholesterol transport which is produced 
in the liver (50%)49, 50 and intestines, with the liver and kidneys being major sites for Apo A1 
catabolism. Thirteen variants have been reported, with the underlying pathogenesis 
involving proteolytic cleavage at amino terminal 83-93 residues incorporated into the 
amyloid fibrils.51 Each variant is associated with varying phenotypes and again differences 
which occur within the family. The main organ involved is the kidney, and consequently 
chronic renal failure, with neurological, cardiac, and hepatic dysfunction also reported. The 
phenotype of the following six variants: Gly26Arg, Trp50Arg, Leu60Arg, Del70-72, Leu75Pro 
and Leu64Pro involve renal involvement with hypertension and proteinuria with the clinical 
presentation of hepatosplenomegaly.52 Other AApoAI variants (Leu90Pro, Arg173Pro, 
Leu174Ser and Leu178His) have been reported with skin and cardiac amyloid deposits with 
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death usually occurring due to progressive cardiomyopathy within 10 years of diagnosis.53, 
54 The exact underlying aetiology of this disease remains uncertain, with the hypothesis of 
mutations destabilising the native structure and facilitating fibrillogenesis and consequent 
proteolysis.55, 56Renal transplantation has offered one therapeutic option with renal graft 
survival exceeding 10-15 years irrespective of recurrent amyloid in the transplanted organ. 
57 Reduction in the variant ApoA1 by 50%, can be sufficient to facilitate extra-hepatic amyloid 
regression in a certain cohort of patients, such as in liver transplantation.58 
Apolipoprotein AII amyloidosis (AApoAII) 
Apolipoprotein AII is an HDL apolipoprotein with Apoliprotein AII amyloidosis described 
initially in 1973 by Weiss and Page,59 with 4 amyloidogenic variants reported to date, but 
less well elucidated.60 Patients typically present with proteinuria and progressive renal 
decline. 
Hereditary Gelsolin amyloidosis (AGel) 
The amyloid fibrils occur due to cleavage fragments of the variant Gelsolin initially described 
by the Finnish ophthalmologist Jouko Meretoja in 1969.61 There are 2 main variants: G654A 
described in Portugal, Japan and Iran, with G654T reported in countries including France, 
Czech Republic and Denmark.62 Gelsolin is an actin-modulating protein facilitating the 
migration into other cells, with the mutated form unable to bind to calcium and hence 
susceptible to proteolysis and fibril formation.63-65 Patients typically present with corneal 
lattice dystrophy during middle age with slowly progressive cranial neuropathies. The clinical 
phenotype can vary greatly from a slight sensory neuropathy to severe ataxia, from mild 
visual impairment to total blindness.66 Interestingly renal amyloid deposits are seen by 123I 
SAP scintigraphy with no corresponding renal functional decline.  
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Lysozyme amyloidosis (ALys) 
Lysozyme is a ubiquitous bacteriolytic enzyme typically found in high quantities in the liver, 
articular surfaces, saliva and tears and expressed in granulocytes, monocytes and bone 
marrow precursor cells. It is typically inherited in an autosomal dominant fashion. Pepys et 
al first described Lysozyme amyloidosis,67 with seven amyloidogenic mutations described 
including: Ile56Thr, Phe57Ile, Trp64Arg, Asp67His, Trp112Arg, Tyr54Asn and D67G with 
patients presenting in their 3rd and 4th decade. Previous studies show that fibril formation by 
human wild type lysozyme was accelerated by fibrils of the variant proteins, with wild type 
lysozyme deposits significantly much lower in concentration compared to amyloidogenic 
variants.67, 68 Patients clinically present with a slowly progressive decline in renal function 
with organ involvement also involving liver, spleen, gastrointestinal tract and lymph node 
involvement. Interestingly certain variants including Try64Arg and Asp67His and lung and 
thyroid tissue involvement with the Ile56Thr variant describe Sicca syndrome due to salivary 
gland amyloid deposits.69 
 
Systemic light chain (AL) amyloidosis 
The presenting symptoms of AL amyloidosis have a wide spectrum: dyspnoea, lethargy, 
weight loss, bleeding tendency, swelling of lower limbs, frothy urine, orthostatic hypotension 
or peripheral neuropathy. Macroglossia and peri-orbital bruising are almost pathognomonic, 
occurring only in a third of all cases (Figure 1.1). The diagnosis of AL amyloidosis is often 
delayed as presenting features are subtle or mimic other more common conditions. Table 
1.1 shows the most common other types of systemic amyloidosis. 
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Figure 1.1: Pathogenesis and presentation of AL amyloidosis:  Direct deposition of amyloid 
fibrils lead to the typical clinical features depicted: peri-orbital bruising; macroglossia with 
indentation of teeth marks of the tongue; nail dystrophy; lower limb oedema with nephrotic 
syndrome; soft tissue infiltration of hands bilaterally; ECG showing small QRS complexes 
and late gadolinium enhancement of cardiac MRI. The pre-fibrillar light chain aggregates 
(and possibly the misfolded light chains) can have direct tissue toxicity. Cardiac toxicity of 
light chains appears to be a significant contributor to myocardial dysfunction seen in AL 
amyloidosis.  This may also be the reason for rapid improvement in NT-proBNP which 
parallels a haematological response to therapy often without any evidence of structural 
cardiac improvement but correlating with clinical improvement in the patients’ cardiac 
symptoms.27 
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Figure 1.1 
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Advanced organ dysfunction has often ensued prior to a clinical diagnosis of amyloidosis 
although monoclonal gammopathy (MGUS)70 or myeloma usually predates a diagnosis of 
amyloidosis. Fifteen percent of patients with myeloma have symptomatic AL amyloidosis 
and up to 30% may have “incidental” deposits, which may become clinically significant with 
improving long term outcomes in myeloma.71 Patients with MGUS and an abnormally 
elevated free light chain (FLC) should be additionally monitored at each visit by 
measurement of serum brain natriuretic peptide (BNP or its N-terminal fragment, NT-
proBNP) and urine for albuminuria – abnormal presence of either may herald development 
of amyloidosis5 before advanced, symptomatic organ damage thus significantly reducing the 
early deaths which are still observed. 
Confirmation of diagnosis needs demonstration of amyloid deposition; pathognomonic apple 
green birefringence by Congo red staining using crossed polarised light on histological 
tissue sections of either the affected organ, bone marrow, rectum or abdominal fat aspirate 
(latter being an easy bedside procedure available for all patients including those with 
haemostatic impairment).72 Fibril typing is critical in deciding appropriate therapy and 
performed by immunohistochemistry (widely available but specific only in 75-80% of cases 
of AL),73 immuno-electron microscopy (highly specific but limited availability)74 or lately, 
mass spectrometry of amyloid deposits obtained by laser capture (rapidly becoming an 
invaluable adjunct)75 (Figure 1.2). Detecting the underlying clone requires serum and urine 
electrophoresis and immunofixation, serum free light chain analysis, bone marrow 
examination and imaging for presence of myeloma related bone disease.  
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Figure 1.2: Confirming the diagnosis and fibril typing in a patient with AL amyloidosis due 
to underlying kappa light chain secreting plasma cell dyscrasia.  Congo red staining 
demonstrates characteristic staining and apple green birefringence under cross polarised 
light.  Immunostaining with antibodies to kappa light chains is positive and there is no 
staining with antibodies to lambda or transthyretin (or SAA (not shown).  Proteomic analysis 
of the amyloidotic tissue shows presence of kappa light chains in addition to other proteins 
known to be present in amyloid fibrils (blue box).  Also note the presence of keratin which a 
common contaminant from the operators skin showing the need for meticulous specimen 
preparation to avoid false positive results.27 
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Baseline assessment of organ function (Table 1.3) is important for prognosis and selection 
of therapy. Formal testing for autonomic and peripheral neuropathy may be needed in 
selected cases.  
 
Table 1.3: Diagnostic and Staging Investigations for systemic AL amyloidosis27  
 
Tissue diagnosis Abdominal fat aspirate 
Salivary gland or rectal biopsy 
Biopsy of involved organ 
Amyloid typing Immunohistochemistry (immuno-electron 
microscopy if available) 
Mass spectrometry 
DNA analysis (if indicated) 
Studies to detect an underlying 
plasma/B cell 
Clone 
Serum and urine electrophoresis and 
immunofixation 
Serum Free light chain measurement 
Bone marrow aspirate / biopsy (plus FISH) 
Imaging studies for bone disease 
Assessing of organ involvement 
and staging 
Cardiac 
NT-proBNP (or BNP), cTnT (or hs-cTnT, or cTnI) 
Echocardiography (plus strain imaging) 
ECG (plus Holter ECG) 
Cardiac MRI (if indicated) 
99mTc-DPD scan (if indicated) 
Renal 
24 h urinary protein 
Serum creatinine (and eGFR) 
Liver 
Liver function tests 
Liver US / CT scan 
Nerves 
Nerve conduction studies (if indicated) 
Autonomic testing 
Whole body amyloid load 
123I labelled SAP scintigraphy (if available) 
FISH - fluorescent in situ hybridisation;  NT-proBNP - N-terminal prohormone of brain 
natriuretic peptide; BNP – brain natriuretic peptide; cTnT  or cTnI – troponin T or I; hs-cTnt 
– high sensitivity troponin T; ECG – electrocardiograph; 99mTc-DPD scan - 99mTc-
dicarboxypropane diphosphonate scan; eGFR – estimated glomerular filtration rate; US – 
ultrasound; CT – computed tomography; MRI – magnetic resonance imaging; SAP – serum 
amyloid P. 
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123I labelled serum amyloid P component (SAP) scintigraphy (if available), is useful for 
diagnosis, quantification and especially valuable in serial monitoring of amyloid deposits 
(Figure 1.3).76 Cardiac magnetic resonance imaging (CMR) is more sensitive and specific 
than echocardiography for diagnosis of cardiac amyloidosis, showing a characteristic 
subendocardial late gadolinium enhancement. A cardiac biopsy maybe needed in a select 
cohort of patients with isolated cardiac amyloidosis and MGUS to differentiate AL 
amyloidosis from senile systemic amyloidosis/ATTR amyloidosis due to V122I mutation. 
Bone scintigraphy tracers, 99mTc-dicarboxypropane diphosphonate (99mTc-DPD) and 99mTc-
pyrophosphate (99mTc-PYP),  are avidly taken up in cardiac ATTR amyloid deposits but not 
in AL77,78– an emerging non-invasive means of differentiating the two conditions (Figure 1.3). 
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Figure 1.3: Radionuclide imaging in amyloidosis. 123I labelled serum amyloid P component 
scintigraphy showing uptake in the spleen and liver in a patient with AL amyloidosis (left).  
The middle panel shows low grade cardiac uptake of 99mTc-DPD in a 
patient with AL amyloidosis compared with marked cardiac uptake of 99mTc-DPD in a patient 
with wild type transthyretin (senile cardiac) amyloidosis (right panel).27 
 
 
 
Risk stratification is an essential part of the diagnostic workup – cardiac involvement 
determines the risk. The Mayo clinic group, using NT-proBNP and troponin T or I (or more 
recently using high sensitivity troponin79) and more recently serum free light chains,80 
defined stages in AL amyloidosis depending on none, one or both being greater than the 
threshold levels (median survival of 26.4, 10.5 and 3.5 months respectively)81 – even with 
newer therapies Mayo stage III disease still has a poor median survival of 7 months.81 NT-
proBNP >8500 ng/L and systolic blood pressure <100mmHg identify a subgroup of stage III 
patients with a very high risk of early death.81 Confounding factors, like renal failure, impact 
123I SAP scintigraphy
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the concentration of NT-proBNP, and measurement of BNP may be preferred in this 
setting.82  
Treatment of AL amyloidosis 
Goals of therapy 
The aim of treatment in AL amyloidosis is eradicating the fibril precursor protein by 
suppressing production of free light chains as rapidly as possible by targeting the underlying 
clonal plasma/B cell dyscrasia, whilst minimising treatment related mortality (TRM) and 
morbidity5 with supportive measures to preserve organ function. Since patients with AL 
amyloidosis have a small clonal burden83 and lack the high risk cytogenetic features seen 
in myeloma such as t(4:14) or del17p,84 shorter courses of dose adapted chemotherapy may 
be adequate to achieve good haematologic responses.85 
Response assessment has two components: haematologic and organ response – the latter 
follows the former.86, 87 dFLC measurement is a key marker to assess clonal disease 
response.87 Consensus criteria for haematologic response assessment have recently been 
published (Table 1.4).88 A very good partial response (VGPR) (defined as dFLC less than 
40mg/L) or better is associated with an OS of 80-90% at 3 years,88 and is currently 
considered the minimum goal of therapy.  
In addition to standard measures of organ function, cardiac biomarkers such as a reduction 
in NT-proBNP of 30% and 300 ng/L from baseline following completion of therapy usefully 
defines a cardiac organ response.87 Lack of such a decrease in NT-proBNP (in patients with 
heart involvement) identifies a subgroup of patients achieving less than CR who need a 
more profound haematologic response. Factors such as worsening renal failure or treatment 
with immunomodulatory drugs may lead to elevated cardiac biomarkers, confounding 
response assessment.89  
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Table 1.4: Consensus Haematologic Response in systemic light chain (AL) amyloidosis87  
 
Haematologic Response Criteria 
Complete Response (CR) 
 
Normal serum free light chain ratio with 
negative serum and urinary immunofixation 
Very good partial response (VGPR) The difference in the free light chains 
(dFLC) less than 40mg/L 
Partial Response (PR) A reduction in the dFLC greater than 50% 
No response A less than 50% response in dFLC 
  
CR - Complete response; VGPR – Very good partial response; PR – partial response; 
dFLC – difference between involved and uninvolved free light chains. 
 
Supportive care 
Supportive treatment, aimed at improving or palliating organ function, maintaining quality of 
life, and prolonging survival whilst anti-plasma cell therapy has time to take effect, has an 
important impact upon survival and is a fundamental part of an integrated treatment strategy. 
It requires the coordinated expertise of several specialists familiar with the disease. Patient 
education with daily weights, judicious diuretic use, low salt diet, salt-poor albumin, cautious 
angiotensin converting enzyme-inhibitors, use of thigh-high stockings, midodrine for postural 
hypotension and close multidisciplinary monitoring make lifesaving differences. Diarrhoea, 
malabsorption and malnutrition may be ameliorated by  antimicrobial therapy for bacterial 
overgrowth, reduced gut motility with opioids (codeine phosphate and loperamide) with 
addition of Octreotide in non-responsive cases; prokinetic agents for gastro paresis,  PEG 
feeding in those with marked macroglossia impairing swallowing or parental feeding in 
malabsorption. Amiodarone may have a role in cardiac arrhythmias, a common cause of 
death in AL. Implantable cardioverter defibrillators (ICD) are increasing considered in 
patients with life threatening ventricular arrhythmias but there is no definite evidence of 
survival advantage at present.78 
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Autologous stem cell transplantation 
High dose melphalan and autologous peripheral blood stem cell transplantation (ASCT) has 
been routinely used as treatment for AL amyloidosis dating back to first reports in the mid 
1990’s at Boston University90, 91 (Table 1.5). Contrary to the common experience with ASCT 
in multiple myeloma, the toxicity of the procedure can be higher in AL e.g. a 15% incidence 
of major complications during stem cell mobilisation and collection, and mortality 2-10%92 in 
patients with cardiac or multi-organ involvement. Over the last decade, complications of 
ASCT in AL patients have been well appreciated and addressed - appropriate patient 
selection is the key to reduction in morbidity and mortality. A small French randomised 
controlled trial failed to show a difference in survival with ASCT over conventional 
chemotherapy with oral melphalan and dexamethasone, with clonal haematologic response 
rates similar; 67% versus 68% respectively93 but major limitations included high TRM of 24% 
in the ASCT arm and small sample size.94 Dose adapted melphalan strategy, with dose 
reduction to 100, 140 and 200mg/m2 depending on renal, cardiac parameters and age, 
increases a potentially suitable patient population, with lower doses potentially offering a 
reduced toxicity, but also reduced haematologic responses.95  
The largest transplant experience in AL amyloidosis comes from the Mayo clinic and Boston 
University. At Boston University, assessment by a multi-disciplinary team and use of risk 
stratification is employed to select patients for ASCT. Eligibility criteria include histological 
proof of amyloidosis, clonal plasma cell dyscrasia, age greater than 18 years, performance 
status (PS) 0-2 (Southwest Oncology Group or Zubrod), left ventricular ejection fraction 
>40%, oxygen saturations >95% on air and supine BP > 90mmHg.5 Of 421 consecutive 
patients treated with ASCT in this centre from July 1994 to December 2008, 55% received 
200mg/m2 of high-dose melphalan and 45% received modified dose melphalan (100-
140mg/m2). On an intention-to-treat basis, 34% achieved a haematologic CR with an OS of 
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6.3 years. Of 340 evaluable patients, 43% achieved a CR and 78% achieved organ 
responses. Comparison of those achieving a CR versus less than CR, the median event 
free survivals (EFS) and OS were 8.3 and 13.2 years in the former and 2 and 5.9 years in 
the latter group respectively. The overall TRM was 11.4%, with 5.6% in the latter 5 years, 
suggesting further refinement to patient selection with added investigations and staging 
criteria lowered the TRM.5  
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Table 1.5: Chemotherapy regimens and ASCT studies in AL amyloidosis27                                     
Chemotherapy / Reference Number 
of 
patients 
Haematologic 
Response 
% (CR %) 
Overall survival 
(months) or 1-3 year 
OS (%) 
Conventional chemotherapy 
Dex (Dhodapkar et al 96) 93 53 (24) 31 
Cyclo/Thal/Dex (Wechalekar et al 85) 75 74 (21) 41 
MDex (Palladini et al 97, 98) 46 67 (33) 61 
MDex (Jaccard et al 93) 50 68 (47) 56.9 
Bortezomib containing regimens 
Bortezomib (Reece et al 99) 70 OW: 68.8 (37.5) 
TW: 66.7 (24.2) 
OW: 94% (1 yr OS) 
TW: 84% (1 yr OS) 
Bor/Dex( Kastritis et al 100) 94 71 (25) 76% (1 yr OS) 
Cyclo/Bor/Dex (Venner et al 101) 43 81.4 (41.9) 97.7% (2 yr OS) 
Cyclo/Bor/Dex (Mikhael et al 102) 17 94 (71%) Not specified 
Bor/Mel/Dex – 33 
Cyclo/Bor/Dex -17 
(Palladini et al 103) 
50 67 (27) stage I & II 
40 (5) stage III 
 
Not reached 
58% (1 yr OS 
projected) 
Lenalidomide containing regimens 
Len/Dex (Sanchorawala et al 104) 34 67 (29) Not specified 
Len/Dex (Dispenzieri et al 105) 23 41 Not specified 
Cyclo/Len/Dex (Palladini et al 106) 21 62 (5) 36  
Cyclo/Len/Dex (Kastritis et al89) 37 55 (8) 41% (2 yr OS) 
Cyclo/Len/Dex (Kumar et al 107) 35 60 (11) 37.8 
Mel/Len/Dex (Moreau et al 108) 26 58 80.8% (2 yr OS) 
Mel/Len/Dex (Dinner et al109) 25 58 (8) 58% (1yr OS) 
Mel/Len/Dex (Sanchorawala et al 110 16 50 (7) Not reached 
Other  Regimens 
Bendamustine/Pred (Palladini et al 
111) 
36 47 (3) 65% (3 yr OS) 
Pomalidomide/Dex (Dispenzieri et al 
112) 
33 48 (3) 76% (1 yr OS) 
ASCT 
ASCT (Jaccard et al 93) 50 67 (61) 22.2 
ASCT (Vesole et al 113) 107 16 (1 yr) 56% (3 yr OS) 
30 day TRM 18% 
ASCT (Cibeira et al 5) 421 34% CR  75.6 
100 day TRM 11.4% 
ASCT (Goodman et al 114) 92 58% CR 63.6 
100 day TRM 23% 
ASCT (Venner et al 115) 88 28% CR  Not reached 
100 day TRM 6.8% 
ASCT & Thal/Dex consolidation 
(Cohen et al 116) 
45 total 
31 TD 
21% CR 
39% CR (1 yr) 
84% (2 yr OS) 
TRM 4.4% 
ASCT & Vel/Dex consolidation 
(Landau et al 117) 
40 total 
23 VD 
27% CR 
58% CR (1 yr) 
82% (2 yr OS) 
100 day TRM 10% 
Mel - melphalan; Pred, prednisolone; Dex - dexamethasone; Cyclo - cyclophosphamide; Bor - 
Bortezomib; Thal - thalidomide; Len - lenalidomide;; ASCT - autologous stem cell transplantation; 
TD -  thalidomide and dexamethasone consolidation; VD - velcade and dexamethasone 
consolidation; OS - overall survival; yr, year; CR - complete remission; PR  - partial remission; OW 
– once weekly; TW – twice weekly; TRM – transplant related mortality 
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A landmark analysis at 1 year in 140 patients with evaluable FLC results, showed a superior 
OS in those achieving a CR and vGPR versus those achieving a PR and NR (Figure 1.4A).2 
The Mayo Clinic reported a series of 422 patients receiving an ASCT from March 1996 to 
December 2009. Transplant eligibility included age < 70 years, PS 0-2, troponin T 
<0.06ng/mL, creatinine clearance >30mls/min (unless on dialysis), New York Heart 
Association class I-II and less than 2 organ involvement. The focus of this analysis was to 
examine the TRM before and after January 2006, with TRM pre 2006 as 12% and 7% post-
2006.118 Troponin T >0.06ng/L and NT pro-BNP>5000pg/ml were  associated with a high 
TRM, whilst patients with both markers below the thresholds had a TRM of 1%.119 Refining 
patient selection has allowed ASCT to be done safely, but eligibility of patients for ASCT 
has reduced outside of centres with extensive transplant experience.  
 
First major organ responses in AL were initially reported after ASCT in 2001 – 36% of 
patients achieved a renal response at 12 months defined by the amyloidosis consensus 
criteria5, 92, 95, 118 proving that clonal responses in AL translate into organ responses. The 
depth of haematologic response strikingly correlated with renal responses. 71% of patients 
in CR had renal responses compared to 11% with persistence of the plasma cell dyscrasia. 
Over the last decade, improvements in quality of life, hepatic and cardiac responses have 
been published. Similar to renal responses, clinical responses in other organ systems are 
more evident with deeper haematologic responses. Organ responses can take up to 6-12 
months or longer to occur. Haematologic CR occurs in just under half of all patients 
undergoing ASCT; strategies to improve haematologic CR rates following ASCT are an 
important focus. These include induction therapy prior to ASCT, novel conditioning and 
consolidation therapy. A current phase II trial to evaluate the role of induction treatment prior 
to ASCT using Bortezomib/Dex is ongoing at Boston. Among the first 22 patients treated, 
by intention-to-treat analysis, haematologic responses occurred in 79% (53% CR and 26% 
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VGPR) of patients (for evaluable patients 67% CR).120 Tandem cycles of HDM have been 
shown to improve the proportion of patients who ultimately achieve a haematologic CR, 
leading to overall CR rate of 67%.121 A pilot study incorporating  Bortezomib with HDM has 
shown promising results with high haematologic response rates.120 Consolidation with 
thalidomide and dexamethasone is too toxic for routine use116 but Bortezomib and 
dexamethasone as consolidation give high responses and durable response rates including 
CR in 58% at 12 months,117 with larger studies needed.  
Combination chemotherapy  
Alkylators and steroid based regimens 
Alkylating agents have formed the backbone of treatment of AL for over 40 years with 
melphalan and cyclophosphamide used in many current therapies. The first randomised 
controlled trials proved the efficacy of melphalan and prednisone122 in this disease, but novel 
treatment options make this regimen less attractive given few and slow haematologic 
responses, poor survival of 18 months and rarer organ responses.122 Similarly, high dose 
single agent dexamethasone96 and vincristine, Adriamycin and dexamethasone (VAD),123 
although effective, have been superseded due to toxicity and ease of administration, 
respectively, with recent regimens.  
Melphalan-Dexamethasone (MDex) regimen, pioneered by the Italian amyloidosis group, is 
well tolerated and associated with good haematologic and organ response rates of 67% and 
33% respectively, a third of patients achieving a complete clonal response. The median PFS 
and OS are 3.8 and 5.1 years respectively;98 results confirmed prospectively in subsequent 
studies (Figure 1.4B).3, 93 This regimen is usually well tolerated, with 10-15% experiencing 
severe adverse events, mainly fluid retention and cytopenias. Oral MDex is generally 
considered as the standard of care for patients outside of clinical trials in a number of 
countries. However, the role of MDex in patients with advanced cardiac disease is uncertain 
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where the median survival is 10.5 months124 and response rates (11% CR and 33% PR in 
61 patients with cardiac AL) - another study reporting a median survival of 17 months and 
28% mortality in the first three months in patients treated with this same regime.125 But high 
early mortality makes this group difficult to treat regardless of the regimen. Intravenous 
intermediate dose melphalan (25mg/m2) had a 12% TRM in a UK study with prolonged 
remission in the responders126 but a recent prospective trial found this too toxic for routine 
use.127 
Reduced toxicity of low dose dexamethasone containing regimens in myeloma,128 make 
these appealing in AL amyloidosis. Melphalan and once weekly dexamethasone was 
associated with lower responses129 than standard MDex98 - raising doubts as to this 
approach in AL where rapid and deep responses are desirable.  
Bendamustine, an alkylator with a novel mechanism of action, with prednisone is useful in 
relapsed/refractory disease and achieved haematologic responses in 47% (n=17) with a 
survival advantage in responders in a 3 months landmark analysis (p=0.036). Three patients 
achieved a VGPR or better in a heavily pre-treated patient group with a 3-year OS of 65%.111 
Grade 3 or greater adverse events (seen in 33%), predominantly cytopenias, were 
manageable. Bendamustine should be explored earlier in the disease course. 
Immunomodulatory agents 
The efficacy of immunomodulatory (IMiD’s) agents in plasma cell dyscrasias opened up 
another treatment avenue for AL amyloidosis. Thalidomide, the first of these agents, has a 
limited role in AL amyloidosis as monotherapy due to unacceptable toxicity at higher doses 
and limited efficacy.130 The combination of thalidomide and dexamethasone (median 
thalidomide dose 300mg) was effective and with clonal response rates of 48% (n=31), CR 
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in 19%, and organ response in 26%. The median time to response was 3.6 months131 but 
60% experienced grade ≥3 toxicity. 
In the UK, a risk adapted strategy based on the patient’s clinical status allowed use of dose 
adapted CTD (cyclophosphamide / thalidomide / dexamethasone) with good and rapid 
haematologic responses85 seen in 74%, with CR and PR in 21% and 53% respectively; and 
organ responses in 33%. Recent analysis of a larger cohort of 202 patients confirmed these 
findings4 (Figure 1.4C). Prospective analysis suggests that toxicity of CTDa still remains 
high with 60% experiencing grade 3 or greater toxicity – mainly fluid overload.132 This regime 
was the standards of care in the UK but Bortezomib based regimes are increasingly being 
used.  
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Figure 1.4: Overall survival in AL amyloidosis stratified by haematological response in 
patients treated with high dose melphalan and autologous stem cell transplantation in a 
landmark analysis of 140 patients showing superior OS in those achieving a CR and vGPR 
(median OS not reached; no significant difference between the groups p=0.13) versus those 
achieving a PR and NR (median OS 77 and 50 months respectively; with no significant 
difference; p=0.39).2 (A); oral melphalan dexamethasone3 (B); dose adapted 
cyclophosphamide-thalidomide-dexamethasone in 202 patients with the median OS 42 
months; not reached at 60 months in patients achieving a CR; 50 months and 33 months for 
those achieving a PR and non-responders respectively4 (C).  The survival is best in patients 
who achieve complete or very good partial response with either treatment modality.  Note: 
These survival curves describe different cohorts of patients with varying selection criteria 
and are not directly comparable to each other.   NR, no response; PR, partial response; 
VGPR, very good partial response; CR, complete response, dFLC; difference in involved 
and uninvolved free light chains.27 
Figure 1.4A 
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Figure 1.4B 
 
Figure 1.4C 
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Lenalidomide is a second generation IMiD with greater anti-myeloma efficacy and 
favourable toxicity profile. Two phase II studies reported that lenalidomide-dexamethasone 
(Len/Dex) treatment showed good haematological responses in 67% (n=24), with CR and 
PR in 29% and 38% respectively.104, 105 Standard lenalidomide doses of 25 mg were poorly 
tolerated with much better tolerance with 15 mg daily. The most common side effects were 
fatigue and myelosuppression accounting for 35%, and thromboembolism in 9% (n=3). Skin 
rashes were experienced in 43%.133 Lenalidomide combined with dexamethasone has been 
used in a small cohort of patients refractory to alkylators, Bortezomib and thalidomide, with 
a 41% response rate and survival advantage in responders, indicating that IMiD’s can have 
a role in salvage treatment,134 with no increased  incidence of secondary malignancies.135  
Complete response rates remain low with lenalidomide based regimes and a number of 
phase II studies have focused on addition of an alkylator to improve the response rates.89, 
106-109 Studies with additional cyclophosphamide or melphalan report overall haematological 
response rates of 55-60% and CRs of approximately 20%. The toxicity of the combination 
is high with nearly two thirds of patients reporting grade 3 or greater toxicity including 
haematologic in 46%; other side effects including fatigue, oedema and gastro-intestinal 
problems. The response rates in advanced stage patients are poor.89, 109 The exact place of 
a lenalidomide-alkylator combination and advantages offered over Len/Dex remains to be 
clearly defined. 
Pomalidomide (a third generation IMiD effective in myeloma refractory to lenalidomide) with 
dexamethasone achieved haematologic responses in 48% of patients with refractory AL112 
with organ responses in 5 patients. The median OS and PFS were 28 months and 14 months 
respectively. A third of all patients withdrew from the study due to adverse events. 
Pomalidomide shows promise as salvage therapy in relapsed refractory patients and its 
combination with proteasome inhibitors needs to be explored further.   
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IMiD’s, although effective and an important part of the treatment in AL amyloidosis, for 
unknown reasons, are poorly tolerated in AL compared to multiple myeloma with fluid 
retention, fatigue and a recently identified phenomenon of paradoxical increase in cardiac 
biomarkers during therapy136 – all needing further study. The latter is of particular 
significance given its role in assessing cardiac responses in AL amyloidosis although a rise 
in the NT pro-BNP following the first cycle of lenalidomide was not associated with poor 
survival or renal deterioration.89  
Proteasome inhibitor based regimes 
Bortezomib-based regimens have changed the treatment paradigm in AL amyloidosis over 
the last few years. Plasma cells in AL amyloidosis appear to be especially sensitive to 
proteasome inhibitors in a preclinical model137 – the accumulation of pre-fibrillar light chains 
after proteasome inhibition adding to the cellular toxicity. The high response rates and good 
tolerance have led to Bortezomib combinations being adopted as front line therapy in AL 
amyloidosis. Prospective evidence of superiority or better tolerability over current standard 
regimens, particularly in elderly subjects with advanced cardiac disease, is still lacking.  
A multicentre retrospective analysis of 94 patients showed high haematologic response 
rates (71%) achieved rapidly (a median response time of 52 days) with associated organ 
responses in 30%. The one year survival rate was 76%. One third experienced grade 3 
toxicity and the most common non-haematological side effects included peripheral sensory 
neuropathy, orthostatic hypotension, gastro-intestinal disturbance or peripheral oedema.100 
A prospective phase I/II trial confirmed the high response rate and reported similar efficacy 
in patients with relapsed refractory AL amyloidosis with both once (OW) or twice (TW) 
weekly schedules in 70 patients.99 Haematologic response, median time to best response, 
one year PFS and ≥ grade 3 toxicities were 68.8%/66.7%, 3.2/1.2 months, 72.2/74.6% and 
50%/79% respectively in the OW and TW groups.99 
 CHAPTER ONE 
 
- 65 - 
A number of groups, including our own, have now studied Bortezomib with additional 
cyclophosphamide (CyBorD) or melphalan (BMDex) in AL amyloidosis.102, 138 Of 17 patients 
receiving CyBorD at the Mayo clinic (58% with symptomatic cardiac involvement), a clonal 
response was achieved in a median of 2 months in 94%, with 71% and 24% achieving a CR 
and PR respectively.102 In the UK, 43 patients received CyBorD (bi-weekly Bortezomib) 
(74%;cardiac involvement and 46% stage III by the Mayo cardiac staging), with overall 
haematologic response rates of 81% (CR - 42%).101 The estimated 2 year PFS was 66% 
and 41% for front-line treatment and relapsed setting respectively. The estimated 2 year OS 
was 98%.101  
BMDex has been studied in a prospective trial in the US139 and in a retrospective cohort in 
Italy.92 An early report from the prospective study has shown a 94% haematologic response 
rate with 38% CRs. However, in the retrospective study haematologic response rates were 
48% (CR 18%, VGPR 21%) with BMDex and the absolute dFLC decrease in responders 
95%; significantly greater than  those treated with MDex (median 83%, p=0.018). The lower 
overall response rate in this study was due to early deaths in  cardiac patients and similar 
results now reported with larger CyBorD treated cohorts140 – highlighting a possible concern 
using Bortezomib in advanced cardiac disease. A randomised prospective trial is ongoing 
in Europe and Australia comparing MDex with BMDex. Ixazomib and carfilzomib are novel 
proteasome inhibitors appearing to have greater efficacy of proteasome inhibition compared 
with Bortezomib with a more favourable toxicity profile. A phase I study of Ixazomib has 
been completed with good tolerance and responses seen in multiply refractory patients.141  
A phase III trial is ongoing.  
Allogeneic stem cell transplantation 
Allogeneic stem cell transplantation is not widely used in AL amyloidosis. Following the first 
successful case was reported in 1998,142 a European Group for Blood and Marrow 
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Transplantation (EBMT) registry study in 2005, reported 19 patients with AL amyloidosis (7 
patients full intensity conditioning; 8 reduced intensity conditioning (RIC)). The overall and 
progression free survival was 60% and 53% respectively at one year, with TRM of 40% 
(TRM 50% in patients receiving total body irradiation). Ten patients achieved  haematologic 
responses and 8 attaining organ responses.143 Anecdotal reports suggest RIC-SCT is 
possible in AL.144 Currently, allogeneic stem cell transplantation may have a role in highly 
selected young fit patients with relapsed disease but, ideally, should only be considered in 
the context of a clinical trial.  
An approach to treatment 
The treatment strategy in a patient with AL amyloidosis is shaped by poignant background 
factors including age, co-morbidities, performance status, contraindications to drugs and 
patient wishes deciding the ultimate choice of the regimen, especially in the lack of clear 
randomised evidence. Figure 1.5 provides a suggested treatment algorithm for patients 
treated outside of clinical trials. The choice of upfront treatment is between autologous stem 
cell transplantation (ASCT) and combination chemotherapy – one not necessarily precluding 
the other. Patients with good performance status, limited organ involvement, good renal 
function, cardiac ejection fraction >50%, CO diffusion capacity > 50%, cardiac troponin T 
<0.06 ng/L and NT-proBNP <5000 ng/L appear to have a <5% TRM during ASCT119, 145, 146 
and should be offered ASCT as a treatment choice. Borderline patients treated with a stem 
cell sparing regime as improved organ function may allow ASCT at a later date. Bortezomib 
has emerged as a key backbone in induction regimens – CyBorD or BMDex are becoming 
the regimens of choice in most non-neuropathic patients.  Cautious low dose regimens are 
needed in advanced cardiac involvement (especially with NT-proBNP >8500ng/L). Patients 
with neuropathy pose a dilemma, with melphalan/dexamethasone or 
lenalidomide/dexamethasone as suitable upfront treatments. Response reassessment at 
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the 3 month point interval is key – patients with a poor response considered for either dose 
increments or an additional drug to improve the response. 
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Figure 1.5: Therapy algorithm for treatment for immunoglobulin light chain (AL) 
amyloidosis.27 Reassessment post 3 cycles of chemotherapy should be undertaken to 
optimise haematologic response according to consensus criteria.87  
 
*NT-proBNP response - >30% and >300ng/l decrease in patients with baseline NT-proBNP ≥650ng/l 
** Renal response maybe delayed with no immediate correlation with haematologic response. 
^ Avoid melphalan containing regimens if eligible for ASCT 
ASCT - Autologous stem cell transplantation; CTD - cyclophosphamide, thalidomide, 
dexamethasone; CyBorD - cyclophosphamide, Bortezomib, dexamethasone; MDex - melphalan and 
dexamethasone; BMDex - Bortezomib, Melphalan, Dexamethasone; C/M – Len-Dex – 
Cyclophosphamide or melphalan with lenalidomide and dexamethasone; VGPR - very good partial 
response; CR – complete response; dFLC - difference in involved and uninvolved free light chains; 
NT-proBNP - N-terminal prohormone of brain natriuretic peptide; SBP – systolic blood pressure 
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Best organ responses occur in those achieving a haematologic CR/VGPR, but partial 
responders may also achieve an organ response. Lenalidomide and Pomalidomide based 
regimens or Bendamustine are useful in the relapsed/refractory setting. The value of 
alkylator based regimes in patients relapsing after a novel agent based regime is uncertain.  
IgM associated AL amyloidosis 
4-7% of all patients with amyloidosis have an IgM secreting (mainly) lymphoplasmacytic 
lymphoma (LPL) as the underlying cause of AL.147, 148 Treatment should be directed toward 
the LPL clone. Single agent alkylators have limited efficacy. Regimes such as 
melphalan/dexamethasone (n=14), purine analogues (n=17) confer good haematologic 
responses of 64% and 73% respectively.147, 148 Recently, 
Rituximab/Bortezomib/Dexamethasone shows promise, with  overall haematologic 
responses of 78% (n=7).149 Larger clinical trials are needed to evaluate this further.  
 
Organ transplantation 
Organ transplantation can be considered in patients attaining a VGPR or better with 
irreversible end-stage organ function, or in a situation to facilitate aggressive chemotherapy; 
not otherwise feasible due to organ dysfunction. Long term control of the underlying clonal 
disorder is needed to prevent recurrence after organ transplantation or progression in other 
organs.  
Cardiac transplantation may be the only option to improve survival in younger patients with 
advanced isolated heart involvement, accounting for  0.14% of heart transplants nationwide 
according to the United Network for Organ Sharing (UNOS).150 A UK study reported 24 
patients from 1984 to 2002 undergoing heart transplantation in 6 UK cardiac transplant 
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centres, 17 diagnosed with AL amyloidosis. The 1 and 5 year OS was 50% and 20% 
respectively not receiving chemotherapy versus 71% and 36% who did.151  Another 
multicentre study included 69 patients receiving heart transplants for amyloidosis (all types), 
reported 1 and 5 year survival as 74.6% and 54% respectively.150 Control of the underlying 
clone is important, and ASCT is generally considered most appropriate treatment. One US 
series between 1994 and 2005 included 11 patients undergoing the two procedures serially; 
9 patients surviving both with 3 eventually dying due to progressive amyloidosis; the earliest 
55 months post ASCT. The 1 and 5 year survival following heart transplantation in this cohort 
was 82% and 65% respectively;139,152 a marked improvement over the otherwise median 
survival of advanced cardiac AL of 3-8 months. Scarcity of organs, risk of amyloid recurrence 
and higher mortality of amyloid patients undergoing heart transplants still makes cardiac 
transplantation a contentious issue.150 
Renal transplantation in AL amyloidosis is considered to improve long term survival and 
quality of life. The largest UK series reports 22 patients undergoing renal transplantation; 
(19 cadaveric donors and 3 live donors), and 3 with extra-renal organ dysfunction. Nineteen 
patients received chemotherapy or ASCT;  74% achieving a haematologic response (11 PR 
and 3 CR) with no graft failures secondary to amyloid recurrence and 1 and 5 year OS 95% 
and 67% respectively.153 The Mayo group reported 19 patients receiving renal 
transplantation (1 cadaveric donor and 18 live donors), 12 having extra-renal involvement 
from 1999 to 2008. All attained a haematologic response (18 CR and 1 PR); 8 receiving 
renal transplantation followed by ASCT, 6 receiving ASCT followed by renal transplantation 
and 5 receiving non-myeloablative chemotherapy followed by renal transplantation, with no 
significant difference between these groups.  The 1 and 5 year OS was 84% and 76% 
respectively.153 Good long-term outcomes appear to be associated with renal 
transplantation in AL in highly selected cases. 
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Outcomes with orthotopic liver transplantation (OLT) for advanced liver AL remain poor. A 
UK study from 1984 to 2009 included 9 patients undergoing an OLT with the 1 and 5 year 
survival from transplantation 33% and 22% respectively.153  
In summary, AL Amyloidosis is rare. It is frequently diagnosed late due to the subtle signs 
and symptoms of the disease. Increasing awareness of this disease poses major 
challenges. Improved diagnostic techniques have enabled better detection of this disease. 
Risk stratification using cardiac biomarkers has refined treatment selection and reduced 
morbidity and TRM. Diagnosis and treatment planning in AL is complex and best considered 
in specialist centres availing expertise of a multi-disciplinary team. Novel agent based 
chemotherapy especially with Bortezomib has improved chemotherapy responses and is 
being explored pre and post ASCT. Bendamustine, lenalidomide and Pomalidomide are 
valuable therapies for relapsed refractory patients. Good haematologic responses (attaining 
at least a VGPR being the goal of therapy87) translates into organ responses and improved 
survival. While cardiac and haematologic responses can be simultaneous, responses of 
other organs may evolve over months or years. Early mortality of patients with advanced 
disease persists. Future directions involving therapies targeting the amyloid deposits - anti-
fibril antibodies are in early phase trials. Exploring the role of minimal residual disease, the 
importance of eradicating this, gaining insight of the microenvironment is needed. Ultimately, 
the most important factor is increasing the awareness to ensure early diagnosis to allow 
therapy before extensive organ involvement. 
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Novel therapies for amyloidosis 
A number of therapies are in development targeting various components of the 
pathophysiology of amyloid fibrillogenesis. Glycosaminoglycans are a universal constituent 
of all amyloid deposits and inhibition of the interaction between GAGs and amyloid fibrils 
which seems a promising therapeutic approach AA type – which may also have merit in AL. 
Eprodisate (Kiacta®, Bellus Health, Canada) is a negatively charged, sulfonated molecule 
of low molecular weight is undergoing phase III trials.154 There is growing interest in 
developing therapeutic antibodies to directly target amyloid deposits. Mu 11-1F4 is a 
chimeric antibody reactive with many AL fibrils,155 localisation of which has been studied in 
patients with PET imaging.156 Its administration as a therapeutic is planned. mAb2A4 is 
another monoclonal antibody, binding AL/AA fibrils and human AL amyloid extracts,157 
reported to cause amyloid regression in mouse models of AA and AL amyloidosis. This 
antibody has been further developed as NEOD001 (Onclave Therapeutics Limited, 
California), recently commencing phase I trials in systemic amyloidosis in the United States. 
Pre-clinical development of small interfering RNAs (siRNAs) have also been explored as a 
treatment in reducing the expression of the amyloid precursor protein, with in vitro studies 
showing inhibition of synthesis of light chains in transfected cells, and in vivo reducing the 
production and circulating free light chains.158 
R-1-[6-[R-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid (CPHPC) 
is a drug which cross-links pairs of SAP molecules in vivo159 resulting in rapid clearance of 
SAP from the liver and almost complete depletion of plasma SAP.160 Some SAP persists on 
the amyloid deposits and lack of plasma SAP allows administration of an anti-SAP antibody 
which can now target the amyloid deposits. Following promising results in transgenic mouse 
model of AA amyloidosis, using anti-SAP immunoglobulin-G (IgG) antibodies and CPHPC,15 
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early phase clinical trials are underway to explore this further with initial patient recruitment 
commencing this year. 
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Aims and scopes of this thesis 
The introduction of this thesis provides a general overview of the different types of 
amyloidosis with a comprehensive overview of systemic light chain amyloidosis and 
treatment options available. This rare disease is often a delayed diagnosis, with the clinical 
presentation masked by many other medical conditions. More recently, advances have been 
paved with use of targeted treatment, monoclonal antibodies or accessibility of newer 
chemotherapeutic agents. Prognostic stratification has emerged as an important tool in 
treating amyloidosis patients. 
The premise of this thesis focuses upon areas of interest. Firstly section one concentrates 
on the investigations important in diagnosing, monitoring, and assessing the prognostic 
utility and potential complications of patients diagnosed with systemic amyloidosis. Chapter 
3 concentrates on the comparison of the utility of free light chain assays currently important 
in diagnosing and monitoring these patients. The current serum FreeliteTM assay measures 
immunoglobulin free light chains using polyclonal sheep antibodies directed against hidden 
epitopes on the light chain molecule giving an accurate measurement of serum free kappa 
and lambda and forms a standard part of the baseline and serial follow up assessments in 
systemic AL amyloidosis161, 162, and is part of the revised Mayo staging system and standard 
international consensus criteria for disease response assessment.80, 86, 87 A group in the 
Netherlands working with Siemens, Germany, has developed this technology using a 
mixture to two kappa and two lambda monoclonal antibodies to the hidden epitopes of the 
constant region of the immunoglobulin light chain molecules.163  With increasing adoption 
by laboratories of the novel assay, it is important to assess the utility of the new assay 
compared to the current reference FreeliteTM assay. We report a comparison of serum free 
light chains analysing the serum samples by both immunoassays at diagnosis and three 
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further time points in during the initial chemotherapy for patients with systemic AL 
amyloidosis.  
Chapter 4 outlines the coagulation abnormalities seen in systemic AL. Systemic light chain 
(AL) amyloidosis is also known to be associated with a bleeding diathesis164, which may 
range from small cutaneous bruising, pathgnomic “racoon eyes” or life threatening bleeds. 
The crucial role of endothelial dysfunction in systemic AL may assist in understanding the 
basis of the light chain toxicity in this disease. We designed a prospective study to 
investigate the endothelial dysfunction in newly diagnosed systemic AL patients, using Von 
Willebrand factor (vWF) antigen (Ag) and factor VIII to serve as a surrogate marker and 
examine its relationship with light chain toxicity. Other coagulation factors were also 
examined. This was performed examining the clinical bleeding manifestations using the 
Royal Free Hospital v4 adapted bleeding questionnaire in conjunction with extensive 
laboratory investigations such as factor assays, protein S, protein C, Anti-thrombin III, 
vWF:Ag and VWF:Ricof and ADAMTS13 assays. Endothelial function was explored using 
vWF antigen (Ag) and factor VIII to serve as a surrogate marker and examine its relationship 
with light chain toxicity. The secondary aim was to assess the prognostic utility of these 
investigations. 
Chapter 5 focuses on a new area of interest which may pose a potential issue in patients 
with systemic amyloidosis – sleep disordered breathing. Cardiac involvement and/or 
macroglossia with soft tissue deposits, risk factors for central and obstructive sleep apnoea, 
are common features of systemic AL amyloidosis. Little data exists on the occurrence of 
sleep disordered breathing (SDB) or recurrent nocturnal hypoxia in amyloidosis. All were 
screened for SDB using Epworth Sleepiness Score (ESS) and STOP BANG questionnaires. 
We report here the results of a pilot study of overnight continuous pulse oximetry in patients 
with systemic light chain (AL) amyloidosis, based on the hypothesis that recurrent nocturnal 
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hypoxaemia (likely due to sleep disordered breathing OSA and/or CSA) could occur in 
patients with amyloidosis reporting a high incidence of recurrent nocturnal oxygen 
desaturations and raise a question whether these desaturations may be the trigger for 
sudden cardiac mortality.  
The second section focuses on a rare type of amyloidosis - localised amyloidosis and a 
subgroup – tracheobronchial amyloidosis. Chapter 6 elaborates on localised amyloidosis. 
Localised deposits of amyloid can occur in various tissues in the body and are usually 
presumed to be of AL type, with the consequent presence of a focal monoclonal B cell 
dyscrasia within the affected tissue.  As such, the clinical effects of the localised amyloid 
deposits depend on their precise anatomical location, and can result in substantial morbidity. 
Localised amyloidosis is much rarer than systemic types, and consequently remains very 
poorly studied; with most knowledge arising from individual case reports or small series of 
less than 20 patients.  There are commonly reported sites include the urinary tract, 
respiratory tract, larynx, skin and eyelids.165  Currently, data on long term outcomes and 
progression to systemic disease is lacking with the need for further exploration in this field. 
We have examined the clinical features and outcomes of a large series of 606 patients with 
localised AL amyloidosis highlighting the striking differences from systemic AL amyloidosis 
with respect to the lack of progression, benefit from debulking procedures, limited need for 
cytotoxic chemotherapy therapy and excellent overall long term outcomes. Chapter 7 
examines a subgroup of localised amyloidosis – laryngeal and tracheo-bronchial 
amyloidosis. This group of patients have a more refractory control of their disease. We 
examined the clinical features, treatment options and also sought to explore the laboratory 
aspect of proteomic analysis in these biopsies to attempt to gain insight into any underlying 
instigating factors. Although amyloid fibril formation and aggregation occurs when high 
concentrations of the key partially folded intermediate is present, other factors including the 
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pH, temperature, amino acid sequence and concentration of the intermediate play a role.  
The presence of ApoA1 and insulin-like growth factor binding protein complex in the LTBA 
proteomic analysis suggests the potential involvement in the development of localised 
amyloid in the laryngeal and tracheobronchial cases. Further studies are needed to 
elucidate the function of these factors before a significant pathogenesis is attributed to the 
latter.  
The third section focuses on 2 types of treatments in systemic amyloidosis – a 
chemotherapeutic option (lenalidomide/dexamethasone post novel agents) and ((R)-1-[6-
[(R)-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl] pyrrolidine-2 carboxylic acid (CPHPC)) 
which has emerged as a potential therapeutic target to deplete SAP.  
Chapter 8 relays our experience with a chemotherapeutic drug option – 
lenalidomide/dexamethasone. We report a substantial cohort of patients treated with 
lenalidomide in the relapsed/refractory setting, following the use of Bortezomib and/or 
thalidomide with long term follow up assessing the impact of previous therapies on 
haematologic responses.  
Chapter 9 outlines a small cohort of patients treated with compassionate use of CPHPC. 
Fibrinogen related amyloidosis has predominant renal involvement with end stage renal 
failure within 5 years of presentation with proteinuria.47 Currently there are no definitive 
therapeutic cures for this condition and we used CPHPC on a compassionate basis to try 
and improve the renal survival duration in these patients, with the use of QoL questionnaires 
to gain a better insight into the patients’ perspective. We also assessed its use in patients 
with dialysis related amyloidosis. 
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Chapter Two:  Materials and methods 
 
Declaration 
I have designed the studies, collected the data and performed analysis of the data 
using 2 software programs – SPSS v20 (IBM SPSS) and Graph pad prism (version 5). 
This thesis includes 3 prospective studies: the coagulation study, sleep disordered 
breathing study and the CPHPC study. I recruited patients for the Coagulation study, 
collected the data and performed the statistical analysis as a clinical research fellow 
based at the National Amyloidosis Centre, University College Medical School (Royal 
Free Campus). I also recruited patients for the sleep disordered breathing study, again 
collected the data and performed the statistical analysis and sent the overnight pulse 
oximetry downloads to Dr Milind Sovani (Respiratory physician) to analyse. I recruited 
patients for the CPHPC study following discussion at our multidisciplinary meeting for 
suitability for compassionate use of CPHPC in these patients. Ms Thirusha Lane, a 
clinical lead nurse at the National Amyloidosis Centre used the QoL software (SF36) 
in giving the output for the quality of life data. Various diagnostic methods were 
undertaken by other individuals in the department and external sources as follows: 
Measurement for biochemical serum and urinary investigations were performed by the 
Royal Free Hospital laboratory services. 
Frozen serum blood samples for the serum free light chain assay comparison were 
collected by Wendy Taylor and Lois Cook, based at the National Amyloidosis Centre. 
Coagulation assays were performed by the Haemophilia department at the Royal Free 
Hospital and these investigations overseen by Ms Anne Riddle, Dr Keith Gomez and 
Dr Pratima Chowdary. 
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Histological and immunohistochemical studies were performed by Janet Gilbertson 
and Karen Boniface, both based at the National Amyloidosis Centre. Laser capture 
techniques were undertaken by Janet Gilbertson and Nicola Botcher, both based at 
the National Amyloidosis Centre. Proteomic analysis was undertaken using the 
Scaffold program by Graham Taylor and Nigel Rendell, both based at the Wolfson 
Centre Research Institute, National Amyloidosis Centre. Analysis of proteomic data 
was performed by Dr Julian Gillmore and Janet Gilbertson. 
The spinning and storing or serum samples for patients on compassionate use of 
CPHPC were performed by the clinical nurses Thirusha Lane, Charlene Kearney and 
Randolph Gaudia. 
Genetic sequencing was performed by Dorota Rowczenio and Hadija Trojer, based at 
the National Amyloidosis Centre. 
Echocardiography was performed by Babaita Pawarova, Oliver Manalo, and Sevda 
Ozer, based at the National Amyloidosis Centre. 
123I-SAP scintigraphy was performed by David Hutt, Dorothea Gopaul and Stephanie 
McKnight, based at the National Amyloidosis Centre. 
Pulse oximetry output using the Minolta 300I pulse oximeter was read by Dr Milind 
Sovani, a respiratory physician at Nottingham University hospital. 
Patient selection 
All of the patients recruited and studied in this thesis have been seen at the National 
Amyloidosis Centre, London. Medical records were retrieved and an electronic 
database has recorded details of all patients attending the centre, which I used. All 
patients included in this thesis provided explicit informed consent. The database 
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recorded dates of deaths according to the Office of National Statistics, updates from 
family members and details of the causes of deaths were specifically sought for by 
contacting local general practioners or hospital consultants caring for the patients. 
Only anonymised data was used. 
Immunoassays 
Serum free light chain assays 
Kappa and lambda serum free immunoglobulin (FLC) concentrations were measured 
using a latex-enhanced immunoassay (Binding Site, Birmingham, UK) on an Ehring 
BNII auto analyser (Dade Behring Marburg, Germany). Antibodies were directed 
against the FLC epitopes within the whole immunoglobulin molecules, with the 
sensitivity quoted as<5mg/L for this assay. The reference range as provided by the 
manufacturers for FreeliteTM: kappa 3.3-19.4mg/L, lambda 5.7-26.3mg/L and 
kappa/lambda ratio 0.26-1.65. The N Latex (Siemens, Germany) immunoassay is a 
turbid metric assay based on monoclonal antibodies. The reference range as provided 
by the manufacturers for N Latex: kappa 6.7-22.4mg/L, lambda 8.3-27mg/L and 
kappa/lambda ratio 0.31-1.56mg/L. In chapter 3, in total, 240 serum blood samples 
were measured in duplicate using the FreeliteTM (Human kappa and lambda free kits, 
Binding site Ltd, Birmingham, UK) and N Latex (Siemens Healthcare Diagnostics, 
Germany) from stored frozen samples.  
Histology 
Congo red staining 
Biopsies were logged into our database once received and the formalin fixed de-
paraffinised tissue sections 6-8µg thick were rehydrated and stained with 
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haematoxylin under running tap water. The Congo red method as described in 
Puchtler el al166 was adopted with sections using this method. Increasing ethanol 
concentrations to xylene were used to dehydrate the sections and eventually mounted 
with DPX mounting medium. The stained slides once dry were viewed in bright field 
under cross polarised light by microscopy.167 A known Congo red positive block 
validated by laser micro dissection and proteomic analysis was used as a positive 
control. 
Immunohistochemistry 
Immunohistochemical staining techniques were used to type the amyloid. Formalin 
fixed de-paraffinised 2µm sections of amyloidotic tissue was used. These sections 
were cleansed; washed with water and endogenous peroxidise activity was quenched 
by incubation in aqueous (0.3%) hydrogen peroxide (H2O2) for approximately 30 
minutes. Rinsing was performed using a phosphate-buffered saline (PBS) containing 
0.05% Tween (Calbiochem) solution. Non-specific tissue binding was abolished by 
incubation for a further 30 minutes in normal non-immune serum from the species 
providing the secondary antibody (Vector Part of the ImmPRESS Kit). These sections 
were incubated overnight with primary antisera at 4oC, and then rinsed with PBS 
containing 0.05% Tween (Calbiochem) and labelled with secondary antibodies. Each 
section was washed in PBS and bound enzyme-antibody bound complexes were 
consequently visualised using a metal-enhanced DAB (Fisher Scientific solution). 
Immunohistochemistry was possible with a panel of anti-human monospecific 
antibodies reactive with: SAA (Eurodiagnostica, Huntington UK) AL kappa, lambda, 
transthyretin and lysozyme (Dako Ltd, Denmark House Ely UK), Apolipoprotein AI 
(Genzyme Diagnostics) and fibrinogen Aα chain (Calbiochem) were used where 
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appropriate. Congo red overlay was used in duplicate sections. Immunohistochemical 
stained sections were counterstained in haematoxylin, ‘blued’ under running tap water 
and stained with Congo-red.168 
When performing TTR staining, pre-treatment was performed for enhanced antigen 
retrieval using a 10 minute incubation with 1% sodium periodate. The slides were then 
washed and  incubated for a further 10 minutes with 0.1% sodium metabisulphate, 
and washed again and incubated for 5 hours at room temperature with 6M Guanadine 
in 0.9% sodium chloride. 
 
Laser capture micro dissection and mass spectrometry  
(Also described in chapter 7) 
Laser capture micro dissection and mass spectrometry (LDMS) techniques were also 
used to identify proteins from formalin-fixed, paraffin embedded tissues and described 
in detail for chapter 7.169 10µm sections were cut from formalin fixed tissue on the 
Director Expression Pathology 50001-024. Stained slides with Congo red (Putchler et 
al) were left to dry after clearing with xylene.  
Visualisation and locating the amyloid was done using bright field and Rhodamine filter 
sets (TRITC) by the Zeis Palm Micro beam Laser capture microscope, with amyloid 
typically yellow on a “red” background. Delineation of the areas of interest were drawn 
around , appearing yellow under a Tritc florescent filter  or under bright field and “cut” 
out using laser capturing in to 0.5ml micro-centrifuge adhesive cap tubes (Zeiss) whilst 
checking the cap to ensure that some tissue has been captured. A 10x concentration 
stock solution of the following reagents were constituted: (1) TRIS: 0.1 M; use 
1.2114g in 100ml, (0.6057g in 50 ml), (2) EDTA: 10 mM; use 0.37224g in 100ml, 
(0.18612g in 50ml) and (3) Zwittergent (Z3/16): 0.02% w/v; use 0.02g in 100ml, 
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(0.01g in 50ml). A 1ml aliquot of each buffer is placed into 1.5 ml microfuge tubes and 
stored in a separate snap seal bag, at -20°C. TEZ Buffer (Tris, EDTA, and 
Zwittergent) and constituted by diluting each buffer in 1:10 in MQ. A glass vial of 
100µg trypsin gold was reconstituted with 50mM Acetic acid and 5 µl aliquots were 
stored in microfuge tubes at -80°C (>for 1 month 1mg/ml). To constitute working 
strength trypsin, 5µl of stored frozen trypsin solution was added to 245µl of TEZ buffer 
(1x)(4 fold concentration of trypsin) and made just prior to use. To constitute the 
Dithiothreitol, 10 mg ml-1 solution in MilliQ water aliquot in 100ul volumes was used 
and stored in a snap seal bag freezer.  
35µl of TEZ buffer was added into each sample and then closed tightly, and the sample 
vortexed.  The sample was inverted and the left on the bench for 20 minutes. The 
capped tubes were inverted, flicked to transfer the liquid to the cap and left to stand 
for approximately 20 minutes at room temperature. The samples were centrifuged at 
5000 rpm x 5 min (Eppendorf bench, 24 fixed positions) to recover the liquid into the 
bottom of the vial.  
The cap lock was fitted to the tubes, with care taken not to disturb the liquid at the 
bottom of the vial and heated at 99°C x 90 minutes, mixing every 20-25 minutes. 
Cooling next and centrifuged at 5000 rpm x 5 min to recover as much condensate as 
possible from the tube lids. The Sonicater was cleaned with 70% alcohol (fume hood) 
and refilled with fresh MQ water. The cap lock was fitted to tubes and sonicated for 60 
minutes at room temperature.  Samples were centrifuged at 5000 rpm x 5 min. Working 
Trypsin Solution was made by taking 5µl of stored frozen trypsin solution and add to 
245µl of TEZ buffer (1x) (4 fold concentration of trypsin). 1.5µl of working trypsin was 
added to each sample, (total volume 36.5µl), and each sample vortexed. Again, 
centrifuging at 5000 rpm x 5 min, with the cap locks fitted to the tubes and allowed to 
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digest overnight at 37ºC. Samples were centrifuge at 5000 rpm x 5 min. Addition of 
5µl DTT to the Trypsin digested samples (reduced with Dithiothreitol (DTT) - (0.008M). 
Centrifuged at 5000 rpm x 5 min. Cap locks were fitted and sample heated for 5 
minutes at 98ºC (total volume 41.5 µl). The samples are cooled, then centrifuged at 
5000 rpm x 5 min. The samples are taken to the equipment room to unfasten the caps 
and place in freezer at -80.  
On the freeze drier turn the drain valve and the air admittance valve clockwise. Ensure 
the mode selector on the pump is at zero (0). Switch pump on at side and leave for 20 
minutes. Dials should be set at 3mb and -40 temp. Select a small dissector and outlet 
valve is turned fully anticlockwise and attach rubber pipe from manifold to outlet valve. 
On manifold turn tail switch to on position (down) and check the dials move to the right 
before falling again. This is removing the air from the rubber tube. Remove samples 
from -80 and place in dissector ensuring lid is in place correctly. Quickly turn outlet 
valve clockwise until the screw thread is just visible. Dials should be fully to the right. 
Check that a vacuum has been created by gently lifting the dissector with the lid – the 
bottom should be raised off the bench if not correct. Check that the dials are falling. 
After 60 minutes check that the dials are at 3mb and -40 temp. Leave to freeze dry. 
The person loading the MS will remove the samples however if this has not happened 
within 24 hours. Remove the samples by reversing the steps and place in -80 with the 
lids tightly shut. 
 The residues were reconstituted with 1% MeCN + 0.1% TFA (20µl/sample), vortexed 
and centrifuged (10 000 rpm x 5 min).  The supernatants transferred to Waters Total 
Recovery vials for LC-MS/MS on the Velos.  A QA sample (six protein mix tryptic 
digest) should be run before and after the samples; all samples should be followed by 
a blank run with a 1% MeCN + 0.1% TFA injection. The data was processed using 
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Proteome Discoverer for MASCOT searching of the NCBI and IPI databases enabling 
mass spectrometry results to be produced. 
Proteomic analysis was performed on the Velos platform and analysed following the 
method of Rodriguez et al.75, 169 Following extraction into 10mM Tris/1mM 
EDTA/0.002% Zwittergent buffer  (99 °C, 1.5h) and sonication (1h), samples were 
trypsinised  (1.5µg w/v) overnight at 37°C and then reduced with Dithiothreitol (50µg) 
at 99°C for 5 minutes.  Digests were run on a nanoACQUITY™ UPLC system (Waters 
Ltd., Elstree, and Hertfordshire, WD6 3SZ) coupled to an Orbitrap Velos Mass 
Spectrometer (Thermo Electron, Bremen, Germany).  MS data files were analysed 
using Mascot software. (Matrix Science, London, UK). 
Genetic sequencing 
Patients with suspected hereditary amyloidosis or clinical features of laryngeal 
involvement had genotyping performed. Patients at their baseline visit had whole blood 
taken which was stored in an EDTA tube consequently frozen and stored, with 
genomic DNA isolated as required.170 The polymerase chain reaction (PCR) adopting 
the ‘ready to go” tubes (GE Healthcare) were used to amplify the coding regions for 
the genes and appropriate exons including: transthyretin (exons 2, 3 and 4), 
apolipoprotein AI (exons 3 and 4) and fibrinogen A α-chain (exon 5). HotStar Taq DNA 
Polymerase kit (Qiagen) was used for the lysozyme gene (exon 2). The primers used 
as part of the PCR process are outlined in Table 2.1. 
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Table 2.1: Genotyping for Hereditary Amyloidosis illustrating the primers used in this 
technique 
 
Primers sequence 
FGA exon  
5-5’end 
  
Forward: 5’-GCTCTGTATCTGGTAGTACT-3’ 
Reverse: 5’-ATCGGCTTCACTTCCGGC-3’ 
ApoA1  exon 
 
 
 
3 
  
Forward: 5’-GGCAGAGGCAGCAGGTTTCTCAC-3’ 
Reverse: 5’-CCAGACTGGCCGAGTCCTCACCTA-3’ 
4 
  
Forward: 5’-CACTGCACCTCCGCGGACA-3’  
Reverse: 5’-CTTCCCGGTGCTCAGAATAAACGTT-3’ 
      TTR exon 
  
2 
 Forward: 5’-TTTCGCTCCAGATTTCTAATAC-3’ 
 Reverse: 5’-CAGATGATGTGAGCCTCTCTC-3’ 
3 
 Forward: 5’-GGTGGGGGTGTATTACTTTGC-3’ 
 Reverse: 5’-TAGGACATTTCTGTGGTACAC-3’ 
4 
 Forward: 5’- GGTGGTCAGTCATGTGTGTC-3’ 
 Reverse: 5’-TGGAAGGGACAATAAGGGAAT-3’ 
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Overnight pulse oximetry 
All patients recruited to the sleep apnoea study had overnight oximetry performed with 
simplified instructions, appendix 2. This information was downloaded using the Minolta 
300I software and then analysed by Dr Milind Sovani using this program. 
Sleep questionnaires 
Patients recruited to the sleep apnoea study completed an Epworth Sleepiness Score 
(ESS) and STOP BANG questionnaires for obstructive sleep apnoea (OSA) to 
correlate the clinical symptoms in conjunction with the overnight oximetry readings 
(appendix 3 and 4 respectively). 
SAP scintigraphy 
This procedure was performed in all patients attending the National Amyloidosis 
Centre at their first assessment, initially 1988. Each patient having this procedure 
received approximately 200µg of SAP with 190MBq of 123I which is the equivalent of 
3.8mSV of radiation. A dose of 60mg of potassium iodide was immediately given to 
each patient prior to 123I SAP scintigraphy and a further 5 doses were administered 
following this over the following 3 days to prevent thyroid uptake. Patients had anterior 
(AP) or posterior (PA) imaging using an IGE-Starcam gamma-camera (IGE Medical 
Systems, Slough, UK) at 6 or 24 hours following the injection.  
A normal scan was defined upon having no abnormal localisation of the tracer. The 
quantification of the amyloid load was based on: small – when uptake within one or 
more organs was visible with the normal intensity in the blood pool; moderate – when 
abnormal uptake was seen within organs and the blood pool was diminished; and 
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lastly large – when the blood pool signal was lost with adjustment of the grey scale to 
include the target organs. 
Progression of the amyloid was defined as increase of the tracer within the affected 
organ(s) and/or decrease in the background blood pool. Regression of the amyloid 
was defined as reduction of the tracer within the affected organ(s) and/or increase in 
the background blood pool. 
PET/CT imaging 
This imaging uses a device combining the use of positron emission tomography (PET) 
scanner and x-ray computed tomography (CT) scanner to acquire images sequentially 
and combine to give a superposed image with the use of 18F-flurodeoxyglucose 
(FDG) PET/CT. An intravenous bolus injection of a dose produced for 2 or 3-FDG is 
made (doses range from 3.7-7.4 megabecaquerels per kilogram of body weight. The 
functional aspect depicts the spatial distribution of metabolic or biochemical activity in 
the body. Quantification of the size of the lesion and location are important. This 
technique was used to assess patients with localised amyloidosis, specifically related 
to lymph node, lung nodules or bone lesions. 
Quality of life (QoL) questionnaire assessments 
The quality of life was assessed at 6 monthly intervals for all patients by the validated 
Quality Metric SF36v2® Health survey. This is designed to measure functional health 
and well-being from the patient’s perspective. There are eight specified health 
domains (physical functioning, role physical, bodily pain, general health, social 
function, role emotional, mental health and vitality) which are assessed are scored 
individually. The result is expressed in comparison to the American norms. The 
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average score for healthy controls in each measure is 50, with higher scores 
representing a better QoL. A change of 10 points or greater in any domain between 
administrations is considered clinically significant. 
Measuring the quality of life (QoL) 
 
Until fairly recently the primary clinical endpoints such a hospitalisation or death were 
the focus of most clinical trials or disease management programs. Previously patient-
reported outcomes (PRO) tended to be in relation to disease specific indicators, such 
as joint pain in rheumatoid arthritis. However, this does not reflect the overall health-
related QoL. As people are living longer, healthcare must focus as much on quality as 
length of life. Medicine regulatory bodies such as the United States (US) Food and 
Drug Administration (FDA) and the United Kingdom (UK) Medicines and Healthcare 
Products Regulatory Agency (MHRA) have become increasingly interested in patient-
reported health-related quality of life, and the pharmaceutical industry, in conjunction 
with academic and clinical researchers, now expected to include validated QoL 
measures as endpoints in clinical studies171   
The Quality Metric SF-36v2® and other SF QoL questionnaires are widely recognised 
as leading PRO measures; used and validated in patients with many different acute 
and chronic conditions. The SF-36v2 has become invaluable to healthcare 
professional as a useful utility in evaluating and monitoring disease and assessing the 
success of therapy.172-175 The SF-36v2  provides a broad overview of a patient’s health 
status and the effect of the disease/health status on his or her physical, social 
emotional and mental functioning – i.e. disease burden.176 In addition to the utility of 
the survey in measuring disease burden, the SF-36v2 may be administered to a single 
patient at multiple time-points, offering a baseline comparator for long term monitoring 
 CHAPTER TWO 
 
- 90 - 
in chronic conditions and whilst having treatment. It is easy and quick to complete, 
allowing easy incorporation into clinical practice177 
The SF-36v2® is composed of 36 questions covering eight health domains or scales: 
Physical functioning (PF): The PF domain is composed of 10 items covering distinct 
aspects of physical functioning including a range of severe and minor physical 
limitations, such as lifting and carrying groceries; climbing stairs; bending, kneeling, 
and walking moderate distances. There is also one item dedicated to describing 
limitations in self-care activities. Low scores indicate significant limitations in 
performing physical activities, whilst high scores reflect little or no limitations in 
performing physical activities. 
Role-physical (RP): This domain includes four items covering a range of physical role 
limitations, including limitations in carrying out work or other usual activities and 
reduction in amount of time spent on work or other usual activities. Low scores indicate 
interference of physical problems with work or typical usual activities. 
Bodily pain (BP*): This domain includes two items: one designed to measure the 
intensity of bodily pain and one measuring the extent of interference with normal work 
activities as a result of bodily pain. Low scores indicate high levels of pain significantly 
affecting normal activities, whilst high scores indicate no pain or impact on normal 
activities. 
General health (GH): The GH scale includes five items, including a rating of health 
from poor to excellent, and four items addressing the patient’s opinion and 
expectations of his/ her health. Low scores indicate a perception of poor general 
health, which is expected to deteriorate. High scores indicate a perception of good 
general health. 
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Vitality (VT): This scale includes a four-item measure of vitality (i.e. energy level and 
fatigue). Low scores indicate feeling tired and worn out the majority of the time, whilst 
high scores reflect feeling energetic most of the time. 
Social functioning (SF). This domain includes 2 aspects; designed to assess health-
related physical or emotional problems on the quantity and quality of usual social 
activities. 
The low scores indicate extreme or frequent interference of health-related physical or 
emotional problems with normal social activities. 
Role-emotional (RE). This domain includes a three-item scale to assess the impact 
of mental health-related problems with respect to limitations related to time spent on 
work or other usual activities. Low scores reflect problems with work or other usual 
activities as a result of emotional problems and high scores reflect no such limitations 
due to emotional problems. 
Mental health (MH). This five-item MH scale includes anxiety, depression, loss of 
behavioural and/or emotional control, and psychological wellbeing. Low scores reflect 
frequent feelings of nervousness and depression all or most of the time, whilst high 
scores indicate feelings of peace, happiness, and calm.177 
Each domain or scale is scored individually, with the result expressed in comparison 
to American norms. Higher scores represent a better QoL and a change of 10 points 
or more in a domain between administrations is considered clinically significant. 
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Cardiac assessment 
An electrocardiogram (ECG) and echocardiogram were performed as part of the 
routine baseline assessment to ascertain whether there was cardiac involvement. 
Cardiac biomarkers including an NT-proBNP and troponin T were performed 
additionally at baseline and NT-proBNP at consequent follow up visits. A cardiac MRI 
was also performed either locally or at the Heart Hospital, London for additional 
assessment to evaluate and discern cardiac involvement and consequent monitoring 
of improvement/deterioration.   
Functional assessment 
Patients were evaluated using the Eastern Co-operative Group (ECOG) performance 
status (Table 2.2).178Cardiac heart failure symptoms are also categorised accordingly 
and were recorded as the New York Heart Association Classification (NYHA) 
symptoms (table 2.3).179 
Table.2.2: Definition of the Eastern Co-operative Group Performance Status 
(ECOG)178 
 
Grade 
 
Summary Description 
0 
 
Normal No restriction to carrying out normal activities 
1 With effort 
Ambulatory, able to do light work. Restricted only in strenuous 
activity 
2 
 
Restricted Self-caring and ambulatory but unable to carry out work 
3 Dependent 
Capable of limited self-care, confined to bed or chair for over 
50% of waking hours 
4 Immobile 
Unable to carry out self-care, completely confined to bed or 
chair 
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Table 2.3: Definition of New York Heart Association Classification (NYHA)179 
 
NYHA 
Class 
Summary Description 
I Normal 
No limitation of physical activity. Ordinary physical 
activity does not cause shortness of breath or undue 
fatigue 
II Mild 
Slight limitation of physical activity. Comfortable at rest, 
but ordinary physical activity results in fatigue, 
palpitation or dyspnoea 
III Moderate 
Marked limitation of physical activity. Comfortable at 
rest but less than ordinary activity causes fatigue, 
palpitation or dyspnoea 
IV Severe 
Unable to carry out any physical activity without 
discomfort. Symptoms of cardiac insufficiency at rest. If 
any physical activity is undertaken, discomfort is 
increased 
 
Electrocardiogram 
This was performed in all patients for baseline features with some patients having a 
history of ischemia heart disease, but also assessing for specific features such as low 
voltage amplitude defined by a mean QRS amplitude less than 0.5mV in leads I,II, III, 
aVL and aVF. 180 
Electrocardiography 
Echocardiography was done on commercially available instruments by GE 
Healthcare: Vivid E9 (S/N VE94922, VE94921) and Vivid S6 (S/N 4544VS6) using the 
EchoPac workstation. Standard LV systolic and diastolic function values were 
collected using 2D and Doppler echocardiography. Determination of the left ventricular 
wall thickness, left ventricular diastolic function, left ventricular systolic function and 
atrial diameter were measured according to the guidelines from the British Society of 
Echocardiography. The tricuspid annular plane systolic excursion (TAPSE) was 
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determined by using an apical 4-chamber view; measured by the total displacement 
of the tricuspid annulus (in mm) from end diastole to end systole. There were 3 
operators, with intra-observer variability reduced by re-examination of all 
echocardiograms by one operator. Normal echocardiographic parameters were 
according to the current guidelines.181 
Assessment criteria for diagnosis of amyloid and assessment of organ 
response 
The definition of organ involvement in systemic amyloidosis and organ responses 
were defined according to the Consensus criteria (Table 2.4). Assessment of 
haematologic response was also assessed and monitored for those patients 
diagnosed with systemic light chain amyloidosis. (Table 2.5)87 
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Table 2.4: Definition of Organ involvement and organ response in amyloidosis86 
Organ 
Definition of Organ 
Involvement 
Definition of Organ Response 
Heart 
Echocardiogram: Mean wall 
thickness >12mm and no 
other cardiac cause or 
CMR showing late 
gadolinium enhancement 
Mean IVSd decreased by 2mm, 
20% improvement in EF, 
improvement by 2 NYHA 
classes without an increase in 
diuretic use and no increase in 
wall thickness 
Kidneys 
24 hour non Bence Jones 
Proteinuria >0.5g, or uptake 
on SAP scintigraphy 
50% reduction in proteinuria (at 
least 0.5g/day) creatinine and 
creatinine clearance must not 
worsen by 25% over baseline  
Liver SAP scintigraphy 
50% decrease in abnormal ALP 
or reduced organ uptake on 
SAP scintigraphy 
Spleen SAP scintigraphy 
Reduced organ uptake on SAP 
scintigraphy 
Adrenal SAP scintigraphy 
Reduced organ uptake on SAP 
scintigraphy 
Soft Tissue 
Tongue hypertrophy, 
periorbital bruising, 
spontaneous bruising, 
pseudo hypertrophy, 
lymphadenopathy, carpal 
tunnel syndrome 
Clinical assessment of 
improvement  
Gastrointestinal 
Tract 
Direct biopsy verification with 
symptoms 
 
Lung 
Direct biopsy verification with 
symptoms, interstitial 
radiographic pattern 
Radiographic evidence of 
improvement in pulmonary 
interstitial amyloid (rare) 
Peripheral 
Neuropathy 
Symmetrical sensorimotor 
peripheral neuropathy in the 
lower limbs 
Clinical assessment 
Autonomic 
Neuropathy 
Impotence, diarrhoea or 
constipation, early satiety 
and/or impaired bladder 
emptying without other overt 
cause. Orthostatic 
hypotension (>20mmHg fall 
in systolic BP) 
Clinical Assessment 
mm – millimetres; CMR – cardiac MRI; g – grams; SAP – Serum Amyloid P; Hg – 
mercury; BP – blood pressure 
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Table 2.5: Consensus Haematologic Response in systemic light chain amyloidosis87 
Haematologic Response Criteria 
Complete Response (CR) 
 
Normal serum free light chain ratio with 
negative serum and urinary 
immunofixation 
Very good partial response (VGPR) The difference in the free light chains 
(dFLC) less than 40mg/L 
Partial Response (PR) A reduction in the dFLC greater than 
50% 
No response A less than 50% response in dFLC 
  
mg/L – milligrams per litre 
Statistical analysis 
Statistical analysis was performed using SPSS v20 (IBM SPSS) software. Kaplan 
Meier estimates were used to calculate the OS and PFS. P values <0.05 were 
considered statistically significant. Graph Pad Prism (Version 5) was also used. The 
statistical analysis is described in each methods/results section of each chapter. 
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Chapter Three:  Comparison of free light chain assays: FreeliteTM 
and N Latex in diagnosis, monitoring and predicting survival in 
light chain amyloidosis 
 
This chapter is written in context of my article: Comparison of free light chain 
assays: FreeliteTM and N Latex in diagnosis, monitoring and predicting survival 
in light chain amyloidosis. Shameem Mahmood, Nancy L Wassef, Simon J Salter, 
Sajitha Sachchithanantham, T Lane, D Foard, Carol J Whelan, Helen J Lachmann, 
Julian D Gilmore, Philip N Hawkins, Ashutosh D Wechalekar, American Journal of 
Clinical Pathology, 2016 Jul;146 (1):78-85 (Original article) copyright permission 
obtained from Oxford University Press, license no.:3917120648467 for use in my 
thesis. 
 
Introduction 
Systemic AL amyloidosis is a rare protein deposition disease.  The underlying 
pathological process driving AL amyloidosis is an underlying clonal proliferation of 
plasma cells producing an excess of unstable immunoglobulin light chains.  There is 
deposition of immunoglobulin light chains in tissues and organs leading to impairment 
of the structure and function of the latter.6, 182  Tracking and monitoring AL amyloidosis 
is a challenge as many patients have barely a detectable intact monoclonal 
immunoglobulin.  However, the discovery that serum free light chains could be 
measured in 2000 led to a development that revolutionised this rare disease.  The 
serum FreeliteTM assay measures immunoglobulin free light chains using polyclonal 
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sheep antibodies directed against hidden epitopes on the light chain molecule giving 
an accurate measurement of serum free kappa and lambda.  Our group initially 
reported the utility of this assay in 2002183 in this disease, with  many studies following 
since.  This assay now forms a standard part of the baseline and serial follow up 
assessments in systemic AL.161, 162  It is a part of the revised Mayo staging system and 
standard international consensus criteria for the disease response assessment.80, 86, 
87 
Polyclonal antibodies to light chain epitopes in the FreeliteTM assay continues to be 
prepared from specifically immunised sheep.  However, in any naturally occurring 
antibody mixture, standardisation remains complex and inter-assay variability is a 
certainly a possibility.  Efforts have been made to develop monoclonal antibodies to 
the hidden light chain epitopes that would recognise and replicate the success of the 
polyclonal assay and thus allow better inter-assay standardisation.  A group in the 
Netherlands working with Siemens, Germany, has developed this technology using a 
mixture to two kappa and two lambda monoclonal antibodies to the hidden epitopes 
of constant region of the immunoglobulin light chain molecules.163  The references 
ranges for both the new N-Latex assay and the polyclonal FreeliteTM assay are similar.  
With increasing adoption by laboratories of the novel assay, it is important to assess 
the utility of the new assay compared to the current reference standard polyclonal free 
light chain assay.  We report a comparison of serum free light chains measured by 
both immunoassays at diagnosis and three further time points in during the initial 
chemotherapy for patients with systemic AL amyloidosis.  
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Methods 
This study was conducted at the National Amyloidosis Centre, London, UK (NAC), 
with recruitment of consecutive patients with systemic AL amyloidosis seen at the NAC 
and under prospective follow up from January 2011 and April 2012 and undergoing 
chemotherapy for AL amyloidosis. Patients were included if they had a baseline serum 
sample at initial diagnosis and at least 3 of 4 blood samples available including from 
baseline 2, 4 and 6 month follow up point intervals following treatment with 
chemotherapy.  Diagnosis of amyloidosis was confirmed in all cases with a tissue 
biopsy showing the characteristic birefringence on Congo red staining. Typing of AL 
amyloidosis was confirmed by immunohistochemical staining with appropriate 
antibodies and exclusion of hereditary amyloidosis, where necessary, by genetic 
sequencing of the genes implicated. All patients underwent systematic review at 
presentation and detailed follow up assessments at 6 monthly intervals or dependant 
on clinical indication.  Assessment included clinical examination, detailed blood and 
urine analysis (including assessment of serum and urine monoclonal immunoglobulin 
and serum free light chains), serial 123I labelled serum amyloid P component (SAP) 
scintigraphy to assess whole body amyloid load, electrocardiogram (ECG) and an 
echocardiogram and routine observations including blood pressure, oxygen 
saturations and pulse.  Organ involvement was defined according to the standard 
international amyloidosis consensus criteria.(18)  Mayo disease stage was defined 
according to the criteria published by Dispenzieri et al and Kumar et al80, 184  
Serum samples were separated and stored at -80ºC.  All retrieved samples were 
tested in duplicate for measurement with FreeliteTM (The Binding site Ltd, Birmingham, 
UK) and N-Latex (Siemens Healthcare Diagnostics, Germany) according to the 
standard manufactures’ protocols on a BNTMII System nephelometer (Siemens, 
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Germany). Examination was undertaken to assess haematologic response on results 
of the free light chain (FLC) assays in available samples at the following points 
including 2 months; 90 FreeliteTM and 90 N Latex, 4 months; 91 FreeliteTM and 89 N 
Latex, 6 months; 61 FreeliteTM and 62 N Latex. The discrepancies in the number of 
available samples for analysis were secondary to the inadequate quantity of serum or 
error readings in the analysed sample, hence excluded for analysis. In total, serum 
free light chains were measured in a total of 240 serum samples in duplicate using 
both the FreeliteTM and N Latex assays.  
We performed a correlation analysis between the 2 FLC assays of results for kappa, 
lambda and kappa/lambda ratio. Haematologic response was assessed according to 
the international amyloidosis consensus criteria.86, 87  The same criteria were used to 
assess a patient as a responder or not by both assays; although we recognise that the 
criteria were developed with results obtained from the FreeliteTM assay. This study was 
not powered or focused to develop new response criteria for the N-latex assay. 
Statistical analysis was performed using SPSS software using a p value of less than 
0.05 considered to be significant. We stated median values with minimum and 
maximum ranges. We calculated the Pearson’s coefficient to evaluate the agreement 
and concordance between the both FLC assays, with use of scatter plots to illustrate 
this. Kaplan Meier curves were used to assess and describe the prognostic utility of 
both assays. 
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Results 
94 patients were identified from the National Amyloidosis database over this period of 
time.  The median age was 64 years (range 55.2 -72.2 years) at diagnosis and 48 
(51%) were male. Cardiac involvement was present in 43%; 23% Mayo stage 3.  The 
baseline patient characteristics and organ involvement features are described (table 
3.1).  Of the patients in this group, 74 (78.7%) had either a monoclonal protein 
detectable in the serum, urine by immunofixation or the presence of an abnormal free 
light chain ratio.  50(53.2%) of this group had a measurable monoclonal protein greater 
than or equal to 1g/L.  The revised Mayo disease stage incorporates the dFLC, using 
FLC measured by FreeliteTM/N-Latex assays are as follows: Stage 1: 20.2%/25.5%, 
Stage II: 47.9%/43.6%, Stage III: 29.8%/30.9%, and Stage IV 2.1%/0%, respectively 
The FLC in baseline samples showed an abnormal kappa in 41% and lambda in 63% 
by the FreeliteTM assay, and abnormal kappa in 32% and 67% by N Latex assay.  The 
kappa and lambda light chain: 17 (18%) and 75 (82%) respectively.  The FreeliteTM 
assay showed a median kappa of 17.3mg/L (range 0.3-1440), median lambda 
48.8mg/L (range 7.5-1430) with median difference in involved and uninvolved light 
chains (dFLC) of 43.2 mg/L (range 55-247.9).  The median abnormal kappa was 
34.75mg/L (range 0.3-1440) with abnormal lambda 93.85mg/L (range 27-1430).  The 
N latex assay had corresponding concentrations as follows: median kappa 16mg/L 
(range 2.35-770), median lambda 52.6mg/L (range 3.65-786) and median dFLC 39.1 
mg/L (range 58.3-247). The median abnormal kappa by the N-Latex assay was 28.1 
(range 2.35-770) with abnormal lambda 77.9 (3.7-786).  
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Table 3.1: Patient characteristics 
Patient Characteristics Number (range of percentage) 
Age 64 (range 55.2-72.2) 
Male 48 (51%) 
Kappa clone 17 (18%) 
Lambda clone 75 (82%) 
Serum paraprotein 50 (53.2%) 
Organ involvement 2 (range 1-3) 
Cardiac involvement 41 (43%) 
Renal involvement 72 (76%) 
Liver involvement 10 (10%) 
Peripheral neuropathy 13 (14%) 
Autonomic Neuropathy 8 (8%) 
Soft tissue 16 (17%) 
Cardiac Mayo Stage I 25 (26%) 
Mayo Stage II 43 (46%) 
Mayo Stage III 26 (28%) 
Clonal parameter Value (range) 
FreeliteTM Kappa (mg/L) 17.3 (0.3-1440) 
FreeliteTM Lambda (mg/L) 48.8 (7.5-1430) 
FreeliteTM dFLC (mg/L) 43.2 (55-247.9) 
N Latex Kappa (mg/L) 16 (2.35-770) 
N Latex Lambda (mg/L) 52.6 (3.65-786) 
N Latex dFLC (mg/L) 39.1 (58.3-247) 
mg/L – milligrams per litre; dFLC – difference between the involved and uninvolved 
free light chains; reference range for FreeliteTM assay – kappa 3.3-19.4mg/L, lambda 
5.7-26.3mg/L, kappa/lambda ratio 0.26-1.65; reference range for N-Latex assay – 
kappa 6.7-22.4mg/L; lambda 8.3-27mg/L; kappa/lambda ratio 0.31-1.56mg/L. 
 
There was not a significant difference in the absolute kappa and lambda values seen 
by either assay (kappa median 34.8 vs. 28.1 p = 0.64; lambda median 93.85 vs. 77.9; 
p = 0.41) (Fig 3.1A and B respectively). 
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Figure 3.1: Comparison of FreeliteTM and N Latex assays with respective kappa (A) 
and lambda (B) values. 
 
The concordance between the two assays was correlated by categorising the results 
into serum kappa, serum lambda and kappa: lambda ratio as abnormally high, normal 
and abnormally low as per the normal ranges by each manufacturer (Table 3.2).  
Table 3.2A: Kappa at presentation 
 
N Latex 
Kappa 
(mg/L) 
FreeliteTM kappa (mg/L) 
 <3.5 3.5-19.4 >19.4 
<6.7 7   
6.7-22.4  41  
>22.4   29 
Concordance 85.5% 
mg/L – milligrams per litre 
  
Freelite kappa N Latex kappa
0
20
40
60
2000
Baseline FLC Assays
k
a
p
p
a
 c
o
n
c
e
n
tr
a
ti
o
n
 (
m
g
/L
)
Freelite lambda N Latex lambda
0
20
40
60
1000
2000
Baseline FLC Assays
la
m
bd
a 
co
nc
en
tr
at
io
n 
(m
g/
L)
 CHAPTER THREE 
 
- 105 - 
Table 3.2B: Lambda at presentation 
 
N Latex 
Lambda 
(mg/L) 
FreeliteTM lambda (mg/L) 
 <5.7 5.7-26.3 >26.3 
<8.3 0   
8.3-27  17  
>27   51 
Concordance 75.5% 
mg/L – milligrams per litre 
 
Table 3.2C: Kappa/Lambda ratio at presentation 
 
N Latex 
ĸ/Ɩ ratio 
(mg/L) 
FreeliteTM ĸ/Ɩ ratio (mg/L) 
 <0.26 0.26-1.65 >1.65 
<0.31 32 37 18 
0.31-1.56 37 27  
>1.56 12  12 
Concordance 78.8% 
ĸ/Ɩ – kappa/lambda; mg/L – milligrams per litre 
 
The concordance for the serum kappa light chain was 85% with R2=0.91 and the 
Pearson correlation co-efficient r=0.804 (p = 0.0001).  The concordance for serum 
lambda was 75.5% with R2=0.52 and he Pearson correlation coefficient r=0.50 
(p=0.0001).  The concordance for the kappa/lambda ratio for the respective values 
78.8%, R2=0.87 and r=0.97 (p=0.0001) (Fig 3.2A, 3.2B and 3.2C respectively and 
Table 3.4). 
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Figure 3.2: Scatter plots of  N Latex and FreeliteTM free light chain assays for (A) 
kappa N Latex (n=91) and FreeliteTM (n=91) and (B) lambda N latex (n=90) and 
FreeliteTM (n=90) and (C) kappa/lambda ratio (n=90) illustrating the concordance of 
both free light chain assays. 
Figure 3.2A 
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Figure 3.2B 
 
Figure 3.2C 
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Table 3.3: Kappa/Lambda ratios at presentation 
 N Latex Ratio 
Normal Abnormal Total 
FreeliteTM 
Ratio 
Normal 27 11 38 
Abnormal 10 42 52 
Total 37 53 90 
 
Table 3.4: Concordance analysis for kappa (A), lambda (B) and kappa/lambda ratio 
(C) for the 2 FLC assays 
Group Number  N Latex FLC 
(mg/L) 
FreeliteTM FLC 
(mg/L) 
Pearson’s  
correlation 
FLC ĸ 90 16.1 (2.35-770) 17.3 (0.3-1440) 0.804 
FLC Ɩ 90 52.6 (3.65-786) 48.8 (7.5-1430) 0.493 
ĸ/Ɩ ratio 90 0.68 (0.01-
63.56) 
0.88 (0.0002-224.7) 0.97 
FLC – Free light chain; mg/L – milligrams per litre; ĸ – kappa; Ɩ – lambda 
 
There were discordant kappa/lambda ratios at presentation: 10/90 abnormal by 
FreeliteTM but normal by N Latex assay, and 11/90 abnormal by N Latex and normal 
by FreeliteTM (Table 3.3). 10 patients had an abnormal ĸ/Ɩ ratio by FreeliteTM assay 
(normal by N Latex assay): positive IFE by both urine and serum (n=4), positive IFE 
only by serum (n=2) and positive IFE only by urine (n=3), negative IFE by urine and 
serum (n=1). There were 11 patients with an abnormal ĸ/Ɩ ratio by N Latex assay 
(normal by FreeliteTM assay): with positive IFE by both urine and serum (n=3), positive 
IFE by only serum (n=3), positive IFE by only serum (n=4) and negative IFE by urine 
and serum (n=1). 
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The diagnostic sensitivity (true positive) and specificity (true negative) with agreement 
of the ĸ/Ɩ ratios of the FreeliteTM and N Latex assays were calculated and recorded 
(Table 3.5 and Table 3.6). 
Table 3.5: Clinical sensitivity and specificity of the FreeliteTM assay and 
immunofixation electrophoresis (IFE) 
                                                         IFE (serum and urine) 
FreeliteTM 
ĸ/Ɩ ratio 
Positive Negative Total 
Abnormal 44 7 51 
Normal 37 2 39 
Total 81 9 90 
Sensitivity 54.3%, Specificity 86.2% 
Table 3.6: Clinical sensitivity and specificity of the N Latex assay and 
immunofixation electrophoresis (IFE) 
                                                         IFE (serum and urine) 
N Latex 
ĸ/Ɩ ratio 
Positive Negative Total 
Abnormal 46 7 53 
Normal 35 2 37 
Total 81 9 90 
Sensitivity 56.7%, Specificity 86.8% 
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We evaluated the clinical impact of the differences in assessing haematologic 
response according to the revised Consensus criteria87 of those with measurable 
dFLC at 2, 4 and 6 months post chemotherapy treatment with serum samples available 
at these time points. The number of patients with samples available: at 2 months - 90 
FreeliteTM and 90 N Latex, at 4 months - 91 FreeliteTM and 89 N Latex, at 6 months - 
61 FreeliteTM and 62 N Latex.  At baseline 54 (60%) and 51 (56.7%) had a dFLC >50 
mg/L (minimum defined to assess the free light chain response). Correlating 
responses of FreeliteTM and N Latex assays respectively, at 2 months, a complete 
response (CR) was achieved in 23% and 32%, partial response (PR) in 17% and 14% 
and no response (NR) in 57% and 49% of the evaluable patients.  There was a subtle 
discrepancy in the proportion classed responders at each time point as depicted in fig 
3.3A and 3.3B.  Assessing a final response assessment at six months, 11.5%, 4.9% 
and 0% were discordantly classed PR, VGPR and CR.  At 2 months, an abnormal 
kappa/lambda ratio was present in 45.6% by FreeliteTM and 46.7% by the N Latex 
assays. Monitoring of the kappa/lambda ratio by both assays produced similar results, 
with subtle differences at 4 months, with 34.4% and 38.2% of patients with available 
serum samples having an abnormal kappa/lambda ratio by FreeliteTM and N Latex 
assays. At 6 months, 30% and 36.1% of patients had abnormal kappa/lambda ratios 
by FreeliteTM and N Latex assays respectively (figure 3.3).There was an “excess” of 
patients classed a partial, VGPR or complete response at the following 2 months 
(21%), 4 months (10.1%) and 6 months (6.5%)  by N-Latex assay relative to the 
FreeliteTM assay. This was calculated by adding the total number of patients achieving 
greater than a PR response by the N Latex assay and subtracting those equivalent 
responders by the FreeliteTM assay. This calculated number was then divided by the 
N-Latex total at that time point giving an overall percentage.  
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Figure 3.3A and 3.3B: Difference in involved and uninvolved free light chain (dFLC) 
response in patients with evaluable disease. (A) Percentage of evaluable patients 
assessed at 2, 4 and 6 months according to haematologic response including no 
response (NR), partial response (PR), very good partial response (VGPR) and 
complete response (CR) with (B) illustrated the differences of the abnormal 
kappa/lambda ratio at set intervals between the FreeliteTM and N Latex assay. 
Figure 3.3A 
 
 
  
0
10
20
30
40
50
60
70
2 4 6 2 4 6 2 4 6
Freelite
N Latex
Time post commencing treatment (months)
NR
PR
VGPR/CR
%
 o
f 
p
a
ti
e
n
ts
 CHAPTER THREE 
 
- 112 - 
Figure 3.3B 
 
The estimated overall survival (OS) for the 94 patients was 24.1 months with a median 
follow-up of 8.6 months. Given the differences in the proportion of patients classed as 
achieving partial response by both assays at 4 months, we evaluated the overall 
survival of patients achieving a partial response or greater at 4 months by both assays.  
There was a significant improvement in the overall survival for patients classified as 
achieving a partial response or better at 4 months by each assay.  The median OS 
was not reached in either assay.  The survival benefit for those achieving a PR or 
better by the FreeliteTM at 4 months was HR 7.84, 95% CI (0.94-65.57), log rank p = 
0.03 and by the N-Latex assay HR 95.47, 95% CI (0.11-79601), log rank p = 0.004. 
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Discussion 
We report here a comparative utility of using two different assays (one using polyclonal 
anti-light chain antibodies and other using a combination of monoclonal anti-light chain 
antibodies) for detection of and serial monitoring of serum free light chains in patients 
with systemic AL amyloidosis undergoing chemotherapy.  This study finds the two 
assays are broadly comparable for detection of abnormal light chains in the serum 
with a greater concordance for detection of kappa than for lambda immunoglobulin 
free light chain.  However, there were discrepancies present with the numbers 
abnormal, the absolute light chain value and time point to reach thresholds for 
haematological responses and also impact on survival. 
 
The FreeliteTM assay was the only assay available for measurement of serum free light 
chains until development of the N-Latex assay.  This is a new and welcome 
development to allow for a different method to study these complex molecules, but 
standardisation is needed between the two assays.  Both these assays have been 
studied in myeloma as well as normal controls to assess imprecision, underestimation; 
antigen excess or non-linear reactivity and overestimation; polymeric forms reacting 
at multiple antigenic FLC sites of results.185-187  Our study did not focus on the 
biochemical or technical aspects of either assay, but designed to assess the clinical 
utility of each assay in a routine clinical setting in systemic where the serum free light 
chains are typically abnormal, but low and where FLC measurements forms the 
cornerstone of patient assessment and monitoring.  Previous studies in patients with 
a monoclonal gammopathy, have the kappa showing the best correlation between 
both FLC assays, followed by kappa/lambda ratios then lambda, with the Pearson 
coefficients 0.97, 0.83 and 0.91 respectively.188 Pretorius et al compared the utility of 
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both the FreeliteTM and N Latex assays in 116 samples showing large variations 
between both assays, precluding the interchange of these results, with statistically 
significant non-linearity occurring in approximately half of the monoclonal and 
polyclonal samples (kappa and lambda) for both assays.189 The precision of the two 
assays were further examined in two other studies, showing comparable levels190 and 
reproducibility.191 
The current study confirms that in systemic AL amyloidosis, there is generally excellent 
concordance between both the assays in detecting an excess of serum free light 
chains with better concordance of kappa than lambda as previously reported.  The 
overall concordance in our study showed kappa, lambda and kappa/lambda ratios as 
85.5%, 75.5% and 78.8% respectively - similar to one study 70-80% 188 but lower than 
in another study with the concordance quoted as approximately 90%.163  The 
diagnostic sensitivity with respect to the serum and urine IFE results was lower than 
expected by both assays, 54.3% and 56.7% by FreeliteTM and N Latex assays 
respectively. Some patients had lower serum free light chain values at diagnosis, with 
the presence of serum and/or urine IFE, clinical symptoms and diagnostic biopsy 
needed to prove the diagnosis in these cases. The serum free light chains are often 
lower than in Myeloma patients. A concerning result was that ~10% cases with each 
assay detected an abnormal FLC ratio that was not detected by the other assay. The 
underlying reason for this discordance is difficult to fully explain or ascertain, given the 
details of antibodies used to detect the free light chains in both assays are 
commercially confidential. Given the nature of the monoclonal disease underlying AL 
amyloidosis, the mutational signature of the plasma cell DNA in each AL light chain is 
unique. A likely explanation is the antibodies in each assay do not recognise the 
epitopes on the respective light chains and hence there is a false negative signal.  The 
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Mayo clinic group, has recently demonstrated that such samples also contain a 
monoclonal light chain using mass spectrometry. Hence suggesting that currently 
neither method is perfect for detection of all abnormal monoclonal free light chains but 
as different patients “detected” or “missed” by either assay, there may be role for 
repeating the FLC measurement by the other assay if an abnormality is not detected 
in a patient with one assay.  This may assist at least partly, overcome the problem in 
AL amyloidosis of lack of evaluable light chains in a certain proportion of all patients.183  
We compared the ĸ/Ɩ ratios and the IFE results showing that both assays had similar 
sensitivities (54.3% and 56.7%) and specificities (86.2% and 86.8%) for FreeliteTM and 
N Latex assays respectively. 
This is the largest study to examine serial parallel sample assessment to assess the 
serum free light chain responses by both assays simultaneously. Although there is 
broad agreement in the response assessment as a percentage of total patients with 
both assays, important differences are present in a proportion of patients who reach 
the currently threshold used to define a partial or very good partial response.  Eighteen 
patients reached a PR and VGPR earlier by the N-Latex assay compared to the same 
class of response by the FreeliteTM assay.  This is concerning, but in a way not that 
unexpected.  The assays have very different antibodies which measure the free light 
chain in the serum and hence the actual slopes of the standard curves are not exactly 
identical.  Hence, it is expected that the rate of change will be different.  The response 
criteria in AL amyloidosis have been derived using ROC analysis based on survival of 
patients using various light chain thresholds attained by the FreeliteTM assay.  Thus 
the current thresholds are clinical and are not biochemical end points.  Assessing the 
results, it appears that the N-Latex assay classified patients as responders at an 
earlier time point than the FreeliteTM assay, designing a study to examine a clinically 
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relevant threshold for defining a response with N-latex is important.  Similarly 
prognostic important thresholds of FLC in AL (dFLC >180 mg/L) may not necessary 
be the same and will need re-defining for this new era.  In this study, 3 patients were 
misclassified as advanced stage III-IV by the revised classification using the different 
assays.  
It is encouraging that the classification of a patient as a haematological responder 
(partial response or greater) translates into a survival benefit.  However, earlier 
classification of a greater proportion of patients as responders by the N-Latex assay 
has risks, as treatment duration in amyloidosis is often shorter than in myeloma with 
a lower threshold to stop treatment earlier in the responders particularly if there are 
problems with tolerance to treatment.  Unless thresholds are redefined, patients may 
be classified as responders by the N-Latex assay may get undertreated and hence 
carry a risk of shorter time to disease progression.   
This current study needs to be interpreted cautiously in the context of certain 
limitations.  The numbers are still small and all patients did not have serial samples 
available.  Although the patients recruited in this study are serial AL patients seen at 
the NAC, there is a selection bias as all patients were required to have serial samples 
for six months, with only six month survivors are recruited thereby excluding a 
substantial number of patients with stage III cardiac AL amyloidosis where there is still 
30-40% mortality in the first six months.192  A study of truly unselected serial patients 
is needed to assess the true correlation of the utility of both these assays.  There was 
higher than expected proportion of patients with non-evaluable light chains, possibly 
due to selection of the survivors who are typically patients with early stage disease 
and serum free light chain burden.   
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In summary, both FreeliteTM and N Latex assays are able to detect the abnormal FLC 
in patients with systemic light chain amyloidosis. Although there is an excellent 
correlation between these assays for detecting the abnormal light chain subtype the 
discordance in the absolute values renders cross assay interpolation impossible.  
Furthermore, each FLC assay appears to have limitations, in missing random yet 
different patients suggesting a further need by both manufacturers to optimise the anti-
light chain antibodies underpinning the respective assays.  Studies using clinical end 
points are important to harmonise the response assessment criteria for each assay so 
that even though the values may not be comparable, the response categorisation is 
comparable.  This is crucially important, given the emergence of the newer assay 
becoming more widely adopted and possibly raising problems in the interpretation of 
clinical and trial results.  Designing future clinical trials in AL amyloidosis incorporating 
FLC measurement by both assays would be ideal to aid in our understanding and 
harmonisation of the field. 
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Chapter Four:  Bleeding diathesis, thrombotic tendencies and 
endothelial dysfunction in amyloidosis patients 
 
This chapter is written with reference to the publication: Utility of factor X 
concentrate for the treatment of acquired factor X deficiency in systemic light-chain 
amyloidosis. Shameem Mahmood, Julie Blundell, Anja Drebes, Philip N. Hawkins and 
Ashutosh D. Wechalekar. Blood. 2014; 123(18):2899-900 (Original article). 
 
Introduction 
Systemic light chain (AL) amyloidosis is the most common systemic amyloidosis. 
Typically the clonal proliferation of a plasma cell clone that consequently results in the 
synthesis of an excess of light chains and toxic intermediates with specific structural 
and mechanical effects resulting in systemic fibril toxicity.193, 194 These fibrils deposit 
in different organs leading to progressive changes in the affected organ’s architecture 
and function.6 Severity of this disease depends on the number of organs involved and 
extent of amyloid deposits, with AL cardiomyopathy carrying a poor prognosis with 
death arising as a consequence secondary to progressive heart failure, contractility 
dysfunction, sudden death and associated arrhythmias or refractory untreatable 
disease.195, 196 Some studies have explored the AL-light chain cardiotoxicity as an 
important causal determinant in this disease.197, 198 Migrino et al demonstrated that AL 
light chains cause microvascular dysfunction leading to apoptotic and necrotic insults 
and related oxidative stress,199, 200 with other studies showing endothelial dysfunction 
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in small and medium sized vessels, which ultimately may contribute to this 
cardiotoxicity.201, 202 
Endothelial dysfunction occurs with reduced bioavailability of vasodilators, especially 
nitric oxide (NO) and consequent impairment of the endothelium and increased 
endothelium contracting factors and pro-inflammatory state203 As such, it is associated 
with coronary artery disease, hypertension, diabetes mellitus, chronic renal failure and 
thought to represent a vital early trigger in the event of atherosclerosis204, 205 with a 
complex interplay of low NO levels, increased oxidative stress and consequent 
changes in the V-CAM, I-CAM and e-selectin adhesion molecules in this inflammatory 
process205, 206 Of several methods used to assess the endothelium, plasma proteins 
such as vWF have been examined extensively in cardiovascular disease and 
atherosclerosis207-210 and used as a surrogate marker of endothelial dysfunction. 
Numerous clinical and experimental reports imply that high vWF levels reflect 
endothelium damage.211  
Von Willebrand factor is a large glycoprotein synthesised by the vascular endothelial 
cells through the luminal and abluminal membranes212 and megakaryocytes. 
Secretion via the abluminal membrane results in some deposition within the vascular 
subendothelium to bridge with circulating platelets212 and forms a non-covalent tightly 
bound complex with factor VIII. Hence circulating levels of factor VIII are closely linked 
to circulating levels of vWF, typically 1 molecule of FVIII to 50-100 vWF subunits.213 
Von Willebrand factor has a dual role in haemostasis: promoting platelet adhesion to 
thrombogenic surfaces and ensuring platelet-platelet cohesion during thrombus 
formation, and acting as a carrier for FVIII; important in its production, stabilisation, 
conformation and immunogenicity.214 Factor VIII serves a role in the intrinsic 
coagulation pathway as a co-factor to accelerate the activation of factor X by factor 
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IXa in the presence of calcium ions on a phospholipid surface.215 Thus the impact of 
this intricate complex and its equilibrium may give us insight into the endothelial 
dysfunction of this disease, but also possible thrombogenic and survival risk factors.  
 
Systemic light chain (AL) amyloidosis is also known to be associated with a bleeding 
diathesis,164 which may range from small cutaneous bruising, pathgnomic “racoon 
eyes” to life threatening bleeds. There are a multitude of underlying factors which may 
be responsible for the coagulation abnormalities in this disease including: factor 
deficiencies and prothrombotic factors, vessel fragility, amyloid load, amyloid fibrils 
and light chain burden216-218. Factor X deficiency has been extensively described in 
the literature with an incidence of 6.3-14% in systemic AL patients164, 218. There is 
limited data as to the clinical bleeding manifestations and the underlying coagulation 
factors which may contribute to this environment. 
 
This prospective study was designed to investigate the haemostasis and endothelial 
dysfunction in newly diagnosed systemic light chain (AL) amyloidosis patients, with 
further exploration of light chain toxicity in this disease. This was performed examining 
the clinical bleeding manifestations using the Royal Free Hospital v4 adapted bleeding 
questionnaire in conjunction with extensive laboratory investigations such as factor 
assays, protein S, protein C, Anti-thrombin III, vWF:Ag and VWF:Ricof and 
ADAMTS13 assays. Endothelial function was explored using vWF antigen (AG) and 
factor VIII to serve as a surrogate marker and examine its relationship with light chain 
toxicity. The secondary aim was to assess the prognostic utility of these investigations.  
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Materials and methods 
Patients 
The study included 100 patients referred to the National Amyloidosis Centre with 
probable newly diagnosed AL amyloidosis between May and December 2013. 
Eligibility was open to all patients, with no exclusions according to age, performance 
status, co-morbidities and naive to previous treatments No patient had a previous 
history of an inherited factor deficiency or thrombotic trait. Eight patients were taking 
warfarin and no patients were taking the newer anticoagulant agents. 
 
Each patient had a detailed baseline assessment of organ function with investigations 
including a full blood count, renal and liver function tests, serum protein 
electrophoresis, serum free light chains, and urinary BJP, electrocardiogram and 
echocardiography and 123I-labelled Serum Amyloid P (SAP) scintigraphy for visceral 
amyloid deposition quantification. Each patient completed a Royal Free Hospital 
bleeding questionnaire v4 (appendix 1). Additional blood samples were taken for 
investigating bleeding and thrombotic tendencies in these patients. The diagnosis of 
amyloidosis was confirmed on histology by Congo red staining and AL type confirmed 
by specific immunostaining of amyloidotic tissue by antibodies to kappa or lambda light 
chains and exclusion of hereditary amyloidosis by gene sequencing, and 99mTc-
dicarboxypropane diphosphonate (99mTc-DPD) scintigraphy for hereditary and non-
hereditary transthyretin based disease. Written consent for retrospective publication 
of data was obtained from all patients in accordance with the Declaration of Helsinki.  
Organ involvement was classified according to the updated international amyloidosis 
consensus criteria.87 
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Haemostasis investigations 
16mL of venous blood was drawn from the ante-cubital fossa vein with minimal use of 
the tourniquet, into 0.106M tri-sodium citrate blood collection tubes [Becton & 
Dickerson, Poole, United Kingdom (UK)].   All samples were centrifuged at 2000g for 
12 minutes, separated into another container then centrifuged again for 12 minutes at 
2000g. The platelet poor plasma (PPP) was removed, aliquoted and then stored at -
45C until testing.   Unless otherwise stated all assays were carried out using an ACL 
TOP™ coagulometer [Instrumentation Laboratory (IL), Bedford, USA].  The following 
investigations were made using each patient’s frozen PPP aliquots:  Prothrombin time 
(PT) using HemosIL™ Recombiplastin 2G, activated partial thromboplastin time 
(APTT) using HemosIL™ SynthAsIL reagent [IL, USA), and to measure Clauss 
fibrinogen levels using HemosIL™ QFA thrombin reagent [IL, USA].  Thrombin times 
(TT) were measured using 3 unit/mL bovine thrombin [Diagnostic Reagents Ltd, 
Thame, UK] titrated to have a normal plasma control time of 14 seconds (s). Reptilase 
times (RT) were measured using Reptilase® reagent (Pentpharm, Aesch, 
Switzerland) also titrated so the normal plasma control had a clotting time of 14s.  The 
measurement of extrinsic clotting factors II, V, VII, and X was by one stage PT based 
clotting assays and intrinsic clotting factors VIII, IX, XI and XII by one stage APTT 
based clotting assays.  All patient clotting factor levels were measured against a 
laboratory standard with known levels of each clotting factor and reported in IU/dL.  
Von Willebrand factor antigen (VWF:Ag), antithombin activity (AT:Act), Protein C 
activity (PC:Act), free Protein S (PS:Free) and activated PC ratios (APC ratio) were 
measured using methods as previously reported.219 The measurement of the VWF 
cleaving protease a disintegrin-like and metalloprotease with thrombospondin type 1 
repeats – ADAMTS 13 - activity was by using the Technozym™ ADAMTS 13 activity 
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assay [Technoclone GmbH, Vienna, Austria] according to the manufacturer’s 
instructions.  
 
Statistical analysis 
The primary end point was to evaluate the prognostic utility of vWF Ag and FVIII in AL 
patients. The median values and ranges are stated as minimum and maximum values. 
Differences in group characteristics were compared (continuous variables) with use of 
non-parametric t-test analysis with the Man Whitney test or the one way anova with 
Post Turkey analysis for comparison of more than one group using Graph pad prism 
5 software. Correlation analysis of coagulation factors was performed using 
scatterplots and the Pearson correlation coefficient determined. ROC curve analysis 
using SPSS v20 software was used to obtain an appropriate threshold for FVIII and 
vWF:Ag levels for survival statistics. Overall survival (OS) was calculated from 
diagnosis until death or last follow-up. Survival endpoints were examined to assess 
the prognostic utility of the haemostasis investigations. Kaplan Meier estimates were 
used using SPSS v20 (IBM SPSS) to calculate the OS and PFS. All p values are 2 
sided, with significance values based on a p <0.05. 
Results 
Patient characteristics 
Table 4.1 presents the baseline characteristics of all patient groups. There were 55 
females and 45 males, with the median age 60.74 years (range 34-87.6). Patients 
were then subdivided according to their diagnosis: 74 with systemic AL, 9 with no 
evidence of amyloid but underlying multiple myeloma, 11 with other types of 
amyloidosis; including transthyretin based disease (ATTR) and localised amyloid, and 
6 with no evidence of amyloid. Examining patients with systemic AL: the median age 
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was 64.7 years (30.9-85.6), and 39.2% were male. 60.8% had lambda light chain 
predominance, with the median dFLC 143.3mg/L. Cardiac involvement was present in 
43.2% with Mayo stage 3 in 29 patients, and greater than 3 organs involved in 15 
patients. 
 
Table 4.1: Patient characteristics 
Patient 
characteristics 
Systemic AL 
amyloidosis 
Localised and 
ATTR amyloid 
Multiple 
Myeloma 
No evidence 
of amyloid 
Number 74 11 9 6 
Male/Female 29/45 8/3 4/5 4/2 
Age 64.7 (30.9-85.6) 74.1 (41.3-86.2) 40.3 (34-49.5) 49.6(45.7-76.5) 
Light chain type     
Kappa 30 NA 3 NA 
Lambda 45 NA 6 NA 
dFLC (mg/L) 54.5 (1.8-3182) 2.1 (0.5-12.4) 523 (8.9-8287) 1.8 (0.6-36) 
Organ involvement     
Heart 32 (43.2%)    
Kidney 53 (71.6%)    
Liver 12 (16.2%)    
PNS 9 (12.1%)    
ANS 9 (12.1%)    
Soft tissue 14 18.9%)    
Mayo stage 1 12 (17.6%)    
Mayo stage 2 34 (41.9%)    
Mayo stage 3 29 (40.5%)    
Number of organs 
involved 
    
1 organ 26 (40.5%)    
2 organs 28 (37.8%)    
≥ 3 organs 15 (21.6%)    
NT-proBNP ng/L 14047 (51-147634) 3645 (25-12956) 178 (33-2012) 736 (135-8067) 
Creatinine (µmol/L) 106 (41-1201) 134 (74-232) 83 (57-738) 88 (64-95) 
eGFR (mls/min) 53 (7-100) 47 (18-100) 61 (10-100) 83 (54-100) 
Albumin (g/L) 34 (16-49) 43 (33-47) 42 (25-50) 48 (34-51) 
Proteinuria 
(g/24hours) 
3.45 (0.1-19.6) 0.2 (0.1-6.3) 1.3 (0.1-10.2) 0.1 (0.1-0.2) 
CRP (mg/L) 3 (1-49) 3 (1-8) 2 (1-73) 2.5 (1-4) 
PT (sec) 11.2 (9.2-28.5) 11.9 (9.6-24.9) 10.7 (10-12.3) 11.4 (10.2-17.9) 
APTT (sec) 29.9 (22.6-43) 30.9 (26.6-37.7) 27.8 (23.4-29.4) 28.9 (28.2-32.6) 
Fibrinogen (g/L) 4.4 (1.6-9.4) 3.5 (2.3-5.8) 3.5 (2.5-7.7) 3.2 (2.4-3.6) 
vWF Ag (IU/dL) 288.5 (89-908) 240 (104-472) 260 (117-732) 130 (81-185) 
FVIII (IU/dL) 260 (56-630) 208 (136-272) 226 (176-348) 137 (102-214) 
FX (IU/dL) 92 (10-146) 78 (14-126) 122 (92-134) 100 (28-142) 
Prot S (IU/dL) 87 (10-216) 87 (52-146) 81 (61-94) 91 (65-189) 
Prot C (IU/dL) 133 (53-243) 126 (43-202) 131 (101-176) 114.5 (78-182) 
ATIII (IU/dL) 98 (54-128) 97 (86-113) 107 (88-118) 107.5 (85-136) 
AL – light chain; dFLC – difference between involved and uninvolved free light chains; mg/L – 
milligrams; per litre; PNS – peripheral nervous system; ANS – autonomic nervous system; NT-proBNP- 
N terminal serum brain natriuretic peptide; ng/L – nanograms per litre; µmol/L – micromoles per litre; 
mls/min – millilitres per litre; g/L – grams per litre; g – grams; mg/L – milligrams per litre; sec – seconds;  
PT – prothrombin time; APTT – activated partial thromboplastin time; FVIII – factor 8;  
vWF Ag – von Willebrand antigen; IU/dL – international units per decilitre  
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Clinical bleeding questionnaire 
The clinical bleeding manifestations of all patients were assessed using the validated 
bleeding questionnaire used in vWF type I disease. Amendments to this questionnaire 
included denoting the duration of bleeding symptoms and the type of anticoagulation 
if received. The bleeding questionnaire reported a bleeding score in 24/100 patients 
(including 1 with multiple myeloma and one with localised gastrointestinal 
amyloidosis), with a median bleeding score range 0-8 and median symptom duration 
of 4 months (range 0.5-36). In comparison to other bleeding disorders, a bleeding 
score greater than 4 was present in only 4 (5.4%) patients and bleeding score of 1 
was present in 13 (17.6%) patients. The sites of bleeding included cutaneous (n=17), 
oral (n=7), epistaxis (n=5), haemarthrosis (n=1), muscle haematoma (n=1) and 
following surgery (n=2). 
 
Coagulation abnormalities 
Prolongation of the PT, APTT and TT occurred in 13 (17.6%), 13 (17.6%) and 35 
(47.3%) patients respectively. Prolongation of both the PT and APTT occurred in 13 
(17.6%) patients, of which 8 were on warfarin. Thirty one patients had a reptilase time 
(RT) performed, and was prolonged in 25 (33.8%) patients. An elevated fibrinogen 
was present in 42 (56.8%) patients. 
 
Factor deficiencies 
All patients had analysis of all factors including FII, FV, FVII, FVIII, FIX, FX, FXI, FXII 
performed with a low FII in 5 patients, low FVII in 3 patients, low FVIII in 1 patient, low 
FX in 8, low FIX in 3 patients and low FXII in 1 patient. The subnormal levels in FII (5), 
FVII (2), FIX (3), and FX (6) corresponded with patients with concomitant warfarin use. 
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Interestingly, elevated levels in FII, FV, FVII, FVIII, FIX, FXI, FXII occurred in 1 (1.4%), 
42 (57.5%), 5 (6.8%), 67 (90.5%), 20 (27%), 8 (10.8%), 2 (2.7%) patients respectively. 
An elevated FVIII was a remarkable new finding, and we compared the FVIII levels in 
the different patients recruited to this study. Figure 4.1A shows a significantly higher 
FVIII in comparison to patients with no evidence of amyloid and a higher trend relative 
to other patient groups.   
 
Von Willebrand factor levels, protein S, C and Anti-thrombin results 
Von Willebrand collagen binding factor (vWF:CB) and von Willebrand factor antigen 
(vWF:Ag) were assessed, with elevated levels in 58/74 (78.3%) and 67/74 (90.5%) 
patients respectively. We compared the different groups recruited into this study for 
comparison of this surprising elevated VWF:Ag result. Figure 4.1B shows that patients 
with systemic AL had a higher median vWF:Ag value relative to patients diagnosed 
other types of amyloid (non-systemic AL), multiple myeloma and patients with no 
evidence of amyloid. There was a significant difference with patients diagnosed with 
systemic AL and patients with no evidence of amyloid. Plasma vWF:Ag showed a 
significant positive correlation with FVIII (r=0.742, p=0.0001), with the thrombin time 
(r=0.634, p=0.0001), and fibrinogen values (r=0.366, r=0.002) and negatively 
correlated with Anti-thrombin levels (r=-0.264, p=0.025) and non-significantly 
correlated with the other variables. Protein S, C and Anti-thrombin assays were 
undertaken in these patients, with low levels in 2, 0 and 6 patients respectively, 
excluding abnormal results on patients taking warfarin. Elevated protein S, C and anti-
thrombin levels were seen in 8, 24 and 6 patients respectively.  
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Figure 4.1A and 1B: Scatter plots comparing FVIII and vWF:Ag levels in all patient 
groups respectively 
 
 
 
ADAMTS13 assays 
Plasma ADAMTS13 activity was determined using the Technozym ADAMTS-13 direct 
assay, with 18 patients having an elevated ADAMTS13 value, and no patients had 
reduced levels.  
 
Anti-thrombin levels and nephrotic syndrome 
Nephrotic syndrome (24 hour proteinuria assessment greater than 3g during this 
period) was present in 39/74 (52.7%) patients, with a range of albumin levels of 16-
36g/L. An albumin less than or equal to 25g/L was present in 16 patients. A low anti-
thrombin activity was present in 9 patients, with the patient characteristics illustrated 
in table 4.2.  
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Table 4.2: Low anti-thrombin levels and nephrotic syndrome 
Patient Albumin Proteinuria SAP 
organs 
SAP load dFLC Protein C ATIII 
1 20 13.9 L,S,K,B large 126 183 81 
2 37 3.0 N/A N/A 1070 109 72 
3 18 5.8 K small 112 68 75 
4 16 19.6 L,S,K moderate 27 169 62 
5 16 13.7 L,S,K moderate 274 155 55 
6 49 0.15 L,S moderate 25 136 77 
7 38 1.25 L,S large 1160 78 77 
8 22 1.42 L,S,K,B large 76 146 78 
9 28 2.00 S,B moderate 32 90 54 
L – liver; S – spleen; K – kidney; B –bones; N/A – not applicable; SAP – Serum Amyloid 
P; dFLC – difference in the involved and uninvolved free light chains; ATIII – anti-
thrombin III. 
 
We performed non-parametric t-tests in all the coagulation factors to assess any 
significant difference of having a threshold albumin less than or more than or equal to 
25g/L, figure 4.1C. An albumin less than 25g/L correlated with a statistically significant 
rise in vWF:Ag, FVIII, FV and fibrinogen, with a fall in protein S and anti-thrombin III.  
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Figure 4.1C: Significant coagulation factors dependant on the albumin less than 25g/L 
in comparison to greater than or equal to 25g/L 
 
 
Prognostic utility of haemostasis investigations 
The median overall survival (OS) for the systemic AL cohort was 26.7 months, with 1-
year and 2-year OS estimates 74% and 64% respectively, and 26 deaths. Univariate 
analysis showed cardiac involvement, NT proBNP, a dFLC greater than 180mg/L, 
FVIII and vWF:Ag thresholds greater than 280IU/dL, ADAMTS13 levels were 
statistically significant, table 4.3.  
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Table 4.3: Variables associated with survival 
Variable HR (95% CI) p 
Univariate Analysis 
Heart involvement 3.02 (1.33-6.86) 0.008 
Log NT-proBNP 2.69 (1.54-4.70) 0.000 
Mayo stage 3 2.37 (1.24-4.50) 0.009 
FVIII>280IU/dL 2.77 (1.24-6.19) 0.013 
vWF:Ag>280IU/dL  2.44 (1.02-5.84) 0.046 
ADAMTS13 0.98 (0.967-0.993) 0.003 
Protein C 0.991 (0.981-1.002) 0.097 
Anti-thrombin III 0.969 (0.945-0.993) 0.011 
dFLC ≥180mg/L 3.85 (1.60-9.24) 0.003 
Multivariate analysis 
Log NT-proBNP 2.48 (1.35-4.53) 0.003 
FVIII>280 IU/dL 2.53 (1.12-5.74) 0.026 
dFLC>180mg/L 3.44 (1.41-8.39) 0.007 
FVIII – factor 8; vWF:Ag – von Willebrand antigen; dFLC – difference between involved and 
uninvolved free light chains; mmol/L – millimoles per litre; mg/L – milligrams per litre; IU/dL – 
international units per decilitre  
 
In the current study, FVIII and vWF Ag levels greater than 280IU/dL significantly 
negatively impacted survival with 2-year OS 51% (p=0.01) and 43% (p=0.039) 
respectively, (figure 4.2A and 4.2B). A Kaplan Meier estimate shows that a dFLC 
greater than 180mg/L also negatively impacted survival, p=0.001(figure 4.2C). This 
analysis showed FVIII> 280IU/dL, log NT-proBNP and a dFLC>180mg/L remained 
significant, with vWF Ag non-significantly linked with survival.  
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Figure 4.2A and 4.2B: Overall survival stratified according to vWF:Ag and 
FVIII>280IU/L respectively 
 
Figure 4.2A 
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Figure 4.2B 
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Figure 4.2C: Overall survival stratified according to a dFLC >180mg/L 
 
 
Bleeding symptoms and association with other variables 
We examined the association of bleeding symptoms by amyloid load by 123I SAP 
scintigraphy. Analysis by scatter plots showed that those patients with bleeding 
symptoms had a non-significant higher median amyloid load by 123I SAP scintigraphy 
in comparison to those not describing any bleeding symptoms, figure 4.3. 
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Figure 4.3: A larger amyloid load by 123I SAP scintigraphy showing a trend to greater 
bleeding symptoms (Mann Whitney t-test, p=0.076) 
 
 
VWF:Ag and FVIII levels post chemotherapy 
Patients re-attending for their follow up visit 6-12 months (n=22) following 
chemotherapy had blood samples taken for vWF:Ag, FVIII and fibrinogen analysis. It 
was not feasible to arrange follow up blood samples in 26 patients due to their 
appointment arrangements with us in the time frame of this study and 26 patients died. 
19 patients exhibited a fall in the vWF:Ag, (figure 4.4A) with a median pre and post 
chemotherapy 360IU/dL and 277IU/dL respectively. Fewer patients (n=4) had a 
corresponding fall in the FVIII level, with pre and post chemotherapy levels 272 IU/dL 
and 277IU/dL, (figure 4.4B). 17 had a starting dFLC greater than 50mg/L and further 
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analysis was performed on these patients. A complete remission (CR) occurred in 7, 
partial response (PR) in 6 and no response in 4 patients. There was no significant 
difference between these individual groups except the notable trend in the fall pre and 
post treatment, figure 4.4C.  
 
Figure 4.4: Pre and post chemotherapy comparison of vWF:Ag (4.4A) and FVIII 
(4.4B), and vWF:Ag according to haematologic response (4.4C) 
 
Figure 4.4A 
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Figure 4.4B 
 
Figure 4.4C 
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Discussion 
To our knowledge, this is the first prospective study investigating the interplay of all 
the various clotting factors in newly diagnosed systemic AL patients. A novel finding 
was the elevated vWF:Ag, vWF:CB and factor VIII in these patients. We then 
examined vWF as a marker of endothelial function and its potential implications in 
relation to light chain toxicity. This raises the hypothesis of these coagulation factors 
forming an instigating factor or possibly arising as a consequence of new amyloid 
deposits, with the thromboembolic potential poorly understood. 
 
We recognise that bleeding complications are also well recognised in AL 
amyloidosis,164,220,221 but little known as to the underlying mechanisms of haemostatic 
factors and co-factors within this environment which may contribute to a bleeding or 
pro-thrombotic tendency. The clinical bleeding manifestations and laboratory 
characteristics of our study group, specifically those diagnosed with AL were explored 
investigating the haemostatic environment with some enlightening findings. In this 
study, we examined the clinical utility of the only validated bleeding questionnaire, 
adapted from the vWF bleeding questionnaire to assess the usefulness of the bleeding 
score and systemic AL amyloidosis. 24 patients reported episodes of bleeding in their 
history with a median duration of 4 months (range 0.5-36), with 17 patients 
experiencing cutaneous bleeding. The literature supports that a bleeding score of 4 in 
other bleeding disorders, namely vWF disease equates to an increased risk of 
bleeding,222 with only 4 systemic AL patients having a bleeding score greater than 4. 
This score in AL patients does not reflect the true nature experienced by many 
patients, predominantly ecchymosis and other cutaneous bleeding manifestations; 
experienced in 17 of the 24 patients in our entire cohort. Other studies of amyloidosis 
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patients have described haemostatic abnormalities with surprisingly fewer bleeding 
complications, which may be explained by the laboratory investigations.223  
 
The fibrinolytic pathway is often affected with prolongation of the PT, APTT, TT and 
high levels of fibrinogen. In our study, prolongation of the PT, APTT and TT was a 
predominant coagulation abnormality, concurring with other studies.164, 224 Previous 
studies in Myeloma have shown high levels of immunoglobulins having a propensity 
to increase the blood viscosity and interfering with the fibrin polymerisation225 Fibrin 
formation is impaired, consequently interfering with the binding of plasmin and FXIII, 
ultimately causing ineffectual clot retraction226 and abnormal clot clumps, with the 
possible propensity to occlude smaller vessels. In our AL cohort, the TT was prolonged 
in 35 patients, yet the majority of patients did not describe a bleeding tendency, 
suggesting other haemostatic defects are needed to result in increased bleeding 
manifestations such as vessel wall amyloid deposition and vessel fragility,227 
enhanced fibrinolysis or down regulation or consumption of certain co-factors.  
 
Within our study group, 2 of 74 (1%) of patients had a Factor X deficiency, compared 
to previous studies of 7% 217 or 14%,164 with the variation clearly dependent upon 
patient characteristics. Baseline FX levels are not predictive of bleeding risk.228  
Previous studies show that rapid clearance of 131I-labelled FX from the circulation to 
areas of amyloid deposition particularly within the spleen216, 229 suggests adsorption 
on amyloid fibrils as a major cause FX deficiency in AL.  Other suggested explanations 
include synthetic dysfunction due to liver involvement or vitamin K deficiency and 
discordance between FX activity and FX antigen.164 These 2 patients with factor X 
deficiency exhibited prolongation of the PT with a normal APTT, with no bleeding 
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complications. Further factor analysis was undertaken to assess any other associated 
factor deficiencies encountered with this disease. Our results reflected a subnormal 
FVIII in 1 patient and subnormal FXII in another patient, with prolongation of the APTT 
in the former and no bleeding complications in either patient. The striking feature when 
analysing the factor levels, was the extent of elevated values for all the factors, 
predominantly for factor V, VIII and IX. Little data exists as to bleeding or thrombotic 
complications related to FV, with only one patient having an activated protein C 
resistance. Interestingly, FVIII results were elevated in 91%. High factor VIII levels are 
thought to be an independent risk factor for venous thrombosis, with levels greater 
than 150% associated with a five-fold increase risk of venous thrombosis.230 Heikal et 
al explored elevated factor IX levels retrospectively in 81 patients, showing an 
association with arterial and venous thrombosis231 The consequence of these elevated 
factors remains undetermined but may provide a more prothrombotic environment. 
 
The FVIII/vWF glycoprotein complex may serve as important platform from which 
endothelial dysfunction can be assessed in this disease. Clearly intertwined in 
equilibrium, vWF is a vital partner for FVIII’s function, stability, structure and 
immunogenicity.214 Electrostatic interactions have been proposed as one driving force 
for the FVIII-vWF complex,232 with Dimitrov et al showing binding of FVIII to vWF 
demonstrated a high sensitivity to acidic pH and sensitivity to ionic strength.233 One 
study showed that 50% high FVIII levels were associated with high vWF Ag levels, 
implying that there are other factors which affect this interaction. Other studies have 
shown that factors including BMI, diabetes mellitus, insulin, fibrinogen and triglycerides 
are associated with elevated FVIII levels.234 Typically a rise in FVIII will lead to a 
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concordant rise in vWF:Ag levels. Our study showed a concordant rise in both vWF 
and FVIII levels. 
 
In the present study, elevated plasma vWF was shown to be associated with patients 
diagnosed with systemic AL amyloidosis, with 90.5% of patients having elevated vWF 
activity, supporting previous studies examining vWF235 Kastritis et al, examined 81 
patients with systemic AL with a serum vWF level of 181 IU/dL (range 20-557) with 
vWF levels greater than 230 IU/dL were associated with a poor survival (median 4 
months versus 47 months, p=0.001). In our study, the vWF activity was significantly 
higher in AL patients in comparison with patients with no amyloid, p=0.014 in 
comparison with other patient cohort groups. We found a significant survival 
disadvantage with a factor VIII level and vWF antigen level greater than 280IU/dL in 
comparison to the Greek group,235 although FVIII levels were not explored by the latter 
group. The differences in the survival differences between the Greek group and our 
study most likely reflect the patient cohorts recruited. In comparing all the patient 
groups in our study, patients with systemic AL and Multiple myeloma (with the latter 
not significantly different from controls) had higher median values of FVIII and vWF:Ag, 
suggesting the underling plasma cell or light chains as the probable instigating factor.  
 
Von Willebrand factor is a large multimeric glycoprotein produced in endothelial cells 
and megakaryocytes playing an important role in haemostasis by promoting platelet 
adhesion. A number of clinical and experimental studies have shown that elevated 
vWF levels reflect endothelial damage and dysfunction.209 Previous studies have 
proposed vWF as a marker of endothelial damage or dysfunction; which is secondary 
to a pro-inflammatory and pro-coagulant state. The increased vWF:Ag and vWF:CB 
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are likely to result in increased platelet plug formation. In systemic AL amyloidosis, 
light chains misfold and aggregate as amyloid fibrils in vital organs. In vitro fibril studies 
show that there are various factors which may play a part in the kinetics and 
morphology of the fibrils: thermodynamic stability, low pH and oxidative stress.236-238 
Earlier studies have shown that amyloid deposits occur earlier within the blood 
vessels, with these patients presenting with early microcirculatory dysfunction.202 Thus 
systemic AL patients with higher levels of vWF signify a unique marker for endothelial 
dysfunction and may lead to a higher risk of thromboembolic disease and 
cardiovascular disease. 
 
Typically, large VWF multimers are produced in and released from vascular 
endothelial cells, predominantly biologically active whilst interacting with platelets 
under a high shear stress. The large multimers are cleaved and degraded into smaller 
fragments by A Disintegrin And Metalloprotease with ThromboSpondin 1 repeats 
(ADAMTS13); an enzyme produced by the liver. To investigate the significantly high 
levels of vWF:Ag and vWF:CB levels, we examined the plasma ADAMTS13 activity in 
these patients. The most remarkable observation of our study was the higher plasma 
vWF Ag levels and normal and elevated levels of ADAMTS13 activity, with the 
biological significance of this uncertain. Low levels of ADAMTS13 activity may be 
secondary to high levels of substrate or sequestration of this protease to the vascular 
endothelial cells. In AL patients, the vWF cleaving protease activity was normal and 
elevated in 18 patients, likely to represent the increased levels of vWF:Ag and hence 
increased need to ensure these multimers are cleaved. 
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Proteins C and S are two vitamin K-dependent plasma proteins acting as natural 
anticoagulants. Activated protein C acts as a proteolytic component of the complex, 
whilst protein S is used as an activated protein C binding protein; both needed for 
assembly of the anticoagulant complex on cell surfaces. This is primarily expressed 
through the selective inactivation of Factors Va and VIIIa. Many patients deficient in 
proteins C and S have been described with an associated thrombotic tendency. There 
are various mechanisms and/or drugs which can lead to acquired deficiencies of these 
proteins including oral anticoagulation, liver disease, DIC and in the case of protein S, 
nephrotic syndrome, lupus erythematosus and certain hormones. Protein S plays an 
important role as a cofactor in the inactivation of FVa and FVIIIa. 
 
Protein C deficiency is known to be associated with thromboembolic phenomenon, 
with little data as to increased protein C levels. In this study, 24 patients (32.4%) had 
high levels of protein C with only 1 patient with activated protein C resistance. This 
highlights the complex interplay of the various coagulation factors and bystanders that 
contribute to proteinuria, not solely a low anti-thrombin level.  
 
In our study nephrotic syndrome was present in 53% of the AL cohort, with 
prolongation in the thrombin time and reptilase time in all these patients, suggesting a 
close link between prolongation of the TT and RT and proteinuria, typically secondary 
to the abnormal fibrin polymerisation that occurs in both cases.239, 240 Low anti-
thrombin levels in nephrotic syndrome have been described in many studies,241-243 
likely secondary to urinary loss and increased consumption. Anti-thrombin acts as an 
important inhibitor of serine protease clotting factors, with heparin and 
Glycosaminoglycans (GAGS) accentuating its inhibitory effect; which bind to amyloid 
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fibrils.244 Gamba et al described increased plasma values of thrombin-antithombin 
(TAT) complexes and enhanced thrombin activation present, chronic consumption of 
AT, accounting for differences in AT activity and AT:Ag levels. Thrombin generation 
may be additionally enhanced by delayed fibrin formation.243 Of the nephrotic patients, 
only 7 had reduced anti-thrombin values, with 5 patients having corresponding albumin 
levels less than or equal to 25g/L. Interestingly the other 2 patients with albumin levels 
of 28 and 38g/L had raised protein C levels and a low quantitative level of proteinuria. 
There is very likely a change in the haemostatic factors including protein C which occur 
prior to lower albumin levels and hence more extensive proteinuria.  
 
Amyloid deposits in the kidneys typically occur within the glomerulus, and 
consequently results in pathological damage, with proteinuria often seen which may 
be nephrotic or sub-nephrotic. The renal tubules function to reabsorb the plasma 
proteins (specifically in the proximal convoluted tubule) which pass through the 
glomerular filtration barrier, which provides a charge and size selective barrier to 
albumin. Podocytes are terminally differentiated glomerular epithelial cells, with 
endothelium activation and loss of selectivity resulting in prolonged exposure of the 
podocytes to these proteins.245 This overall damage leads to reduced vascular 
endothelial growth factors (VEGF).246 Previous studies have explored the risk of 
thromboembolic disease in nephrotic syndrome.247-249 In our study, comparison of 
patients with an albumin less than 25g/L and those with an albumin greater than or 
equal to 25g/L for the different coagulation factors showed definite differences. The 
former group showed differences to the latter, with significantly higher vWF:Ag, FVIII, 
FV, and fibrinogen levels and lower protein S and ATIII levels. This is the first study to 
compare all coagulation factors to assess the possible aetiology of thrombotic 
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phenomena or bleeding risks in patients diagnosed with systemic AL. Understanding 
of the coagulation cascade has shown that elevated levels of FVIII and fibrinogen, 
lower levels of protein S and anti-thrombin contribute to a prothrombotic tendency. The 
latter findings were found in patients with an albumin less than 25g/L.  Although these 
factors work as part of a cog wheel together, this study highlights the potent risk of 
prothrombotic tendency in patients with an albumin less than 25g/L, and hence the 
awareness and need for prophylaxis or full anticoagulation consideration.  
 
There is limited data as to managing patients given the paradox of bleeding and 
thrombotic risks. A common finding in our study and previous studies164, 224, 250 was 
the prolongation of TT and RT. Typically, hyperfibrinolysis may be related to lower 
levels of α2-antiplasmin or increased urokinase type plasminogen activity. As such, ε-
aminocaproic acid are effective in controlling some bleeding complications.251 Until 
recently, Factor X deficiency treatment deficiency therapeutic options included fresh 
frozen plasma (FFP), prothrombin complex concentrates (PCCs), activated 
prothrombin complex concentrates (aPCC) or recombinant factor VIIa (rFVIIa)252 – 
each with significant risks in this fragile patient population.  A larger series reported 
44% of patients had complications when treated with rFVIIa preoperatively including 
bleeding, thrombosis, or death.228. In addition to FFP, PCC, aPCC or rFVIIa, 
tranexamic acid, plasma exchange253 and splenectomy217 were anecdotally reported 
as treatments for FX deficiency in AL; the latter targeted at removing the splenic 
amyloid fibril burden.  As a result of a variable amount of FX in FFP, large volumes 
are needed to achieve a haemostatic effect with the true clinical risk of fluid overload 
in patients with cardiac involvement, especially those with advanced cardiac 
involvement or elderly population.  A serious concern arises regarding thrombotic risks 
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of FVIIa or aPCC in patients with AL amyloidosis who are elderly with cardiovascular 
risk factors and often nephrotic due to renal involvement (hence inherently 
prothrombotic).  BPL (Bio Products Laboratory Ltd, Elstree, UK) have also developed 
a high purity plasma derived factor X concentrate and currently undergoing phase III 
clinical trials used in patients with hereditary factor X deficiency. In one analysis, one 
patient with inherited Factor X deficiency presenting with a shoulder haemarthrosis, 
achieved good haemostatic response following FX dose of 25IU/kg daily254 with a 
biological half-life 24 to 48 hours. 
Our Centre also reported an initial report of using high purity factor X (HP-FX) 
concentrate in two patients with systemic AL amyloidosis and acquired FX 
deficiency.255 This involved 2 patients with biopsy proven AL amyloidosis, with 
evidence of liver involvement and a large amyloid load by 123I serum amyloid P 
component scintigraphy, one patient presenting with a forearm haematoma and the 
second patient presenting with a ruptured spleen and knee haemarthrosis due to 
acquired FX deficiency (both with FX levels 8 IU/dL). HP-FX concentrate was used to 
treat each bleeding episode in each case given as a single dose of 40IU/kg (with the 
FX activity assessed by one stage clotting prothrombin time (PT) based assays) and 
haemostasis achieved in conjunction with supportive measures. There was an obvious 
difference between the FX recovery times between patients with inherited FX 
deficiency in comparison with our AL patients; the latter showed less predictable 
kinetics, and a more rapid decline to baseline in 2-4 hours, consistent with the theory 
of FX adsorption on amyloid fibrils.  Each patient with AL amyloidosis has a different 
amyloid load and a unique fibril sequence with a potentially different avidity for binding 
FX – both likely to lead to large differences in the half life and dose needed as in the 
second patient with a larger load and earlier decrease in FX levels.  We tried to 
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ascertain whether there was a correlation between bleeding symptoms and amyloid 
load by 123I SAP scintigraphy, not showing a statistically significant difference.255 High 
purity factor X concentrate is useful to treat bleeding due to acquired factor X 
deficiency in systemic AL amyloidosis.  Higher and/or more frequent dosing is likely to 
be required to achieve adequate FX levels for haemostasis with frequent monitoring 
of FX levels given the unpredictable kinetics; target FX thresholds similar to patients 
with inherited FX deficiency: doses of 10-15 IU/dl for minor bleeding and >50 IU/dl for 
major bleeding, trauma or surgery. Thus HP-FX has the advantage that the 
haemostatic response can be monitored and treatment tailored to the patient individual 
needs.255 
Light chain toxicity may also serve as a further insult in this process of AL deposits. 
Various experiments have attempted to explore the underlying mechanisms of light 
chain toxicity, with no correlative factor for endothelial dysfunction. Previous studies 
have proposed vWF as a marker of endothelial damage or dysfunction; which is 
secondary to a pro-inflammatory and pro-coagulant state. The increased vWF:Ag and 
vWF:CB are likely to result in increased platelet plug formation. Bauer et al described 
the concept of vWF fibres laid down within the lumen of the cancer associated vessel 
wall, with tumour derived VEGF inducing angiogenesis, thus affecting the 
pathophysiology and activation of the endothelium.256 In systemic AL amyloidosis, light 
chains misfold and aggregate as amyloid fibrils in vital organs. In vitro fibril studies 
show that there are various factors which may play a part in the kinetics and 
morphology of the fibrils: thermodynamic stability, low pH and oxidative stress.236-238 
Earlier studies have shown that amyloid deposits occur earlier within the blood 
vessels, with these patients presenting with early microcirculatory dysfunction. 202 As 
such, it seems feasible that systemic AL patients have higher levels of vWF signifying 
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a unique marker for endothelial dysfunction and may lead to a higher risk of 
thromboembolic disease and cardiovascular disease. In comparing all the patient 
groups in our study, patients with systemic AL and Multiple myeloma (with the latter 
not significantly different from controls) had higher median values of FVIII and vWF:Ag, 
suggesting the underling plasma cell or light chains as the probable instigating factor.  
 
The underlying mechanism of light chain toxicity remains unknown, with some reports 
showing that the prefibrillar light chain proteins, consequent endothelial dysfunction 
and ischaemic vascular injury occurs prior to amyloid deposition. 200, 202 Exposure to 
light chains and oxidative stress and microvascular dysfunction has been proposed in 
the AL pathophysiology.199 Recently further exploration to examine the dysregulation 
of an autophagy flux in the setting of proteotoxicity of the light chains has shown to be 
important in those with cardiac AL. Guan et al found that inhibition of the autophagy 
flux, specifically lysosomal dysfunction is important in the AL-light chain cardiotoxicity 
and hence development of AL cardiomyopathy.257 In vitro experiments showed that 
lysosomal dysfunction is an early point in the cascade of events that occur in cardiac 
AL, specifically the light chain toxicity, followed by mitochondrial dysfunction, ROS 
dysfunction and consequent cell death and dysfunction. This also highlights the 
potential for a possible autophagy related targets, replicated in vivo halting cardiac AL 
mortality using rapamycin and transient overexpression of transcription factor EB 
(TFEB).257 
 
This resultant rise in vWF and FVIII are likely to create a consequential pro-coagulant 
and pro-inflammatory environment. Several studies have attempted to explore 
whether FVIII or vWF are the causative stimulant in arterial or venous thrombogenesis. 
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The ARIC study examined strong associations of FVIII and vWF as risk factors for 
hypertension, diabetes mellitus, body mass index or triglycerides. Some of the latter 
variables are associated with endothelial and vascular inflammation.211, 258 The 
consequent high shear forces especially within narrowed vessels lead to increased 
vWF secretion by the vascular endothelium, which stimulates platelet adhesion and 
aggregation at the damaged arterial walls, with the high risk leading to thrombus 
formation.259 
 
Previous studies have shown that high levels of factor FVIII over time are present in 
patients with thrombosis260, and not reflective of an acute phase reaction261 We 
compared the C-reactive proteins (CRP) in each group to ascertain whether the 
elevated vWF Ag and FVIII were secondary to an inflammatory or infective pathology; 
with the former showing relatively low levels except for occasional patients with 
infection (table 4.1). The latter finding negates underlying inflammation as a trigger for 
the vWF rise. 
 
In an attempt to explore the relationship between FVIII and vWF Ag with light chains, 
we repeated blood samples for these coagulation factors post chemotherapy. This has 
not been explored before, with the results showing that 86% (19/22 patients) with 
these investigations undertaken exhibited a fall in the vWF:Ag level following 
chemotherapy, suggesting a likely correlative relationship. Interestingly the FVIII levels 
did not fall in the majority of patients. The type of haematological response did not 
correlate with the level of fall in the vWF:Ag implying there is a much more complex 
interplay of the light chains, the vascular endothelium and formation of amyloid 
deposits. It is difficult to interpret this, with small numbers and no experimental or 
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electron-microscopy to aid with understanding. One possible hypothesis would 
suggest that treatment with chemotherapy in an attempt to reduce the light chains, 
also serves to improve the function of the vascular endothelium, but may still provide 
a thrombotic environment.  
 
Our study highlights the prothrombotic potential in patients with newly diagnosed 
systemic AL, irrespective of the presence of nephrotic syndrome or type of 
chemotherapy regimen used. This raises the question as to what the optimum 
treatment of thrombotic risk should involve. Ordinarily thromboprophylaxis would 
suffice, but given the additional elevated risk factors of vWF:Ag, FVIII, fibrinogen and 
lower anti-thrombin and protein S levels, further analysis is needed to explore whether 
full anticoagulation is necessary. 
 
In summary, this is the largest series prospectively examining all the underlying 
coagulation factors, protein C and S, anti-thrombin in newly diagnosed AL amyloidosis. 
Little is known in the setting of AL amyloidosis with the paradox of a bleeding diathesis 
and thromboembolic disease. Haemostatic dysfunction likely results from different 
interacting pathogenic pathways and coagulation factors. From our data, we showed 
that prolongation of the thrombin time was a common finding and low levels of anti-
thrombin activity and proteinuria were associated with albumin levels less than 25g/L. 
In addition these patients had elevated pro-thrombotic factors and reduced 
anticoagulant factors which will contribute to the pro-thrombotic status of these 
patients. An elevated FVIII and vWF:Ag level greater than 280IU/L carried a significant 
survival disadvantage. Thromboprophylaxis or treatment anticoagulation is an 
important consideration in all these patients not having bleeding complications.  
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Our study points to underlying vascular endothelial damage that occurs in systemic 
AL, and possibly contributing to the light chain toxicity environment. The correlative 
fall in the vWF levels post chemotherapy may reflect the underlying vascular 
endothelial changes which occur. Further studies to better understand the 
pathophysiology of these findings are needed to explore the endothelium by electron 
microscopy, and hence the utility of the prognostic findings as part of patient risk 
stratification. 
 
.
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Chapter Five:  Frequent occurrence of recurrent nocturnal 
desaturations in systemic AL amyloidosis 
 
This chapter is written in the context of my publication: High prevalence of 
recurrent nocturnal desaturations in systemic AL Amyloidosis: a cross-
sectional study. S Mahmood, M Sovani, P Smith, L George, C Quarta, S 
Sachchithanantham, M Fontana, CJ Whelan, HJ Lachmann, JD Gillmore, PN 
Hawkins, AD Wechalekar. Sleep Medicine. Accepted for publication and available 
online December 21st 2016. (Original article). Copyright permission obtained from 
Elsevier publishers, license no.: 4025341342092 for use in my thesis. 
 
Introduction 
Systemic AL amyloidosis is a rare disorder caused by deposition of misfolded 
immunoglobulin light chains in organs or tissues.  Outcomes of patients with 
amyloidosis depend predominantly on the extent of cardiac disease, although 
involvement of other organs and, particularly, soft tissues of the oropharynx contribute 
to significant symptoms and morbidity.  It is well recognised that early and unexpected 
cardiac deaths account for 20-40% of all deaths within a few months of diagnosis in 
AL amyloidosis. The exact terminal event and its triggers remain unclear. 
Bradyarrhythmias262 or other arrhythmias may be the cause. Central sleep apnoea 
(CSA), characterised by the faulty respiratory drive during sleep, is a well-recognised 
complication of heart failure and can lead to recurrent episodes of nocturnal 
hypoxemia worsening symptomatic heart failure,263 causing increased morbidity and 
mortality.  Obstructive sleep apnoea (OSA) is now a well-recognised cause of acute 
and chronic adverse cardiovascular effects.  In addition to cardiovascular effects, both 
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CSA and OSA cause marked day time fatigue and/or sleepiness contributing to 
morbidity.   
Systemic AL amyloidosis is one of the few disorders which cause acquired progressive 
heart failure and can also be associated with marked infiltration of the oropharyngeal 
soft tissues – both potential risk factors for CSA or OSA, respectively, or CSA and 
OSA together in patients with soft tissue and cardiac disease.  The recurrent hypoxic 
episodes could have a profound effect on the cardiac function in patients with 
advanced amyloidosis.   
We report here the results of a pilot study of overnight continuous pulse oximetry in 
patients with systemic light chain (AL) amyloidosis, based on the hypothesis that 
recurrent nocturnal hypoxaemia (likely due to sleep disordered breathing OSA and/or 
CSA) could occur in patients with amyloidosis reporting a high incidence of recurrent 
nocturnal oxygen desaturations and raise a question whether these desaturations may 
be the trigger for sudden cardiac mortality.  
Methods 
Study population 
This study included consecutive patients seen at the UK National Amyloidosis Centre 
with amyloidosis between July 2013 and June 2014 who underwent overnight pulse 
oximetry, using the Minolta 300I pulse oximeter.  The main inclusion criteria were:  the 
presence of clinical macroglossia and/or cardiac amyloidosis.  Written consent for 
retrospective publication of data was obtained from all patients in accordance with the 
Declaration of Helsinki.  Amyloid deposition was confirmed on a tissue biopsy by the 
presence demonstration of Congo red positivity under cross polarise light and fibril 
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typing was done by immunohistochemistry or mass spectrometry. All patients had a 
detailed assessment for organ involvement as per standard protocol at the National 
Amyloidosis Centre. Blood tests included a full blood count, renal, liver and bone 
profiles, cardiac biomarkers including N terminal fragment of the prohormone brain 
natriuretic peptide (NT-proBNP) and troponin T. Other investigations included an 
electrocardiograph (ECG), echocardiography and 123I serum amyloid P component 
(SAP) scintigraphy. Organ involvement, haematologic and organ responses were 
classified according to the updated international amyloidosis consensus criteria.87  All 
patients underwent overnight pulse oximetry, with instructions given to each patient 
(appendix 2).  An episode of significant desaturation was defined as per the standard 
definition as 4% or greater decrease in oxygen saturations from the average oxygen 
saturations in the preceding 120 seconds lasting for more than 10 seconds. The 
oxygen desaturation index (ODI), the hourly average number of desaturation episodes 
over the whole night, was calculated.  ODI is a standard measure used to score oxygen 
desaturations, but may not always show evidence of  hypopnoea.264  Heart rate (HR) 
variability was defined as HR change of >6 beats per minute – tachycardia is a normal 
physiological response to desaturation.181  
All patients completed the Epworth Sleepiness Score (ESS) (appendix 3) and STOP 
BANG (appendix 4) questionnaires for obstructive sleep apnoea (OSA).  The 
STOPBANG (Snoring, Tiredness during the daytime, Observed apnoea, high blood 
Pressure, Body mass index, Age, Neck circumference and Gender) and ESS (Epworth 
Sleepiness Scale) (included as supplementary data) are validated screening tools of 
OSA with a high sensitivity265  but low specificity.  Patients were classified as high risk 
of OSA if the STOP-BANG score was greater than and equal to 3 and low risk if the 
score was less than 3. The ESS (Epworth Sleepiness Scale) questionnaire is based 
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on the probability to fall asleep during different situations266  and patients were 
classified as being high risk if the ESS score was greater than or equal to 10.   
 
Analytical plan 
Baseline characteristics and clinical investigations are presented as medians with 
minimum and maximum values for continuous variables and percentages with 
proportions for categorical variables. Statistical significance for comparison between 
groups was analysed with the one way anova variance for continuous variables and 
Turkey post-test analysis using the Graph pad prism version 5 software. Correlation 
statistics were performed using linear scatter plots and Pearson coefficients. A two-
sided P value of less than 0.05 was considered as statistically significant. A univariate 
model was used to assess the poor prognostic features of those diagnosed with 
cardiac AL.  Multivariate models are not presented due to instability from small patient 
numbers.  Survival was assessed by the method of Kaplan-Meier analysis and patients 
with cardiac AL amyloidosis and those with transthyretin amyloidosis were analysed 
separately due to a different disease natural history. 
 
Results 
Baseline characteristics 
A total of 72 patients were included in this study. The median age of all patients was 
68.8 years (47-83), with 80.5% with cardiac involvement, median NT-proBNP 
2568ng/L (136-146203) and median 4%ODI 7.9 (0.9-59). Patients were stratified as 
systemic AL amyloidosis with cardiac involvement, AL amyloidosis with macroglossia, 
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AL amyloidosis with both macroglossia and cardiac involvement, and wild type 
transthyretin amyloidosis (ATTR), (Figure 5.1A).  Table 5.1 illustrates the baseline 
presenting characteristics in each group.  
Figure 5.1 Study Population. A total of 72 patients initially recruited, with proven 
cardiac and/or macroglossia amyloid. Specifically transthyretin (n=17), cardiac light 
chain amyloidosis (n=25), cardiac and macroglossia light chain amyloidosis (n=16) 
and patients with light chain amyloidosis with solely macroglossia (n=14). 
 
  
Patients with clinical macroglossia and/or cardiac 
symptoms
Clinical macroglossia 
and/or cardiac amyloid
n=72
ATTR
N=17
Cardiac 
AL
N=25
Cardiac and 
macroglossia AL
n=16
Macroglossia 
AL
n=14
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Table 5.1: Patient characteristics 
Type 
Number 
Cardiac AL 
n=25 
Macroglossia 
AL 
n=14 
Cardiac & 
Macroglossia 
AL n=16 
ATTR 
n=17 
Patients Who 
died n=12 
Age (years) 66 (49-80) 71 (47.4-83.8) 65 (39.3-81) 75 (61-83) 69 (59-83) 
Organ 
Involvement  
     
Heart 25 0 16 17 12 
Kidneys 14 4 5 0 7 
Liver 8 0 0 0 3 
Macroglossia 0 14 16 0 3 
Mayo 
Disease 
Stage 
     
1 4 7 2 2 1 
2 9 6 6 5 1 
3 12 1 8 10 10 
NT-proBNP 
(ng/L) 
5585 (136-
146203) 
186 (34-
11788) 
1314 (136-
13288) 
3703 (847-
12712) 
6619 (424-
146203) 
Troponin T 
(ng/L) 
0.1 (0-0.8) 0.02 (0.01-0.1) 0.07 (0.01-0.15) 0.083 (0.04-
0.63) 
0.09 (0.01-0.8) 
Albumin (g/L) 42 (24-49) 40.5 (30-46) 40.5 (30-52) 46 (43-50) 36 (25-46) 
Alk Phos 
(IU/L) 
81 (37-636) 76 (59-123) 82 (49-135) 109 (69-187) 83 (64-315) 
Creatinine 
(µmol/L) 
105 (58-
582) 
75 (46-472) 88 (45-385) 126 (70-188) 109 (71-226) 
eGFR 
(mls/min) 
59 (10-100) 73 (10-100) 71 (10-100) 52 (31-100) 60 (26-77) 
GGT (U/L) 49 (12-621) 34 (7-213) 21 (9-153) 114 (42-310) 39.5 (9-621) 
Urinary 
protein (g/24 
hours) 
0.2 (0.1-6.8) 0.2 (0.1-4.8)  0.2 (0.1-0.4) 0.9 (0.1-6.8) 
TDI (cm/s) 0.12 (0.08-
0.18) 
0.15 (0.09-
0.21) 
0.12 (0.06-0.2) 0.09 (0.05-
0.17) 
0.11 (0.06-0.19) 
TAPSE (mm) 15 (6-27) 22 (12-31) 17.5 (7-31) 12 (7-20) 12 (6-22) 
AL – light chain; BMI – body mass index; ATTR – transthyretin; BP – blood pressure; 4%ODI 
- hourly average number of desaturation episodes defined as a 4% decrease in saturations 
from the average saturations in the preceding 120seconds and lasting for more than 
10seconds; NT-proBNP – N terminal of the prohormone brain natriuretic peptide; eGFR – 
estimated glomerular filtration rate; GGT – gamma-glutamyltransferase; RV TDI – right 
ventricle tissue Doppler imaging; TAPSE – tricuspid annular pulmonary systolic excursion; cm 
– centimetres; bpm – beats per minute;; pMol/L – picomoles per litre; ng/L – nanograms per 
litre; g/L – grams per litre; IU/L – international units per litre; µmol/L – micromoles per litre; 
mls/min – millilitres per minute; U/L – units per litre; g – grams; cm/s – centimetres per second; 
mm – millilitres. 
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Overnight oximetry 
Overnight oximetry tracings were recorded and collected in all 72 patients.  Table 5.2 
shows findings in systemic AL amyloidosis with cardiac involvement, AL amyloidosis 
with macroglossia, AL amyloidosis with both macroglossia and cardiac involvement, 
and wild type transthyretin amyloidosis (ATTR) and those patients who died. The 
mean oxygen saturation of all patients in the study was 93% (±SD 1.99, 87-96).  The 
mean oxygen saturations were similar in all groups. The ATTR group had the lowest 
number of abnormal oximetry tracings.  Figures 5.2A and 5.2B illustrate a normal and 
abnormal overnight oximetry tracing in 2 patients with cardiac amyloidosis 
respectively. 
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Table 5.2: Oximetry data in the different amyloid groups 
Type 
Number 
Cardiac AL 
n=25 
Macroglossia 
AL 
n=14 
Cardiac & 
Macroglossia AL 
n=16 
ATTR 
n=17 
Patients Who 
died n=12 
BMI  25 (18-30) 25.5 (19-45) 25.3 (19-32) 26 (21-37) 23.4 ( 19-26) 
Neck circ (cm) 39 (31-44) 39 (34.3-43) 38 (33-42) 41 (34-45) 40 (34-43) 
Mean pulse 
(bpm) 
77 (60-108) 68 (55-93) 72 (56-89) 69 (53-80) 80 (61-108) 
Mean systolic 
BP (mmHg) 
109 (91-150) 117 (102-154) 120 (102-166) 123 (106-151) 102 (96-150) 
Mean oxygen 
saturations 
93 (88.7-96) 93 (87-96) 94 (91-96) 94 (91-96) 93 (88-96) 
Abnormal 
Oximetry 
21/25 (84%) 11/14 (79%) 10/16 (63%) 9/17 (53%) 9/12 (75%) 
4% ODI 11 (1-48) 6 (3-41) 6 (0.9-52.1) 8 (0.57-59) 6 (3.8-26) 
Heart rate 
change >6bpm 
12 (1.9-113) 13 (4.3-51.5) 20 (2.3-69.7) 24 (0.3-80) 10 (0.3-113) 
ESS score 8 (0-15) 6 (2-13) 6 (1-12) 5 (2-17) 8 (0-15) 
ESS>10 7/25 (28%) 3/14 (21%) 3/16 (19%) 4/17 (24%) 4/12 (33%) 
STOP BANG 
score 
3 (1-5) 3 (2-5) 3 (1-6) 4 (1-6) 3 (1-4) 
STOP BANG>3 16/25 (64%) 10/14 (71%) 11/16 (69%) 12/17 (71%) 8/12 (67%) 
AL – light chain; ATTR – transthyretin based disease; circ – circumference; n – number; BMI – body 
mass index; cm – centimetres; bpm – beats per minute; 4%ODI – hourly average number of 
desaturation episodes defined as a 4% decrease in saturations from the average saturations in the 
preceding 120seconds and lasting for more than 10 seconds; STOP BANG - Snoring, Tiredness during 
the daytime, Observed apnoea, high blood Pressure, Body mass index, Age, Neck circumference and 
Gender; ESS – Epworth Sleepiness Score; mmHg – millimetres of mercury 
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The number of significant nocturnal desaturations (4% ODI) was non significantly 
higher in patients with cardiac AL  (median 11 episodes (range 1-48)) compared to 
patients with macroglossia, cardiac and macroglossia and ATTR amyloidosis (6.02 
(p=0.94), 6.03 (p=0.17) and 8.39 (p=0.34) episodes respectively, (Figure 5.3A).  
Figure 5.1B illustrates a normal tracing of overnight oxygen desaturations and pulse 
in a patient with cardiac amyloidosis showing repeated desaturations, with an 
abnormal tracing of these parameters illustrated in Figure 5.1C.  
Figure 5.2A and 5.2B: Overnight oximetry tracing of 2 patient with cardiac 
amyloidosis showing oxygen saturations (red tracing) and pulse variability (blue 
tracing). A normal oximetry tracing is illustrated in Figure 5.2A, with the mean SpO2 
of 94.6% and 3% ODI of 3.6 events per hour. Figure 5.2B illustrates grossly abnormal 
oximetry findings with the mean SpO2 of 96% and 3% ODI of 46 events per hour.  
Figure 5.1A 
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Figure 5.1B 
 
Repeated desaturations were frequent and the total number of episodes of 4% ODI in 
one night in patients with cardiac AL, AL macroglossia, AL cardiac and macroglossia 
and ATTR were: more than 15 per night – 32%, 14%, 18% and 29% respectively; and 
between 10-15 episodes per night in 20%, 21%, 6% and 12% respectively. Heart rate 
variability (a HR change of >6 beats per minute), a normal physiological response to 
desaturation, was seen in: cardiac AL amyloidosis - 17/25(68%), patients with 
macroglossia - 10/14(71%), ATTR - 15/17(88%), and cardiac and macroglossia 
patients - 13/16 (81%), and in the patients who died - 8/12 (67%), (Figure 5.3B). The 
patients who died, as a group, had a lower blood pressure, more abnormal oxygen 
oximetry readings, a high ESS score (including proportion with ESS >10), in addition 
to markers of poorer cardiac function like a higher NT-proBNP and lower TAPSE.  
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Figure 5.3A and 5.3B: Relationship of 4%ODI and heart rate change greater than 
6bpm in different types of amyloid respectively. This illustrates that cardiac AL 
patients experience the highest number of oxygen desaturations and have reduced 
heart rate variability. 
Figure 5.3A 
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Figure 5.3B 
 
 
The STOP-BANG and ESS questionnaires were completed by all 72 patients. The 
STOP-BANG score all four groups were high (71%, 69%, 71% and 64%) and would 
suggest a high risk of OSA, (Figure 5.3C).  An abnormally high ESS score (>10) was 
seen in 28%, 21%, 19%, 24% in patients in the four groups, (Figure 5.3D).  It was 
higher in those with cardiac AL (28%) and those who died (33%). 
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Figure 5.3C and 5.3D: STOP BANG questionnaire and ESS questionnaires in 
different amyloid groups respectively, showing evident elements of obstructive sleep 
apnoea and central sleep apnoea in these different groups. There is a relative lower 
risk of obstructive sleep apnoea and high risk of central sleep apnoea in cardiac AL 
patients. 
Figure 5.3C 
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Figure 5.3D 
 
Relationship between overnight oximetry and cardiac amyloidosis 
In all patients with AL amyloidosis, increasing NYHA class directly correlated with 
higher incidence of 4% ODI p=0.05, figure 5.4.  A higher NT-proBNP significantly 
correlated with reduced heart rate variability (correlation coefficient r2 0.185, 
p=0.0002)   There was no correlation of 4% ODI with right ventricle Doppler imaging 
(RVS TDI) (r2=0.02, p=0.4) or tricuspid annular plane systolic excursion (TAPSE) 
(r2=0.02, p=0.4).  There was no correlation between TAPSE and heart rate variability 
(r2=0.030; p = 0.30). 
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Figure 5.4: Relationship between 4%ODI and NYHA class symptoms in AL patients, 
showing a statistical trend in NYHA class I and III patients (p=0.05). 
 
The median follow up for all cardiac amyloidosis patients was 10 months (range 2-15), 
with 12 deaths: 11 with cardiac AL and 1 with TTR.  Higher NYHA class and NT-
proBNP, well recognised markers of poorer prognosis in cardiac amyloidosis, were 
also markers of poorer prognosis in this study.  The median OS of patients with AL 
amyloidosis with cardiac involvement was 12.7 months, macroglossia was 14.6 
months and ATTR was 12.3 months (Figure 5.5A).  The OS of patients with newly 
diagnosed AL was 10.4 months compared to those with AL previously treated 14.4 
months (log rank p=0.004) from entry into the study, (Figure 5.5B).   The recurrent 
oxygen desaturations may influence prognosis in cardiac AL patients within the initial 
phase of chemotherapy; number of 4%ODIs showing subtle changes in this period, 
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(Figure 5.5C). 4% ODI did not impact survival in the patients with ATTR amyloidosis 
or AL amyloidosis with just macroglossia. 
Figure 5.5: Kaplan Meier curves illustrating the (A) overall survival categorised by the 
type of amyloidosis: including cardiac AL (blue line), soft tissue involvement with 
macroglossia (green line) and ATTR (yellow line); (B) overall survival comparing newly 
diagnosed cardiac AL (green line) and previously treated cardiac AL patients (blue 
line) (C) overall survival risk stratified on the 4%ODI frequency, with 4%ODI<10 (blue 
line), 4%ODI 10-15 (green line) and 4%ODI >15 (yellow line) in patients diagnosed 
cardiac AL patients. 
Figure 5.5A 
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Figure 5.5B 
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Figure 5.5C 
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On univariate analysis of newly diagnosed cardiac AL patients (table 5.3), the factor 
significantly impacting survival was:  TAPSE (HR 0.69, p=0.01). Small patient numbers 
make a multivariate model unreliable.   
Table 5.3: New cardiac AL 
Variable HR (95% CI) p 
Univariate Analysis 
Neck circumference* 1.37 (0.31-6.13) 0.68 
Body mass index*  0.81 (0.63-1.04) 0.10 
Mean oximetry* 1.03 (0.7-1.52) 0.88 
Mean pulse*  1.05 (1.0-1.11) 0.12 
Systolic blood pressure* 0.96 (0.92-1.01) 0.13 
Heart rate variability>6bpm* 1.03 (0.97-1.07) 0.08 
4%ODI* 0.95 (0.87-1.04) 0.28 
TAPSE* 0.69 (0.51-0.92) 0.01 
dFLC >180mg/L 0.14 (0.02-1.18) 0.07 
Log NT-proBNP* 2.79 (0.54-14.38) 0.22 
bpm – beats per minute; TAPSE – tricuspid annular pulmonary systolic excursion; 
dFLC – difference between involved and uninvolved free light chains; 4%ODI – hourly 
average number of desaturation episodes defined as a 4% decrease in saturations 
from the average saturations in the preceding 120seconds and lasting for more than 
10seconds; AL – light chain. 
* denotes continuous variables 
 
Discussion 
Treatment of patients with systemic AL amyloidosis with cardiac involvement remains 
a challenge.  There is a complex interaction between tissue deposition of the amyloid 
fibrils leading to multi-organ dysfunction causing often unexpected problems in cardiac 
patients which have the potential to worsen or complicate the clinical picture.  In this 
study, we report the occurrence of repeated and significant nocturnal hypoxaemia by 
overnight pulse oximetry.  This pattern is strongly suggestive of sleep disordered 
breathing which is likely to be central sleep apnoea in patients with cardiac 
amyloidosis, obstructive sleep apnoea in those with soft tissue amyloidosis and 
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possibly a combination of the two in patients with simultaneous occurrence of both 
cardiac/soft tissue amyloidosis.  The nocturnal desaturations correlated with the 
worsening grade of heart failure and worse right ventricular function – both markers of 
poor prognosis.  The impact of these repeated oxygen desaturations on the function 
of an already fragile myocardium is unclear but may potentially cause worsening of 
function or predispose to arrhythmic events.  The observation of repeated nocturnal 
hypoxia opens the possibility of simple and easy to use oxygen supplementation for 
such patients.  It also raises the possibility of using overnight pulse oximetry to provide 
objective data which could potentially be used to monitor disease progression or to 
assess response to treatment. A particularly interesting finding in patients who died of 
cardiac amyloidosis was the loss of ability to mount an appropriate heart rate response 
to hypoxia – possibly a marker of involvement of the sympathetic nerves. 
Overnight pulse oximetry is an easy screening method for sleep apnoea, with the 
sensitivity ranging from 31 to 98% and specificity 41-100%.267-269  It gives a continuous 
recording of oxygen desaturations with a characteristic pattern of overnight oxygen 
saturations.  Clinical prediction models are useful with sensitivities between 76-96% 
and specificities 13-54% and useful in excluding a diagnosis,270 but in conjunction with 
pulse oximetry can confirm the presence of sleep apnoea.271 
The striking finding in our study was presence of significant overnight oxygen 
desaturations in all groups of patients.  Our initial supposition was that we may find 
marked hypoxemic episodes in patients with macroglossia or soft tissue amyloid 
deposits due to the severe anatomical alterations.  Although such patients also had 
4% ODIs, these were less frequent than in the cardiac AL group and were not seen in 
all cases.  In obstructive sleep apnoea which occurs in absence of amyloidosis, the 
laxity of the oropharyngeal soft tissues is an important component in causing the 
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collapse of the tissues during inspiration leading to obstruction of the upper airways.  
The current findings of less than expected severe hypoxia in patients with significant 
soft tissue amyloid deposits raises an interesting question whether increased stiffness 
of the soft tissue, which is a hallmark of amyloid deposition, actually protects against 
the “traditional” cause of OSA and true OSA in amyloidosis only occurs when there 
enough amyloid deposition to alter the anatomy towards obstruction a supine position.   
Central sleep apnoea (CSA) is a well-recognised complication of systolic heart failure 
and leads to repeated episodes of nocturnal hypoxia.  CSA is worse in patients with 
an ejection fraction of <40% and has been reported to be associated with increase in 
non-sustained ventricular tachycardia as well as reduction in heart rate variability.272  
The occurrence of repeated severe nocturnal oxygen desaturations seen in patients 
with cardiac amyloidosis strongly suggest CSA also occurs in AL amyloidosis – a 
finding that will need formal confirmation by polysomnography.  In our study, the 
oxygen desaturations were greatest in those with cardiac AL and ATTR amyloid, again 
with the median number of desaturations higher in those with cardiac AL. Moreover, 
4% ODI correlated with NYHA class and NT-proBNP – suggesting a direct correlation 
with worsening amyloid burden/heart failure with ODI.  Although there was no direct 
impact of the number of 4% ODIs on overall survival in patients with newly diagnosed 
AL amyloidosis, these repeated insults with other factors are likely to influence these 
patients. This is a strikingly different finding from that in systolic heart failure where the 
cardiovascular impact of CSA is universal.  In AL amyloidosis, newly diagnosed 
patients have the most unstable heart disease with 30-40% patients dying of 
cardiovascular complication within 6 months of the initial diagnosis.  The impact of 
nocturnal hypoxia correlating with increased deaths raises important questions – do 
the repeated hypoxemic changes increase the vulnerability of an already fragile 
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myocardium to arrhythmias?  Ventricular arrhythmias have been proposed as a causal 
mechanism for the peak of sudden cardiac death during sleeping hours in OSA 
patients.273 The risk of cardiac arrhythmias with OSA appears to be related to disease 
severity - majority of OSA patients presenting significant arrhythmias have moderate 
or severe forms of the disease.274-276 The amyloidogenic light chains are directly toxic 
to the myocardium in AL amyloidosis and additional hypoxemic insults may compound 
this toxicity.  Lastly, patients receive chemotherapy soon after diagnosis and 
hypoxaemia may influence the toxicity of chemotherapy.  Repeated nocturnal hypoxia 
beyond the newly diagnosed setting may have different consequences.  In CSA, the 
hypoxaemia has consequences in addition to worse mortality, which include increase 
in day time sleepiness, worsening fatigue and poorer quality of life.277, 278  Although 
the latter two were not studied in our cohort, a very high proportion of patients with 
cardiac AL amyloidosis and ATTR had abnormal ESS questionnaires – a measure of 
day time sleepiness.  Persistent and profound fatigue is a symptom in AL amyloidosis 
which has never been adequately explained.  It is always vaguely assumed to be 
multifactorial from the wide range of organ involvement.  The current findings suggest 
that CSA/OSA may be a substantial contributor to this symptom. Recurrent hypoxemia 
was seen in both AL and ATTR cardiac patients but were more marked in the AL 
cohort – in keeping with the worse cardiac profile of AL patients compared to ATTR in 
general.     
An interesting finding in this study was the lack of or markedly reduced heart rate 
variability in patients with cardiac AL amyloidosis.  This lack of heart rate response to 
hypoxia was greater in AL amyloidosis than those with ATTR cardiac amyloidosis.  
Autonomic dysfunction is a known phenomenon in AL amyloidosis but the current 
finding had no correlation with clinical autonomic neuropathy.  Cardiac autonomic 
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denervation is well recognised feature of systolic heart failure279, 280  and 123I-MIBG – 
Metaiodobenzylguanidine (MIBG) scintigraphy is a useful tool for its identification.279, 
281  MIBG scans have been reported to be abnormal in cardiac amyloidosis both AL 
and ATTR type.281-284  The most marked lack of heart rate variability was seen in the 
patients who died.  Due to a restrictive left ventricle in cardiac AL, any needed 
increases in cardiac output are largely dependent on appropriate increase in the heart 
rate.  The lack of physiologic tachycardia in response to hypoxia could make the 
systemic consequences more profound.  This finding suggests that further 
assessment of cardiac autonomic denervation may be provide useful information in 
AL amyloidosis and open a potential therapeutic avenue for consideration of device 
therapy to counter a lack of the autonomic drive.  
The markedly abnormal findings in this pilot study, if confirmed by polysomnography, 
suggests possible avenues for intervention.  For many years, there was a suggestion 
that correction of CSA in systolic heart failure would improve outcomes.  A randomised 
study (SERV-HF) in  systolic heart failure and moderate to severe heart disordered 
breathing showed that assisted servo ventilation (ASV) controlled sleep disordered 
breathing but it did not improve survival; in fact there was increased cardiac mortality 
in the ASV group.285 The restrictive cardiomyopathy in AL is very different from the 
patients in reported in that study and those findings cannot be extrapolated to cardiac 
amyloidosis.  In addition, newly diagnosed AL is a disease of very high mortality not 
just chronic morbidity, in which SDB may impact.  Just as drugs which treat systolic 
heart failure effectively, like beta-blockers and ACE inhibitors, often have profoundly 
negative consequences in AL - impact of intervention on sleep disordered breathing 
in AL may have different consequences and will need a separate study of formal 
polysomnography sleep study to confirm occurrence of SDB (CSA and/or OSA) as 
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well as impacts of intervention with simple oxygen supplementation or indeed more 
complex intervention for SDB.      
We recognise the limitations of this pilot study – a small study cohort and the use of 
overnight pulse oximetery only.  The group of patients was mixed with newly 
diagnosed AL, those on longer term follow up as well as ATTR amyloidosis limiting 
ability to assess survival impact in subgroups.  There was no polysomnography to 
confirm the cause of the recurrent nocturnal hypoxia or clarify type of SDB.  
In conclusion, recurrent nocturnal oxygen desaturations are very common in patients 
with cardiac amyloidosis (both AL and ATTR type) as well as in patients with soft tissue 
amyloid deposits affecting the oropharyngeal tract.  A high proportion of patient score 
‘high risk’ for sleep disordered breathing by questionnaires designed to screen for such 
patients.  Increased number and frequency of nocturnal desaturations may be 
associated with poorer survival in patients with newly diagnosed cardiac AL 
amyloidosis.  Lack of heart rate variability (suggesting cardiac autonomic neuropathy) 
is a frequent occurrence on cardiac AL and particularly in those patients who died – 
findings which need further clarification. The role of hypoxia in precipitation of cardiac 
arrhythmias or sudden death in AL needs to be clarified.  Nocturnal hypoxia is a simple 
target for intervention in cardiac AL amyloidosis and could potentially help to reduce 
early mortality in AL which has remained an unmet medical need for over 25 years. 
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Chapter Six:  Natural history and outcomes in localised 
immunoglobulin light chain (AL) amyloidosis: a long-term 
observational study 
 
This chapter is in context of my publication: Natural history and outcomes in 
localised immunoglobulin light-chain amyloidosis: a long-term observational 
study. Shameem Mahmood, Frank Bridoux, Christopher P Venner, Sajitha 
Sachchithanantham, Janet A Gilbertson, Dorota Rowczenio, Thomas Wagner, Rabya 
Sayed, Ketna Patel, Marianna Fontana, Carol J Whelan, Helen J Lachmann, Philip N 
Hawkins, Julian D Gillmore, Ashutosh D Wechalekar. Lancet Haematology. 2015; 
2(6):e241-50. (Original article) copyright permission obtained and given by Lancet 
Haematology editors, 2015 for use in my thesis. 
 
Introduction 
Amyloidosis comprises a heterogeneous group of disorders produced by the 
extracellular deposition of misfolded proteins in an insoluble fibrillar form.286  Systemic 
light chain (AL) amyloidosis is the most common and serious type, where the amyloid 
fibrils are derived from circulating monoclonal immunoglobulin light chains produced 
by an underlying plasma cell or B-cell clone.  Hereditary systemic amyloidosis is 
associated with mutations in numerous variant proteins including transthyretin (ATTR 
amyloidosis) and apolipoprotein AI (AApoA1 amyloidosis).287   In systemic types of 
amyloidosis, the respective amyloid fibril precursor protein is present and circulating 
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in the bloodstream and results in relentless amyloid deposition throughout the body, 
progressive vital organ dysfunction and early death.288   
Localised deposits of amyloid can occur in various tissues in the body and are usually 
presumed to be of AL type, with the consequent presence of a focal monoclonal B cell 
dyscrasia within the affected tissue.  As such, the clinical effects of the localised 
amyloid deposits depend on their precise anatomical location, and can result in 
substantial morbidity.  
Localised amyloidosis is much rarer than systemic types, and consequently remains 
very poorly studied; with most knowledge arising from individual case reports or small 
series of less than 20 patients.  There are commonly reported sites include the urinary 
tract, respiratory tract, larynx, skin and eyelids.165  Currently, data on long term 
outcomes and progression to systemic disease is lacking with the need for further 
exploration in this field. We have examined the clinical features and outcomes of a 
large series of patients with localised AL amyloidosis highlighting the striking 
differences from systemic AL amyloidosis with respect to the lack of progression, 
benefit from debulking procedures, limited need for cytotoxic chemotherapy therapy 
and excellent overall long term outcomes.   
Methods 
Study design 
All the patients with a specified disease setting of localised amyloidosis diagnosed, 
assessed and followed up at the UK National Amyloidosis Centre (NAC) between 
January 2, 1980 and December 15, 2011 were identified using the NAC database and 
written medical records.  There was no exclusion criteria dependant on age or 
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performance status, with all comorbidities permitted. All the patients were newly 
diagnosed and treatment naïve. Localised amyloidosis was typed with biopsy proven 
amyloid deposition confined to a single site or tissue (with the relevant histology of the 
tissue examined), and no evidence of vital organ involvement, the latter defined as 
cardiac, renal, liver involvement or peripheral or autonomic neuropathy. Soft tissue 
involvement was defined as clinical evidence of a single deposit of amyloid in the 
tongue or one site of deposition in other soft tissues. Standard tests of vital organ 
function were assessed and absence of visceral uptake was documented by 123I serum 
amyloid P component (SAP) scintigraphy.289  All patients had SAP scintigraphy 
performed at their first visit except those diagnosed before 1988 (when the technique 
was introduced into clinical practice), and had this following availability of the 
procedure, which was invaluable in assessing for any visceral organ uptake.  A 
detailed protocolised assessment was followed by all patients at baseline and follow 
up visits to assess disease evaluation including a full blood count, renal and liver 
function tests, serum and urine protein electrophoresis and immunofixation, 
electrocardiogram (ECG), echocardiography and 123I SAP scintigraphy.  Serum free 
light chains (FLC) were also measured prospectively on all patients diagnosed after 
2002 on blood samples at presentation and consequent follow up visits; and also 
retrospectively on stored serum samples, where available, for patients prior to 2002. 
A bone marrow assessment was performed in patients with a proven plasma cell 
dyscrasia for further investigation. Histological confirmation of amyloid deposition of 
the affected tissue was conducted by showing Congo red staining and demonstration 
of typical birefringence under cross polarised light. Fat biopsies were not performed in 
addition to the affected tissue biopsy. The AL fibril type was determined by 
immunohistochemical (IHC) staining using a panel of antibodies and defined as 
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staining with antibodies kappa and lambda immunoglobulin light chains and/or no 
staining with antibodies to transthyretin, serum amyloid A protein (SAA) and ApoA1, 
with AL the likely type. Hereditary amyloidosis was excluded by genetic sequencing in 
patients in whom the clinical features could be in keeping with hereditary types – 
particularly all patients with laryngeal symptoms underwent Apo A1 gene sequencing; 
with laryngeal amyloid deposits a recognised feature of patients with Apo A1 
mutations. Transthyretin gene sequencing was performed if any biopsies had 
transthyretin staining to exclude ATTR. F18-flurodeoxyglucose positron emission 
tomography (FDG-PET/CT) was performed in 18 patients following this technique 
becoming an investigative tool at our centre.  
Local disease progression was defined as progression or recurrence of the amyloid 
deposit within the original localised site. Progression to systemic AL amyloidosis was 
clarified as development of a new vital organ involvement or new evidence of visceral 
amyloid deposits by 123I SAP scintigraphy, and stated as a number and percentage of 
the total localised amyloidosis cohort.  Statistical analysis in assessing survival 
endpoints was performed using SPSS version 20.  The overall survival (OS) was 
determined from the date of diagnosis defined from the date at which a biopsy proof 
of amyloidosis was obtained.   The overall survival was estimated by the Kaplan Meier 
method, calculated from the date of diagnosis until death or last follow-up, with the 
causes of death known in those who died. All the patients consented to their details 
being used anonymously and the study received approval from the Royal Free 
Hospital ethics committee.   
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Results 
Study population 
The recruitment to this study included a total of 606 patients with localised amyloidosis 
identified.  Overall, this accounted for 12% (606/5050) of 5050 newly diagnosed 
patients with all types of amyloidosis evaluated at our Centre during the study period. 
97 patients with laryngeal symptoms had Apo A1 gene sequencing, and interestingly 
transthyretin staining was present on 3 bladder biopsies, with transthyretin gene 
sequencing performed to exclude ATTR.  For the purposes of survival statistics, 11 
patients were excluded as three patients had ATTR amyloid deposition on bladder 
biopsy (with ATTR was not seen at any other localised site), 4 with lichen amyloidosis, 
3 with insulin amyloidosis and 1 patient had AApoA1 amyloid deposition in a laryngeal 
biopsy and shown to be heterozygous for ApoA1 Ala164Ser mutation by ApoA1 gene 
sequencing. These patients were excluded from only survival analysis with few 
numbers and little known as to underlying prognosis and complications of this group. 
All remaining patients were included in analyses of survival and progression to 
systemic disease illustrated in Figure 6.1A.  
The survival outcomes are available for all patients with data obtained from the Office 
of National Statistics in the UK.290  Baseline characteristics are illustrated in Table 6.1, 
with the median age 59.5 years (range 48.8-87 yrs, IQR 50.2-74.5) and 51% (307/606) 
were male.  The median symptom duration was 7 months (range 0.5-360 months, IQR 
4-24) prior to diagnosis. There were many sites of localised amyloidosis including: 
bladder 95/606 patients (15.7%); laryngeal/tonsillar 92/606 (15.2%); cutaneous 
84/606 (13.9%); pulmonary nodular 47/606 (7.8%); gastrointestinal 36/606 (5.9%); 
oral 36/606 (5.9%); tracheobronchial 35/606 (5.8%); lymph node 31/606 (5.1%); 
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conjunctival 27/606 (4.5%); bone 24/606 (4%); eyelid 22/606 (3.6%); orbital 21/606 
(3.5%); breast 13/606 (2.1%); ureteric 10/606 (1.7%); urethral 10/606 (1.7%); soft 
tissue 10/606 (1.7%); prostate 9/606 (1.3%); cerebral 3/606 (0.5%) and aortic valve 
1/606 (0.1%), (Figure 6.1B). Some patients had amyloid deposits at more than one 
localised site including cutaneous (9 patients) and within the gastrointestinal tract (2 
patients). The multiple deposits within the skin included - 5 patients with deposits in 
both lower limbs, and 3 patients having 2 separate skin sites involved (right calf and 
right elbow, face and skin over the breast, right hand and left elbow). Patients with 
gastrointestinal involvement included (gastric involvement in 7 patients, small bowel 
involvement in 10, 17 with large bowel involvement and 2 with small and large bowel 
involvement). 
 
  
 CHAPTER SIX 
 
- 182 - 
Figure 6.1A: Progression to systemic AL amyloidosis or need for therapy. A flow chart 
illustrating the patient flow, outcomes, treatment and progression to systemic AL in all 
606 patients described in the series. Light blue denotes patients in the study, with the 
dark blue showing additional information regarding the immunohistochemistry.  
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Figure 6.1B: Overall distribution of localised amyloidosis by site of amyloid deposition 
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Table 6.1: Patient characteristics 
Patient Characteristics Number (%)/Median(range) 
Age  59.5 years (48.8-87, IQR 50.2-74.5) 
Male 307 (51%) 
Duration of symptoms  7 months (0.5-360, IQR 4-24) 
Monoclonal protein  76 (12.5%) 
Monoclonal protein level  6.5 g/L (1-35, IQR 3-12) 
Monoclonal protein type  
IgG 38 (6.2%) 
IgA 8 (1.3%) 
IgM 29 (4.7%) 
IgD 1 (0.2%) 
Serum free light chains  
Abnormal kappa/lambda ratio 79 (13.0%) 
Abnormal lambda 28 (4.6%) 
Abnormal kappa 51 (8.4%) 
Involved light chain (iFLC) 56.2 mg/L (range 5.6-2100, IQR 5.6-
59.3) 
Difference between involved  
and uninvolved FLC (dFLC) 
 43.75 mg/L  
(range 3.2-2023, IQR 3.2-44.2) 
dFLC >50mg/L 37 (6.1%) 
Creatinine  79 µmol/L (range 69-91, IQR 69-90.5)  
Estimated glomerular filtration rate  81ml/min (range 70-100, IQR 70-100)  
Alkaline phosphatase  72 U/L (range 59-89, IQR 60-89)  
Albumin  44 g/L (range 42-46, IQR 42-46)  
24 hour urinary proteinuria  <0.1 g (range 0.1-3.2, IQR 0.1-0.2) 
Haemoglobin  13.5 g/dL (range 12.5-14.3, IQR 12.5-
14.4)  
Patients diagnosed in time intervals 
1980-1985 24   (4%) 
1986-1990 23   (3.8%) 
1991-1995 40   (6.5%) 
1996-2000 78   (12.9%) 
2001-2005 132 (21.8%) 
2006-2011 309 (51%) 
g/L – grams per litre; U/L – units per litre; µmol/L – micromoles per litre; g/dL – grams per 
decilitre.  Normal ranges for kappa: 3.30-19.4 mg/L, lambda: 5.71-26.3 mg/L, kappa/lambda 
ratio: 0.26-1 
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The presenting symptoms were determined by the site of amyloid deposition and 
Table 6.2 summarises the clinical features for each site of amyloid deposition, median 
age and duration of symptoms and accompanying ranges stated as minimum and 
maximum values.  Figure 2 shows different types of localised amyloidosis. 67 of 606 
patients (11.0%) were known to have an autoimmune disorder including 17/606 (2.8%) 
with Sjögren’s syndrome, 18/606 (3.0%) with hypothyroidism, 8/606 (1.3%) having 
rheumatoid arthritis and 6/606 (1.0%) diagnosed with systemic lupus erythematosus 
(SLE).  Taking into account the 17 patients with Sjögren’s syndrome, amyloid 
deposition was present in the lungs in 5, breast in 3, conjunctiva in 2 - accounting for 
10.6% (5/47), 23.1% (3/13), 7.4% (2/27) of all lung, breast and conjunctival 
amyloidosis patients respectively- and four in the skin. The remainder had amyloid 
deposition at a variety of other localised sites.  An unrelated history of non-
haematological malignancies was present in 37 patients (6.1%); cervical and ovarian 
cancer 3, carcinoma of the prostate 10, sigmoid cancer 6, transitional cell carcinoma 
4, Essential Thrombocythaemia/Polycythaemia Rubra Vera 3, breast carcinoma 7, 
renal cell carcinoma 2, brain tumour 1, and lung cancer 1. All these malignancies had 
occurred at a site remote from the presenting site of localised amyloid deposition. 
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Figure 6.2: A clinical spectrum of showing localised amyloidosis: (A) 123I labelled 
SPECT/CT showing a localised amyloidoma in the parieto-temporal region in a patient 
presenting with unexplained visual problems; (B) F-18 PET/CT scan in a patient with 
cutaneous amyloidosis showing multiple subcutaneous areas of FDG avidity at sites 
of amyloid deposition; (C) Bronchoscopy in a patient with tracheobronchial 
amyloidosis showing nodular amyloid deposits in the tracheo-bronchial tree; (D) A 
large cutaneous amyloid deposit in the scalp; (E) An enlarged axillary node in an 
elderly patient with localised lymph node amyloidosis; (F) and (G) A left iliosacral 
lesion in a patient with isolated localised bone amyloidosis showing marked uptake 
the lesion with 123I labelled SPECT-CT (F) which has completely disappeared at six 
months after completion of local radiotherapy with no 123I uptake at the site of the 
lesion and some sclerosis (G).  
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Table 6.2: Patient characteristics according to amyloid type 
Amyloid 
Type 
(n) 
Gender Age at 
diagnosis 
Median 
yrs. 
(range) 
Predominant 
Symptom 
Symptom 
Duration 
Median 
months 
(range) 
Associated 
underlying 
clonal 
disorder 
Parapro
tein 
(n) 
Abnor
mal 
κ/λ 
ratio 
(n) 
Surgical 
Intervent
ion 
(n) 
 
Progressi
on at the 
primary 
site 
(n) 
Non-surgical 
treatment  
 
PET 
Positive 
(positive/n with 
total PET scan) 
Laryngeal and Pulmonary System 
Laryngeal+ 
Tonsillar 
(92) 
46M 
46F 
57.4 
(13-83.3) 
Hoarse voice 10.5 
(1-360) 
 3 7 51 63 **Chemotx 
(1) 
*Radiotx (1) 
 
Tracheobro
nchial 
(35) 
14M 
21F 
47.6 
(31-81.7) 
Shortness of 
breath 
4.3 
(1-78) 
 2 5 18 22 **Chemotx 
(1) 
*Radiotx (3) 
 
Nodular 
Pulmonary 
(47) 
13M 
34F 
65.5 
(36-80) 
CXR 
abnormality 
Haemoptysis 
6 
(1-180) 
MALT (2) 9 1
0 
4 4 *Chemotx 
(2) 
7/18 
Urothelial System 
Bladder 
(95) 
35F 
60M 
64 
(37.1-87) 
Haematuria 6 
(1-120) 
 6 4 29 32 *DMSO (7)  
Urethral 
(10) 
10M 39.8 
(27.1-78.6) 
Urinary tract 
infections 
12 
(2-36) 
  2 5 5   
Ureteric 
(10) 
6M 
4F 
59.6 
(43.1-78.4) 
Haematuria 8 
(2-112) 
 1 1 14 8   
Cutaneous and Soft tissue System 
Cutaneous 
(84) 
44M 
40F 
56.1 
(24-80.9) 
Rash/lump 12 
(3-240) 
MM (1) 
NHL (1) 
12 1
5 
25 26 
*** 
**Chemotx 
(2) 
*Radiotx (1) 
1/18 
Soft tissue 
(10) 
3M 
6F 
65 
(35-78.6) 
lump 12 
(4-72) 
MM (1) 
LPL (1) 
1  6 6 **Chemotx 
(2) 
*Radiotx (2) 
2/18 
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Oral and Gastrointestinal System 
GI 
(36) 
29M 
7F 
61.4 
(37-83.9) 
PR bleeding 
Abdominal 
pain 
4 
(1-37) 
MM (1) 
MALT (1) 
8 9 8 8 
**** 
*Chemotx 
(2) 
 
Oral 
(36) 
17M 
14F 
58.2 
(24-78) 
Persistent 
lump 
6 (1-55.3) NHL (1) 
MALT (1) 
2 1 23 15 *Radiotx (1) 1/18 
Eye Related Systems 
Orbital 
(21) 
7M 
15F 
42.44 
(25.3-84.2) 
Ptosis 7.5 
(1-62) 
 2 5 6 6 *Radiotx(2)  
Eyelid 
(22) 
8M 
13F 
60.03 
(26.7-81) 
Lump 12 
(4-83) 
 4 3 20 18   
Conjunctiva
(27) 
11M 
16F 
51.1 
(24.6-76) 
Swelling 12 
(1-79) 
 1 0 20 22   
Lymph node, Bone and Sexual Organ Systems 
Lymph 
Node 
(31) 
17M 
14F 
62.1 
(34-77.8) 
Persistent 
lymph node 
7 
(1-57.1) 
MM (3) 
LPL (1) 
10 9 15 9 *Chemotx 
(2) 
**Chemotx 
(1) 
*Radiotx (2) 
6/18 
Bone 
(24) 
12M 
12F 
63.4 
(47-82.2) 
Bone pain 6 
(1-132) 
MM (1) 7 8 7 7 *Radiotx (5) 
 
1/18 
Breast 
(13) 
13F 59.9 
(36-78.3) 
Breast lump 3.5 
(2-4.75) 
MALT (1) 1  11 9   
Prostate 
(9) 
9M 68.1 
(57.6-73.5) 
Haematuria 8 
(5-16.5) 
MM (1)   7 3 **Chemotx 
(1) 
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Head and Cardiac Systems 
Cerebral 
(3) 
2M 
1F 
62 
(30-68) 
Weakness 4 
(2-6) 
    2 **Chemotx 
(1) 
*Radiotx (1) 
 
Aortic Valve 
(1) 
1M 71.6 asymptomatic 0.5    1 0   
 
PET - positron emission tomography; M – male; F – female; PR – per rectum; GI – gastrointestinal; DMSO – Dimethylsulpoxide; CXR – chest 
radiograph; Radiotx – radiotherapy; Chemotx – chemotherapy; MM – multiple myeloma; LPL – lymphoplasmacytic lymphoma; NHL – non-
Hodgkin lymphoma; κ/λ – kappa/lambda; * - Cytotoxic treatment for amyloidosis; ** - Cytotoxic treatment for underlying plasma cell dyscrasia;  
*** - 9 patients with cutaneous involvement had multiple amyloid deposits;2 patients with gastrointestinal involvement had multiple amyloid 
deposits. 
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A circulating monoclonal immunoglobulin or an abnormal serum free light chain (FLC) 
excess was present in 121/606 (20%) of patients, with Seventy six 76/606 (12.5%) 
having a monoclonal protein in the serum, and 79/606 (13.0%) having an abnormal 
FLC. A certain proportion of patients; 34/606 (5.6%) had the presence of a monoclonal 
protein and an abnormal FLC. The monoclonal immunoglobulin was measurable in 
52/606 (8.6%), with a median concentration of 6.5 g/L (range 1-35 g/L, IQR 3-12), and 
a kappa or lambda serum free light chain (FLC) excess was present in 51/606 (8.4%) 
and 28/606 (4.6%) patients respectively. The 79/606 patients (13.0%) with a 
monoclonal light chain had IHC confirming amyloid deposits of AL lambda and AL 
kappa type in 16 and 5 patients respectively, with the monoclonal light chain in the 
serum and IHC staining of the same isotype in all these cases. The presence of 
scattered lymphocytes and/or plasma cells was frequently seen at the site of amyloid 
deposition but these were too scanty in number to demonstrate clonality by IHC.  
Interestingly one patient with an involved FLC (iFLC) of 2100mg/L with cutaneous 
amyloidosis had no vital organ involvement and a normal bone marrow assessment. 
Seventeen patients showed evidence of a clonal plasma/B-cell disorder by bone 
marrow assessment.  The bone marrow examination was otherwise normal and did 
not reveal a clonal plasma cell or B lymphoid dyscrasia.  In 490/501 (97.8%) patients, 
amyloid deposits were in keeping with AL type. Immunohistochemical staining 
confirmed 67/501 (13.4%) consistent with AL kappa and 24/501 (4.8%) of the AL 
lambda type.  However in the 410/501 (81.8%) remaining patients, with no significant 
staining with antibodies to kappa, lambda, and no staining with SAA, transthyretin and 
ApoA1 and thus were more in keeping with a diagnosis of AL type. No patients had 
visceral uptake on 123I SAP scintigraphy at presentation.  The 18 patients who had a 
FDG-PET/CT showed FDG avidity at the site of amyloid deposition with a median 
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standardised uptake values (SUV) of 2.7 (2.5-10) in 14 of the 18 patients with reported 
SUV values (Appendix 5, Supplemental table 1).  
Treatment 
Complete details regarding interventions at the local disease site were available in 
527/606 (87%) cases, and incomplete treatment details in 72/606 (11.9%), with 
survival details also present in these patients. In total, 90/606 (14.9%) patients opted 
for local follow up preferably, with the open option of re-attending the National 
Amyloidosis Centre should they developed progressive symptoms or want to be seen 
at the NAC. A certain proportion of patients, 257/527 (48.8%) required no 
interventional treatment following the diagnostic biopsy or excision.  270/527 (51.2%) 
proceeded to at least one interventional procedure for symptom relief and 112/527 
(21.3%) patients required more than one repeat procedure. The symptom triggering 
the need for intervention was often the predominant/presenting symptoms based on 
site of deposits (table 6.2 illustrates these symptoms). The symptom of increasing size 
of the lesions usually prompted the need for intervention in cutaneous, oral, soft tissue, 
lymph node, nodular pulmonary and breast lesions. Pain was the trigger for in urethral 
and bone amyloid deposits. Interventional procedures included surgical treatment in 
44% and laser therapy in 7% (Table 6.2).  The surgical removal (n=4) or radiotherapy 
treatment (n=4) of the amyloid deposits in 8 patients led to disappearance of the 
circulating clonal markers, (Appendix 5, Supplemental table 2). 
Local radiotherapy has been used to treat patients more recently, and 18 patients were 
treated with this modality in our cohort (table 2). Symptomatic improvement was 
evident in 10/18 patients - 5 with bone lesions, 4 laryngeal/tracheobronchial and 1 
patient with a localised amyloidoma in the femoral nerve/lumbar plexus.  Three 
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patients received radiotherapy for tracheobronchial amyloidosis and one diagnosed 
with laryngeal amyloidosis following failure of prior surgical resections and stent 
insertions.  With a median follow up of 11 months (range 2-14 months), all patients 
noticed a significant improvement in their symptoms. 
Chemotherapy was used in four patients: 2 having symptomatic pulmonary and 2 with 
lymph node amyloid deposits with stabilisation of symptoms but no significant 
improvement.  There were a proportion of patients in whom corticosteroids alone were 
used; 12/606 (2%) cases (in 7 patients with tracheobronchial amyloidosis).  Topical 
dimethylsulfoxide (DMSO) was used in 7 cases of bladder amyloidosis with 5 cases 
noticing a symptomatic benefit.  Eleven other patients were treated with chemotherapy 
for progression of an underlying haematological disorder, not particularly for amyloid 
progression; with no significant impact on the local amyloid deposits.  
Progression and survival 
The median follow up of the study cohort is 74.4 months (range 3.7-349.2 months, 
IQR 37.2-132), and 51% (309/606) of patients were diagnosed after 2006 and 27.2% 
(87/606) before 2000 (illustrated in table 6.1). Progression at the primary site was 
present in 264/606 (43.5%) patients (table 6.2). Progression to systemic amyloidosis 
was rare, occurring in only 7/606 cases (1.2%); (five had a circulating monoclonal 
protein and one had a with detectable plasma cell clone in the marrow). The latter 7 
patients included 5 patients with lymph node (LN) involvement, one had eyelid and 
another bone involvement, progressing at a median on 51 months (20, 51, 60, 77, 84, 
48 and 51 months in each case respectively) from the diagnosis point. The site of 
progression to systemic amyloidosis included: three patients with soft tissue 
progression, two developed renal amyloidosis (one with additional soft tissue) and one 
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each having new lymph node or bone lesions (Appendix 5, Supplemental table 3).  
One patient developed asymptomatic uptake within the spleen by SAP scintigraphy. 
During the follow up period, there were a total of 94 deaths, and only three deaths 
directly attributed due to progression to systemic AL. The cause of death was 
determined in 84 cases from the death certificate data from the Office for National 
Statistics.290 In 10 patients, the patient’s general practice doctor was contacted to 
ascertain the cause of death. The majority of patients had other co-morbidities 
including chronic obstructive airways disease, sepsis, ischaemic heart disease, 
autoimmune disease and cancer of other aetiology.  The 5 and 10 year estimated 
survival was 90.6% (95%CI; 87.7-92.9) and 80.3% (95%CI; 75.7-84.1) respectively 
(illustrated in Figure 6.3A); with the median survival not reached for the entire cohort. 
The median survival for patients aged 70 years or older was 12.1 years (95% CI; 10.5-
13.7).  We compared our localised AL cohort to systemic AL patients diagnosed during 
this same time frame, (Figure 6.3B) showing the estimated survival for systemic AL 
amyloidosis over this time period was significantly shorter, 1.6 years (95%CI; 1.1-2.1) 
and 5 and 10 year estimated survival 37.0% (95%CI;0.37-0.43) and 26% (95%CI;0.23-
0.28)% respectively. We examined the OS of patients diagnosed over different time 
periods of this 30 year study when assessed as 5-yearly cohorts (except 1985-1995; 
included as one group due to smaller patient numbers) (Figure 6.3C), showing no 
significant difference and the numbers diagnosed showing an increasing trend. The 5 
year survivals were as follows: 1980-1995 [(97%(95%CI;0.82-0.97) and 
(87%(95%CI;0.75-0.94)], 1996-2000 [(88%(95%CI;0.79-0.93)and (77%(95%CI;0.67-
0.85)], 2001-2005 [(91%(95%CI;0.84-0.94) and (79%(95%CI;0.68-0.85)],  2006-2011 
[(91%(95%CI;0.86-0.94) and (85%(95%CI;0.76-0.91)]. 
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Figure 6.3A: Kaplan-Meier curve with overall survival in all patients with localised 
amyloidosis 
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Figure 6.3B: Kaplan Meier curve illustrating difference between patients diagnosed 
with systemic AL amyloidosis (blue) and localised AL amyloidosis (green). The median 
survival of patients with localised AL amyloidosis has not been reached compared to 
a median of 1.6 years for patients with systemic AL diagnosed over the same time 
period.  
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Figure 6.3C: Kaplan-Meier curve illustrating the overall survival in all patients with 
localised Amyloidosis divided into 5 year intervals (except 1980-1995 (as there were 
smaller patient numbers)).  The number of patients in each group was 1980-1995 – 
4% (24/606) during1980-1985, 3.8% (23/606) during 1986-1990, 6.5% (40/606) during 
1991-1995, 12.9% (78/606) during 1996-2000, 21.8% (132/606) during 2001-2005 
and 51% (309/606) during 2006-2011. 
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Discussion 
This study describes the largest cohort of patients with localised AL amyloidosis with 
clinical features and natural disease course showing stark differences from systemic 
AL amyloidosis.  Localised AL amyloidosis is classified as having a relatively indolent 
disease course that rarely evolves systemically.  Most patients can be managed 
adequately with local interventions, which is the primary treatment modality.  In this 
series, in striking contrast to systemic AL amyloidosis, localised amyloidosis does not 
appear to impact survival and, with only 3 deaths directly attributed to progression to 
systemic AL amyloidosis. 
Defining localised amyloidosis is critically important in assessing isolated deposits and 
the also in determining progression.  We defined localised amyloidosis as a patient 
with amyloid deposition at one single non-vital organ site with no evidence of 
amyloidotic end organ damage by the diagnostic criteria of the international society of 
amyloidosis of systemic organ involvement (in relation to no cardiac, renal, liver, nerve 
or macroglossia).  We had a unique modality to rule out visceral amyloid deposition 
with a very high level of confidence, due to the availability of SAP scintigraphy (a very 
sensitive and highly specific method for imaging visceral amyloid deposits) at our 
centre.  Hence, in absence of SAP scintigraphy, this diagnosis has to be approached 
with greater caution especially with those with a detectable FLC excess or M-protein 
and follow up would reveal the true nature of the diagnosis.  
Systemic AL amyloidosis typically affects the heart, kidney, liver, peripheral and 
autonomic nerves.86  In contrast, localised AL amyloidosis occurs mainly in mucosal 
sites (affecting the airways, bladder, gastrointestinal tract, and conjunctiva), skin or 
glandular sites (like breast) as in the current series and also previously reported.291-293  
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The presenting symptoms are site specific and may range from a localised lump (e.g. 
under the skin or breast lump), bleeding due to mucosal erosion (symptoms of 
haematuria or haemoptysis or melena) to obstructive symptoms when deposits are 
located at a luminal site (bronchial, ureter or GI tract obstruction). Multiple sites of 
involvement were present in certain patients with cutaneous and gastrointestinal 
amyloidosis. 
Localised amyloidosis has generally been reported to be of AL type. In the current 
series, of a total of 606 patients with localised amyloidosis, we considered 98% 
(490/501) patients to be in keeping with the AL type. However, we do recognise one 
of the limitations of our study was typing amyloid deposits with a high proportion of 
cases in the present series having staining with antibodies to both kappa and lambda 
light chains (although lacking staining with antibodies to SAA, transthyretin and 
ApoA1).  In the era before access to laser capture followed by mass spectrometry (the 
current gold standard), AL amyloidosis was a diagnosis of exclusion in cases where 
specific staining with light chain antibodies could not be demonstrate by excluding the 
presence of amyloid deposits of other types by appropriate staining.  Due to the long 
duration of this study, the vast majority of the patients were diagnosed using this 
algorithm.  However, it was notable that the staining with antibodies to kappa or 
lambda was much lower than generally seen in patients with systemic AL amyloidosis, 
and forward planning with the use of proteomic analysis will assist in this clarification.  
A recent case series of nodular pulmonary amyloidosis from the Mayo group, using 
laser capture micro dissection followed by tandem mass spectrometry (LC-MS) for 
fibril typing, suggested that amyloid fibrils are a mixture of heavy (AH) and light chain 
(AL) type;294  a potential explanation for difficulties in accurate staining by anti-light 
chain antibodies.  The retrospective nature of this study over a long period limited the 
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scope of LC-MS being undertaken for the current series and does remain a limitation 
of this series. 
Generally, over 95% of patients diagnosed with systemic AL amyloidosis have a 
detectable monoclonal protein or abnormal FLC295 (which directly impacts on 
prognosis296) and a detectable bone marrow plasma cell clone; in contrast with the 
present series in which a normal bone marrow was seen in those with an abnormal 
FLC or monoclonal protein (except 17 patients with an underlying plasma cell 
dyscrasia/B-cell clone) and 80% with no evidence of a circulating M-protein or 
abnormal FLC.  In our study, 20% (121/606) had a monoclonal protein or abnormal 
serum free light chain excess, with the presence of a monoclonal protein in 76/606 
(12.5%) and abnormal serum free light chain excess in 79/606 (13.0%), and some 
overlap of these groups. We recognise this figure may be higher than other centres, 
and this difference predominantly due to referral bias and age of the referred 
populations in different respective centres. Previous studies have shown that 5-10%  
of the population have an incidental monoclonal protein in those older than 70 years 
of age.297 Patients with lymph node involvement had a higher chance of having a 
detectable monoclonal protein, with one study showing this group as having a high 
risk of progressing to systemic AL.298 Of seven patients who progressed to systemic 
AL, 5 had evidence of a detectable clonal marker in the serum.  Patients with systemic 
AL amyloidosis having abnormal light chains for many years prior to diagnosis,299 
localised AL patients with an abnormal FLC still warrant long term follow up for 
progression. Lack of clonality by bone marrow assessment in localised amyloidosis 
supports previous reports of limited clonal proliferation at the site of amyloid deposition 
as documented by highly sensitive methods like IgH-PCR300, 301 with only few patients 
of the present series having an obvious local clonal cell infiltrate.  The location of skin 
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and mucosal sites raise the possibility of chronic antigenic stimulation or autoimmunity 
as drivers for local clonality302 particularly as Mucosa-associated lymphoid tissue 
(MALT) lymphoma is a reported cause of lung and breast amyloidosis.303, 304 23% of 
all cases of breast amyloidosis in this series were associated with Sjögren’s syndrome 
(an association in 17 cases in total), also a previously reported association of localised 
amyloidosis with MALT.305  The lack of detectable clonal cells remains an enigma in 
most cases.  Oligomeric light chains may be toxic to cells and tissues – with one theory 
suggesting that plasma cells in localised AL are part of a “suicide” neoplasm and die 
to due to light chain toxicity locally.306  Hence, this is an interesting hypothesis to 
explain lack of cells as well as lack of systemic progression.  
Serial monitoring of patients with localised amyloidosis is a difficult hurdle since the 
standard serum or urine markers are frequently normal or not contributory with 123I 
labelled SAP scintigraphy rarely abnormal.  Surprisingly, all 18 patients who had a 
FDG-PET/CT performed in the current series (Supplementary table 1) showed 
presence of FDG avidity at the site of amyloid deposition, in keeping with previous 
reports of high proportion of FDG-PET/CT positivity in localised amyloidosis.307  This 
potentially useful finding is a metabolic conundrum given the lack of identifiable clonal 
cell infiltration in the deposits.  Inflammatory or giant cells within the amyloid deposits 
have been suggested as a potential cause of the metabolic activity detected by FDG-
PET/CT.308  Further studies are needed to investigate the utility FDG PET/CT in both 
diagnosis and monitoring of patients with Localised amyloidosis.  
In contrast to systemic AL amyloidosis, approximately 50% of the patients in the 
current series did not require any intervention following the diagnostic biopsy/excision.  
Patients with obstructive/pressure symptoms or bleeding needed endoscopic or 
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surgical resection.  Half of all patients needed one such procedure and a fifth of all 
patients required repeated procedures for symptom control highlighting the need for 
long term monitoring.  Four patients in the current study needed chemotherapy for 
localised amyloidosis.  Radiotherapy (targeting the presumed clonal proliferation) 
appears to be a useful, and possibly underutilised, treatment modality in localised 
amyloidosis with all patients in the current series treated with radiotherapy showing 
lack of progression and over half achieving good symptomatic improvement following 
radiotherapy.  Tracheo-bronchial deposits can be very troublesome and symptomatic 
with marked morbidity and are a particular challenge amongst Localised AL.  In this 
group, radiotherapy has been reported to give symptomatic benefit (in 8/10 309 and 7/7 
310 patients treated) and this was also evident in all three treated patients in the current 
cohort.  The dose and scheduling of radiotherapy require further systematic study.  
Systemic AL amyloidosis typically remains a disease with a poor prognosis with a 
median overall survival of about four years and, despite much progress, nearly a third 
of all patients die in the first few months following diagnosis.192 We compared our 
localised cohort with patients diagnosed with systemic AL during this same time frame, 
with an explicitly better prognosis in the former. This large series reassuringly 
examines the natural disease course of Localised amyloidosis, showing it has an 
excellent prognosis with a median survival not reached in our cohort compared with 
an overall surviall of 1.6 yrs for patients with systemic AL amyloidosis seen during the 
same period.  Most of the patients died of other causes and only three deaths 
attributable directly to localised AL.  The suvival of the patients compared with that 
expected in the British population (medain survival of the over 70 yrs patients in the 
current series 12.1 yrs which was similar to that for the British person at the age of 70 
years) (date from Office of National Statistics UK).290 Another cruciaal point was that 
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only seven patients or 1.2% progressed to systemic AL amyloidosis. We specifically 
ruled out visceral deposition by serum amyloid P (SAP) scintigraphy and cardiac 
involvement by echocardiography plus normal cardiac biomarkers. There are two 
groups of patients with localised AL which pose some problems – those with lymph 
node involvement and those with a detectable circulating light chain/M-protein having 
the same isotype as the amyloid type.  It is contentious whether we can confidently 
say that some patients with a localised lymph node amyloid deposit have localised 
disease or “systemic” disease. Patients with no vital organ involvement and a localised 
lymph node were categorised as localised amyloidosis, however this group is very 
different from the other types of localised amyloidosis; with the increased risk of 
“systemic disease” and spread through the lymphatic system, akin to other types of 
lymphoma. In our series, 5/31 patients with lymph node involvement progressed to 
systemic AL and 6/79 patients with a clonal light chain excess progressed (5 of these 
having lymph node patients), with only one patient with no obvious light chain excess 
progressed. We recognise that patients with isolated lymph node amyloidosis are 
deemed at high risk of progression, and similarly those with an isotypic excess of FLC 
also need careful monitoring.  The very low chance of systemic progression in other 
patients with localised amyloidosis implies that these patients should not be subjected 
to frequent invasive monitoring.   
There are a number of gaps in our knowledge of localised amyloidosis, with the 
retrospective nature of this study. A longer median follow up is always important in 
following and understanding a disease entity, recognising that 51% (309/606) of 
patients were diagnosed after 2006. Accurate identification of the amyloid fibril type by 
LC-MS is important with immunohistochemistry sometimes inadequate for fibril typing 
in this setting.  Novel approaches to clarify the nature of the underlying clonal 
 CHAPTER SIX 
 
- 203 - 
disorder(s) is required to guide therapy and unravel the prediliction for specific sites.  
International colloborative studies are needed to prospectively evaluate the utility of 
radiotherapy and other treatment modalities. 
In summary, localised AL amyloidosis is a disease different from systemic AL 
amyloidosis.  Local surgical resection is adequate in most cases when treatment is 
needed.  Radiotherapy appears to have a useful role in patients not controlled by local 
measures.  Progression to systemic AL amyloidosis is extremely rare except in  
patients with lymph node involvement.  Patients with lymph node involvement and 
those with a isotypic specific circulating free light chains warrant closer follow up for 
development of systemic AL. The majority with localised AL have excellent long term 
outcomes. Most die with the disease rather than as a consequence of it. 
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Chapter Seven:  Laryngeal tracheobronchial amyloidosis: clinical 
and proteomic analysis showing an association with Apo A1 and 
insulin-like growth factor binding protein complex 
 
Introduction 
Laryngo-tracheobronchial amyloidosis is a rare type of localised amyloidosis, 
characterised by insoluble fibrillar proteins deposited within the upper and lower airway 
tract.311, 312 The underlying amino acid sequences and building block structure of this 
and other types of amyloidoses share a common β-sheet conformation of the 
polypeptide backbone,313 and thus forming a fibrillar, insoluble, proteolytic resistant 
structure in all types of amyloid. Exploring the mechanism of the amyloid fibril 
formation is vital in gaining insight into the mechanisms in the underlying 
polymerisation of the soluble, monomeric peptide into the insoluble β-pleated sheet. 
Earlier studies have shown that this conversion of a soluble peptide to an insoluble 
fibril often includes the formation of a partially unfolded intermediate.314, 315 Some 
studies propose a nucleation dependant polymerisation model to explain the fibril 
formation.316 The underlying pathogenic factors are unknown, with the hypothesis 
including a population of clonal plasma cells or B cells instigating this process in a 
localised area. This entity is clearly different from systemic light chain (AL) 
amyloidosis, in which the clonal plasma cells arise from the bone marrow and secrete 
excessive quantities of monoclonal immunoglobulins which then circulate to target 
organs.317 
The aims of this study were to (a) report our experience of patients presenting with 
laryngeal and tracheobronchial amyloidosis, examining the clinical symptoms, 
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treatment strategies and overall survival from a clinical perspective, (b) analyse the 
laryngeal /tracheobronchial biopsies and undertaking proteomic analysis of these 
patients and ascertain any potential underlying pathogenic instigators in this process 
from a laboratory perspective. 
Patients and methods 
Patients 
Patients with laryngeal and tracheobronchial amyloidosis between January 1980 and 
December 2011 were identified from the database of the UK National Amyloidosis 
Centre. Written consent was obtained from all patients in accordance with the 
Declaration of Helsinki.  Exclusion of systemic AL and vital organ involvement 
(including cardiac, renal, liver, peripheral or autonomic neuropathy) was performed on 
review of a detailed baseline assessment of organ function and no uptake by 123I 
serum amyloid P component (SAP) scintigraphy, with patients before 1988 (availability 
of 123I SAP scintigraphy) having this procedure later in their follow up course. Baseline 
investigations included a full blood count, renal and liver function tests, serum protein 
electrophoresis, serum free light chains (prospectively in samples after 2002 and 
retrospectively on stored serum samples where available), and urinary BJP, 
electrocardiogram and echocardiography and 123I SAP scintigraphy. Histological 
analysis was performed on all biopsies with Congo red staining and apple green 
birefringence and immunohistochemical staining for kappa, lambda, transthyretin or 
serum amyloid A (SAA) antibodies undertaken in the majority. Genetic sequencing 
was undertaken dependent upon clinical details and immunohistochemical staining, 
such as Apolipoprotein (Apo) AI in all patients with available blood samples. During 
this time frame, 63 patients with laryngeal involvement and 34 patients with 
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tracheobronchial amyloidosis with biopsy proven amyloid deposition were recruited. 
The pathology slides were requested and reviewed at our centre and laser capture of 
the slides undertaken to then perform proteomic analysis, with a total of 60 biopsies 
retrieved. A total of 37 biopsies were not able to be analysed due to inaccessibility of 
the original samples requested from the local hospitals/referring centres. 
Patient questionnaire with quality of life assessment 
A patient questionnaire was sent to all patients to ascertain the following data with 52 
responses and 46 responses concerning quality of life. The questionnaire comprised 
of 2 questions related to symptoms and duration and treatment options, and quality of 
life with a grading score 0-10; score of 0 depicting a poor quality of life and 10 
describing an excellent quality of life. The median overall score and ranges were 
gained to reflect an understanding in the clinical impact of this disease from a patent’s 
perspective. 
Protocol for laser capture 
Laser capture micro dissection and mass spectrometry (LDMS) is an invaluable tool 
for identifying proteins from formalin-fixed, paraffin embedded tissues, with more in 
depth procedure described in the methods chapter.169 Visualisation and locating the 
amyloid was done using bright field (Figure 7.1A) and Rhodamine filter sets (TRITC) 
on the Zeis Palm Microbeam Laser capture microscope, with amyloid typically yellow 
on a “red” background. (Figure 7.1B) Areas of interest were drawn around, appearing 
yellow under a Tritc florescent filter (Figure 7.1C) or under bright field (Figure 1D) and 
“cut” out using laser capturing into 0.5ml micro-centrifuge adhesive cap tubes (Zeiss) 
and checking the cap to ensure that some tissue had been captured. Figure 7.1D 
illustrates the amyloid tissue post dissecting the tissue of interest and the figure 7.1E 
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shows the dissected amyloid tissue for proteomic analysis, with figure 7.1F showing 
the dissected tissue. Figure 7.1G shows congo-red staining of the tissue and apple-
green birefringence illustrated in figure 7.1H. 
Figure 7.1A:. Isolation of amyloid under bright field and (B) the TRITC filter 
 
 
Figure 7.1C and 7.1D: Demarcation of the areas of amyloid to be dissected under 
TRITC filter (C) and (D) under bright field 
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Figure 7.1E: Tissue under bright field post dissecting the amyloid tissue 
 
Figure 7.1F: The dissected piece of tissue for proteomic analysis 
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Figure 7.1G: Congo red staining of tissue 
 
Figure 7.1H: Apple green birefringence of the tissue 
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The data was processed using Proteome Discoverer for MASCOT searching of the 
NCBI and IPI databases enabling mass spectrometry results to be produced. 
Statistical analysis and overall survival 
Data was analysed and summarised using the number (percentage) and median 
(minimum and maximum range). Quality of life assessments were based upon a score 
0-10, with 0 and 10 equating to no quality of life and an excellent quality of life 
respectively. Kaplan Meier curves were used to estimate the overall survival (OS); 
calculated from the start of symptoms until death or last follow-up for the laryngeal and 
tracheobronchial cohorts. Kaplan Meier estimates were used using SPSS v20 (IBM 
SPSS) to calculate the OS and PFS. All p values are 2 sided, with significance values 
based on a p <0.05. 
Results 
Patient population 
The study was conducted between January 1980 and December 2011 and clinical 
characteristics are summarised in table 7.1 and 7.2 with the symptoms within each 
group illustrated in figure 2A and 2B. No patient developed systemic AL amyloidosis. 
Genetic sequencing was performed in 59 patients, with only 1 patient diagnosed with 
laryngeal involvement heterozygote for the Apolipoprotein A1 Ala160Ser mutation and 
no evidence of other organ dysfunction. 
 
  
 CHAPTER SEVEN 
 
- 211 - 
Table 7.1: Patient characteristics in laryngeal group (n=63) 
Patient Characteristics Number (%) 
Male 29 (46%) 
Age 57.4 (44.7-66) years 
Symptom duration 10.5 (6-24) months 
Personal history of cancer 8/56 
Smoking history 16/56 
Autoimmune disorders 7/56 
GORD 6/56 
Hypertension 10/56 
Location  
Supra-glottic 6 
Vocal cord/tonsil 33 
Subglottic 16 
Not specified 8 
Investigations  
Creatinine 78 (54-128) µmol/L 
Estimated glomerular filtration rate 87 (49-100) ml/min 
Albumin 45 (33-52) g/L 
Alkaline phosphatase 70 (30-131) U/L 
24 hour urinary protein 0.1 (0.1-0.5) g 
Haemoglobin 13.5 (10-17.3) g/dL 
Positive serologic clonality 10 
Immunoparesis 0 
Quality of life score 8 (3-10) 
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Table 7.2: Patient characteristics in tracheobronchial group (n=34) 
Patient Characteristics Number (%) 
Male 12 (35%) 
Age 47.6 (54-62.5) years 
Symptom duration 4.3 (8-24) months 
Personal history of cancer 4/28 
Smoking history 22/28 
Autoimmune disorders 3/28 
GORD 2/28 
Hypertension 7/28 
Location  
Tracheal 4 
Right sided bronchial 11 
Left sided bronchial 3 
Bilateral bronchial 12 
Not specified 4 
Investigations  
Creatinine 80.5 (40-358) µmol/L 
Estimated glomerular filtration rate 84 (10-100) ml/min 
Albumin 43 (32-50) g/L 
Alkaline phosphatase 70 (39-207) U/L 
24 hour urinary protein 0.1 (0.1-3.2) g 
Haemoglobin 14 (10-16.6) g/dL 
Positive serologic clonality 10 
Immunoparesis 0 
Quality of life score 5 (1-9) 
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Figure 7.2A: Presenting symptoms in the laryngeal cohort 
 
Figure 7.2B: Presenting clinical symptoms in the tracheobronchial cohort 
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Treatment strategies 
Surgery 
Surgical and laser therapeutic options were pursued in 39/63 (62%) and 18/34 (52.9%) 
patients with laryngeal and tracheobronchial amyloidosis with 29% (n=18) and 24% 
(n=8) requiring repeated procedures respectively. 
Radiotherapy 
A total of 4 patients with symptomatic airway amyloidosis involvement (1 laryngeal and 
3 tracheobronchial) received radiotherapy with a median dose of 20 Gy in 10 fractions. 
Following a median follow up of 18.7 months range (6-47), all patients had 
experienced symptomatic local control.  
Chemotherapy 
One patient with laryngeal involvement and one patient with tracheobronchial 
amyloidosis received chemotherapy; each with a lambda light chain excess and no 
evidence of an excess of plasma cells by bone marrow assessment. Both patients 
achieved a fall in the lambda light chains to less than 40mg/L with minimal 
improvement in their symptoms. It is difficult to ascertain or comment on whether their 
symptoms would have progressed with no treatment. 
Quality of life assessment 
A patient questionnaire was sent to all patients, with a response in 46 patients. The 
median quality of life score in 33 laryngeal patients and 13 tracheobronchial patients 
was 8 (range 3-10) and 5 (range 1-9) respectively. This is illustrated in table 7.1 and 
7.2. 
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Overall survival 
The 2 and 5 year OS for the laryngeal and tracheobronchial cohort were 90% and 
81%, and 93% and 83% respectively, figure 7.3. The majority of patients had other co-
morbidities with the median age of death in the laryngeal cohort 69.5 years (45.2-82.5) 
and tracheobronchial cohort 65.3 years (55.1-79.2). 
Figure 7.3: Kaplan Meier curve comparing overall survival in patients diagnosed with 
laryngeal amyloidosis with tracheobronchial amyloidosis, although not statistically 
significant (p 0.66), the curves show a clear difference in the time course in each 
disease following approximately 75 months. 
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Proteomic analysis 
The proteomic analysis on 60 patients diagnosed with laryngeal and tracheobronchial 
amyloidosis showed evidence of the 3 signature amyloid proteins – Serum amyloid P 
(SAP), Apo A4 and Apo E. Interestingly, these patients all had evidence of insulin-like 
growth factor binding protein complex and Apo A1. Comparison was made between 
these samples and in those patients diagnosed with systemic immunoglobulin light 
chain (AL) and transthyretin based disease, with patients with the systemic disease 
showing no proteomic evidence of insulin-like growth factor binding protein complex 
and a much lower ApoA1 peptide quantification than patients with laryngo-
tracheobronchial disease.  
We analysed laryngeal and tracheobronchial normal tissue in 5 samples; acting as 
normal controls. The results showed that insulin-like growth factor binding protein 
complex and Apo A1 were not normal constituents of this tissue. 
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Figure 7.4: Proteomic analysis of a micro-dissected amyloidotic area showing the 
presence of the amyloid signature proteins, along with light chains, 3 insulin-like 
growth factor binding protein complex and other proteins.  
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Figure 7.5. Protein sequence showing a repeating peptide sequence (red) in 
patients with localised laryngeal and tracheobronchial amyloidosis by proteomic 
analysis. 
 
Genetic sequencing 
Genetic sequencing was undertaken in all patients for Apo A1, with only 1 patient 
being heterozygote for the Ala160Ser mutation.  
Discussion 
This is the first and largest study examining patients diagnosed with laryngeal and 
tracheobronchial amyloidosis, from a clinical and laboratory perspective. The clinical 
symptoms differed between these groups, with some overlap. Treatment options are 
limited and typically directed toward the site of amyloid deposition including surgical, 
laser techniques and in limited cases radiotherapy and chemotherapy. Proteomic 
analysis in 60 samples demonstrated the presence of all 3 amyloid signature proteins 
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in all samples as expected, and interestingly the presence of Apo A1 and insulin-like 
growth factor binding protein complex, a feature not present in patients with systemic 
disease. This finding may serve as a platform to better understanding of patients with 
localised amyloidosis of the airway tract. 
Strengths and limitations of the study 
This study reports the largest patient series of the upper and lower airway tract; 
invaluable in gaining insight into a disease where little is known about the clinical 
outcomes, treatments and underlying aetiology. Clinical characteristics were collated 
using medical records, computerised database of the UK National Amyloidosis Centre 
and patient questionnaires to enable a more extensive and complete data collection. 
The main limitation was the retrospective nature of this study, with some incomplete 
data as to the clinical symptoms and although a large number, only 60 histological 
samples of the 97 patients available for mass spectrometry analysis. Proteomic 
analysis of these 60 samples enabled us to hypothesise a relationship with 2 
underlying proteins Apo A1 and insulin-like growth factor binding protein complex. 
Clinical presenting features 
Amyloidosis affecting the upper and lower airway tract present with respiratory 
symptoms like many other respiratory tract conditions, with a prior history of a laryngitis 
and asthma/bronchitis in 4 and 7 patients respectively. Analysis of our cohort show 
that the median age is 57.4 (range 44.7-66) and 47.6 (54-62.5) in both laryngeal and 
tracheobronchial groups with a greater female predominance. Figure 7.2A and 7.2B 
illustrate the symptoms experienced. The median symptom duration was shorter in the 
tracheobronchial group 4.3 months (range 8-24) versus 10.5 months (range 6-24) the 
upper airway tract, corroborating another large case series.318 Triggering factors have 
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not been defined in these diseases 318, 319. In our series, smoking was present in 16/56 
28.5% (laryngeal) and 22/28 78.6% (tracheobronchial). Within the laryngeal group, the 
location of the lesion was situated in the supra-glottic region, vocal cords, subglottic 
and not stated in 6, 33, 16 and 8 patients respectively. The predilection for bilateral 
and right sided bronchial deposits may arise secondary to the anatomy of these lower 
airway tracts, with the right bronchial tract wider, shorter and more vertical than the 
left. Previous studies have reported the location of the lesion has having a major 
bearing upon the risk to respiratory failure, specifically higher risk patients with 
proximal and mid-bronchial lesions. 320 
 
Treatment strategies 
Excisional therapeutic options are the primary modality in managing these patients.321-
323 Here the focus is to remove the tissue containing amyloid deposits and associated 
plasma/B cells. Systemic chemotherapy is not used frequently due to the low clonal 
plasma/B cell burden, making the risks and toxicity of this treatment outweighing the 
potential gain, despite the possible associated serum light chain excess or monoclonal 
protein311 
Radiotherapy has been described in some cases with LBTA309, 311, 318, 324 with the basis 
that plasma cells are radiosensitive, with the majority of patients being treated with 20 
Gy in 10 fractions.309 Similarly, in our series one patient with laryngeal involvement 
and three patients with tracheobronchial amyloidosis received radiotherapy, following 
failure with prior surgical resections and stent insertions to achieve local control. With 
a median follow up of 18.7 (6-47) months, these patients have had notable 
improvements in their quality of life, consistent with previously published literature. 
 CHAPTER SEVEN 
 
- 221 - 
Truong et al described outcomes in 10 patients post-radiotherapy with symptomatic 
airway amyloidosis patients (3 laryngeal and 7 tracheobronchial). With a median follow 
up of 6.7 years (1.5-10.3) 8 of 10 patients had symptomatic improvement.309 
Overall survival 
The OS of localised laryngeal and tracheobronchial amyloidosis is excellent with the 
2 and 5 year survival 90% and 81%, and 93% and 83% respectively. Figure 3 
illustrates the latter with comparison of both groups. Although not statistically 
significant (p 0.66), the OS following 75 months shows a sharper decline in the 
tracheobronchial group. These differences are most likely due to the underlying 
pathogenic factors, possibly the extent of the localised deposits, smaller bronchial 
anatomy and likeliness to occlude the airway tract.  
Laser capture and proteomic analysis 
Laryngeal and tracheobronchial amyloid deposition was characterised further with 
laser capture and proteomic analysis. All 60 cases exhibited evidence of 3 amyloid 
protein signature proteins serum amyloid P (SAP), Apo E and Apo AIV in conjunction 
with Apo A1 and insulin-like growth factor binding protein complex. Proteomic analysis 
was also performed in a total of 60 patients with systemic AL amyloidosis (renal, 
cardiac and liver biopsies) or transthyretin based disease (cardiac, bone marrow) as 
a control, with none of these samples showing evidence insulin-like growth factor 
binding protein complex and a much lower peptide content of Apo A1.  
Apo A1 has been described in hereditary and non-hereditary cases. In hereditary 
ApoA1, deposition of amyloid occurs in different organs and tissue caused by the 
germline mutation in the ApoA1 gene. Non-hereditary ApoA1 is characterised by the 
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non-variant protein and has been described in atherosclerotic intima325 and within the 
respiratory tract; thought to be reduced in patients with chronic pulmonary disease 
(COPD) resulting in airway limitation.326  
Insulin growth factor (IGF) and insulin growth factor binding proteins (IGFBP) 
proteases are involved in somatic growth, cell proliferation, cell transformation and 
apoptosis.327-329 IGFBPs and IGF may form binary compounds and  allowing selective 
transport into tissues327  Insulin growth factor (IGF) is thought to be a key modulator 
of lung fibroblast proliferation and is found at sites of inflammation330, 331 Further 
studies have shown the regulation of IGF signalling via expression/down regulation of 
ligands, receptors and/or regulatory binding proteins in previous malignancies.332 IGF-
1 genetic polymorphisms may represent the long term exposure of IGF-1 on the 
cellular and circulatory sites. 
The literature supports increasing evidence that amyloid fibril formation and 
aggregation arises from a partially folded conformation of the aggregating protein, 333 
with the initial lag in fibril formation thought to be secondary to the slow assembly of a 
critical nucleus in a nucleation-polymerisation mechanism.334 Although aggregation 
occurs when high concentrations of the key partially folded intermediate is present, 
other factors including the pH, temperature, amino acid sequence and concentration 
of the intermediate play a role.  The presence of ApoA1 and insulin-like growth factor 
binding protein complex in the LTBA proteomic analysis is a new finding and further 
work is needed to elucidate the significance in localised amyloid in the laryngeal and 
tracheobronchial cases. Further studies are needed to elucidate the function of these 
factors before a significant pathogenesis is attributed with exploration in other types of 
localised amyloidosis.  
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Future directions 
Further studies are needed to ascertain whether Apo A1 and insulin-like growth factor 
binding protein complex assist in instigating an underlying inflammatory process, 
bystanders or involved in maintaining the self-limited localised nature of this disease. 
In summary, we believe that LTBA is a type of localised amyloidosis with a more 
troublesome clinical and hence problematic therapeutic quandary than other types of 
localised amyloidosis. 
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Chapter Eight:  Lenalidomide and dexamethasone for systemic AL 
amyloidosis following prior treatment with thalidomide or 
Bortezomib regimens 
 
This chapter is written in the context of the publication: Lenalidomide and 
dexamethasone for systemic AL amyloidosis following prior treatment with 
Thalidomide or Bortezomib regimens. Shameem Mahmood, Christopher P. 
Venner, Sajitha Sachchithanantham, Thirusha Lane, Lisa Rannigan, Darren Foard, 
Jenny H. Pinney, Simon D. J. Gibbs, Carol J. Whelan, Helen J. Lachmann, Julian D. 
Gillmore, Philip N. Hawkins and Ashutosh D. Wechalekar. British Journal of 
Haematology. 2014; 166(6):842-8. (Original article) copyright permission obtained 
from John Wiley and Sons, license no.: 3784261189203 for use in my thesis. 
 
Introduction 
Amyloidosis is a disorder characterised by protein misfolding leading to formation and 
deposition of amyloid fibrils in different tissues with change in structure and 
consequent dysfunction of the affected organs. Systemic immunoglobulin light chain 
(AL) amyloidosis is the most common type286 resulting from an underlying plasma cell 
dyscrasia and treatment targeted toward suppressing this underlying clone.  
Treatments are directed against the underlying clone and hence have been adapted 
from those developed for treatment of myeloma. Immunomodulatory drugs (IMiDs) are 
emerging as an important backbone for treatment of AL amyloidosis in both the 
relapsed/refractory (Dispenzieri, et al 2007 Sanchorawala, et al 2010, Wechalekar, et 
al 2007 Palladini, et al 2012) and upfront setting.85, 105, 108, 335 Small phase II studies 
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have shown good clonal responses using lenalidomide-dexamethasone in 67% 104, 105 
and similar clonal response rates of 50%-62% with the addition of alkylating agents. 
89, 106-108 Very few series have reported organ responses following lenalidomide 
treatment.  It is well recognised that organ responses are usually generally delayed in 
AL amyloidosis with the exception of cardiac responses based on biomarkers, with the 
latter difficult to interpret in patients in IMiD based therapies.136 Premature assessment 
of an organ response may lead to not recognising the full clinical impact of any 
treatment in this disease.   
We report a substantial cohort of patients treated with lenalidomide in the 
relapsed/refractory setting, following the use of Bortezomib and/or thalidomide with 
long term follow up assessing the impact of previous therapies on haematologic 
responses.  This study reports an unexpectedly high rate of organ responses on long 
term follow up in patients treated with Lenalidomide based treatment.  
Patients and methods 
This patient cohort comprised of all patients with systemic AL amyloidosis followed at 
the UK National Amyloidosis Centre from July 2007 to August 2013 who received 
treatment with lenalidomide for relapsed (n=62) or refractory (n=22) clonal disease, 
with at least one prior line of therapy.  Confirmation of amyloidosis was confirmed by 
histology with Congo red staining and AL type confirmed by specific immunostaining 
of amyloidotic tissue by antibodies to kappa or lambda light chains with exclusion of 
hereditary amyloidosis by gene sequencing depending on the clinical details.  All the 
patients had evidence of either an abnormal serum free light chain (FLC) ratio or a 
monoclonal immunoglobulin component by serum or urinary immunofixation by 
electrophoresis. Written consent for retrospective publication of anonymous data was 
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obtained from all patients in accordance with the Declaration of Helsinki.  Organ 
involvement, haematologic and organ responses were classified according to the 
updated international amyloidosis consensus criteria, and a renal response was 
described as a 50% decrease and at least a decrease of ≥ 0.5g/24 hours of 24 hour 
urinary protein in patients with baseline urinary protein >0.5g/L, with no worsening of 
the creatinine/creatinine clearance by 25% above the baseline. Patients with no urine 
or urine quantification less than 0.5g/24 hours had assessment of their renal outcome 
based according to the estimated glomerular filtration rate and are reported separately.  
FLC and monoclonal protein response criteria were according to the updated 
Consensus guidelines.87 Patients received 21 days of a 28 day cycle of lenalidomide 
with the addition of variable doses of dexamethasone 10-40mg once weekly, (Table 
8.1).  Lenalidomide treatment was given until there was disease progression or 
unacceptable toxicities.   
The overall survival (OS) was assessed from the start of lenalidomide treatment until 
death or last follow-up. Progression-free survival (PFS) was calculated in responding 
patients from the commencement of treatment with lenalidomide until relapse, death 
or last follow-up.  Survival endpoints were also examined to assess the impact of 
previous treatment lines.  Statistical analysis was performed using SPSS v20 (IBM 
SPSS) software. Kaplan Meier estimates were used to calculate the OS and PFS. P 
values <0.05 were considered statistically significant. 
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Table 8.1: Patient Characteristics336 
Patient Characteristics (n=84) n (%)/median(range) 
Male/Female 43 (51%)/41(49 %) 
Age (yrs) 64.5 (45.5-79.1) 
Detectable Monoclonal protein 35 (41.7%) 
Light chain type 
Kappa 
Lambda 
 
31 (37%) 
53 (63%) 
Involved FLC (mg/l) 109.5 (19.5-1480) 
dFLC (mg/L) 92.6 (6.4-1478) 
Number of previous therapies 2 (1-6) 
Prior Thalidomide 64 (76.1%) 
Prior Bortezomib 58 (69%) 
Treatment strategies 
Prior ASCT 13 
Lenalidomide dose  
5 mg 10 (11%) 
10 mg 8 (10%) 
15 mg 21 (25%) 
25 mg 45 (54%) 
Dexamethasone  
10 mg 17 (20%) 
20mg 48 (57%) 
40 mg 19 (23%) 
Organ involvement 
Heart 42 (50%) 
Kidney 52 (61.9%) 
Liver 18 (21.4%) 
PNS 23 (27.3%) 
ANS 17 (20.2%) 
Soft tissue 32 (38%) 
Number of organs involved 
1 organ 20 (23.8%) 
2 organ 29 (34.5%)  
≥ 3 organs 36 (42.9%) 
Mayo Stage  
                  Stage I 24 (28.6%) 
                  Stage II 47 (56%) 
                  Stage III 10 (11.9%) 
mean LV wall thickness (mm) 12 (10-18) 
NT-proBNP (ng/L) 1034 (110-79,576) 
Serum creatinine (µmol/L) 110 (47-976) 
eGFR (mls/min) 51 (10-100) 
CKD stage 4 and 5 17 (20.2%) 
24 hour proteinuria (g) 0.7 (0.1-16) 
n, number; k, kappa; l, lambda; FLC, free light chain; mg/L, milligrams per litre; dFLC, 
difference in involved and uninvolved free light chains; NT-proBNP, N-terminal fragment of 
brain natriuretic peptide; ng/L, nanograms per litre; mm, millilitres; µmol/L, micromoles per 
litre; mls/min, millilitres per minute; eGFR, estimated glomerular filtration rate; CKD, chronic 
kidney disease; LV left ventricular; ASCT, autologous stem cell transplantation; mg, milligrams 
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Results 
A total of 84 patients were identified from our database listing all registered patients. 
The baseline clinical characteristics are illustrated in table 8.1. The median age was 
64.5 years (range 45.5-79.1) and 52% were male. 37 (44%) had 3 or more organs 
involved.  48 (56%) and 17 (20%) patients had a recorded pre-treatment estimated 
glomerular filtration rate (eGFR) < 60 ml/min and < 30 ml/min respectively. The median 
pre-treatment N-terminal fragment of brain natriuretic peptide (NT-proBNP) was 1034 
ng/L with 11 patients having an NT-proBNP >8500ng/L, and a median threshold of 
1881ng/L at 6 months.  The median number of lines of treatment was 2 (range 1-6).  
Seventy six percent and 68%, respectively received prior treatment with thalidomide 
and Bortezomib based regimens.  The median time from diagnosis to the 
commencement of lenalidomide based treatment was 26.4 months (range 6-394). The 
median duration of lenalidomide treatment was 6.5 months (1-52), with 31 (37%) 
patients continuing following 12 cycles.   
Haematologic response and survival  
Lenalidomide regimens were used in the relapsed setting for 62 patients, with the 2 
year OS and PFS 82% and 73%, respectively, versus 84% and 74% in the refractory 
setting (n=22).  On an intention-to-treat (ITT) basis, 51 (61%) achieved a 
haematological response with a complete response (CR) in 17 (20%), very good 
partial response (VGPR) in 6 (8%), partial response (PR) in 28 (33%) and no response 
(NR) in 33 (39%) at 6 months (range 1-13) when the haematological response was 
assessed.  The median time to haematologic response was 3 months (range 1-19), 
with haematological responses seen in 36 (56%) (VGPR or better in 14 (22%)) patients 
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treated with prior thalidomide and in 32 (55%) (VGPR or better in 13 (22%)) patients 
treated with prior Bortezomib. 
The median follow-up for this study was 21 months (range 1.2-80.6) and 21 deaths 
occurred during this time.  The estimated 1 and 2 year overall survival (OS) was 90% 
and 84% respectively (Figure 8.1A) with the estimated 1 and 2 year PFS 82% and 
73% respectively (Figure 8.1B). Previous exposure to thalidomide did not confer a 
worse survival outcome and the estimated 2-year OS with and without thalidomide 
treatment was 82% versus 83% ((HR 1.45 (0.48-4.38); p = 0.51), respectively.  The 
estimated 2-year PFS for those receiving prior thalidomide therapy was 80% in 
comparison to 36%; those not receiving thalidomide ((HR 0.82 (0.36-1.85); p=0.623)).  
Similarly, previous exposure to Bortezomib did not confer a worse survival (estimated 
2-year OS 80% versus 85%, (HR 1.56 (0.6-4.06); p=0.36)) and the PFS ((estimated 2 
year PFS 78% vs. 57%; HR 1.32 (0.60-2.91); p=0.492).   
Patients who achieved a partial haematological response or better conferred an 
estimated 2 year survival of 85% in comparison to 66% for those not responding (HR 
0.45 (0.19-1.08); p 0.67). Achieving a light chain response but not necessarily a 
paraprotein response was important in translating to a survival advantage with patients 
achieving at least a partial dFLC response (PR or greater) having a median estimated 
2 years OS of 79% in comparison to 65% for non-responders (HR 0.25 (0.08-0.72); 
p=0.014)) (Fig. 8.1C). A paraprotein response in isolation, did not confer a similar 
survival advantage (HR 0.71 (0.16-3.22); p=0.66)) (Fig. 8.1D). Multivariate analysis 
showed that lack of a dFLC response and NT-proBNP >8500 ng/L were the sole 
independent factors adversely impacting on survival (table 8.2). 
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Figure 8.1A: Kaplan Meier estimated overall survival on an intention to treat basis.  
The median overall survival has not been reached336 
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Figure 8.1B: Kaplan Meier estimates of progression free survival. The median 
progression free survival was 44.5 months336 
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Figure 8.1C: Overall Survival stratified by the dFLC response achieved.  Patients 
achieving a partial dFLC response or greater (solid line) had a significantly better 
overall survival than those who did not achieve a dFLC response (dashed line)336 
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Figure 8.1D: Overall Survival stratified by the monoclonal protein response.  There 
was no significant impact of an isolated monoclonal protein response on survival 
(patients achieving a partial haematological response or greater (solid line) and no 
response (dashed line))336 
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Table 8.2: Variables associated with survival336 
 
Variable HR (95% CI) p 
Univariate Analysis 
Age >65 years 1.73 (0.72-4.13) 0.45 
Heart involvement 2.93 (1.17-7.36) 0.02 
NT-proBNP≥8500ng/L 4.23 (1.47-12.1) 0.001 
Paraprotein haematologic response 0.71 (0.16-3.22) 0.659 
dFLC haematologic response 0.25 (0.08-0.72) 0.014 
Performance status ≥3 2.96 (0.39-22.66) 0.296 
dFLC ≥180mg/L 1.52 (0.51-4.52) 0.45 
Organ involvement ≥3 1.16 (0.49-2.73) 0.74 
Multivariate analysis 
dFLC response 0.34 (0.12-0.95) 0.039 
NT-proBNP≥8500ng/L 2.75 (0.94-8.04) 0.065 
IVSd, interventricular septal dimension; mm, millimetres; NT-proBNP, N-terminal 
fragment of brain natriuretic peptide; ng/L, nanograms per litre; LVEF, left ventricular 
ejection fraction; dFLC, difference in involved and uninvolved free light chains; eGFR, 
estimated glomerular filtration rate 
 
We undertook a subgroup analysis taking into account the dexamethasone dose (10, 
20, 40mg) with a 2 year OS (HR when compared to dose of 40 mg) of 76% (HR 2.32 
(093-5.78 p 0.07)), 84% (HR 1.1 (0.46-2.61 p 0.84)) and 93% (reference) respectively 
and 2 year PFS 57% (HR 2.44 (1.13-5.27) p 0.023)) 73% (HR 1.08 (0.51-2.26) p 0.85)) 
and 89% (reference) respectively. 
Organ responses 
We assessed the median time to first organ response assessment as 6 months (range 
6-24).  On an ITT basis, at six months, organ responses were observed in 14/84 (16%) 
of patients. 5/42 evaluable (12%) patients achieved a cardiac response and 2/18 
(11%) achieved liver responses.  Twenty one out of 38 (55%) evaluable patients 
achieved a renal response (40% on an ITT basis) – 7 (18%) at 6 months, 7 (18%) at 
12 months and an additional 7 (18%) patients at 18 months by long term follow up.  
The median duration of lenalidomide in these 38 patients was 11 months in total (range 
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6-52 months).  An eGFR <15 ml/min was present in 5 patients and could not be 
included in any renal response analysis.  Two patients with proteinuria <0.5g had 
stable eGFR values following treatment and 1 patient experienced a decline in eGFR 
from 41ml/min to 15 ml/min. Fifty seven patients had evaluable visceral amyloid 
deposition by 123I serum amyloid P component scintigraphy with regression evident in 
17 (30%) patients at 6 months. 
Toxicity 
Twenty three patients experienced grade 3-4 toxicity (27%): neutropenia in 14 
patients, sepsis in 4 patients, skin rash in 3 patients, thrombosis in 1 patient and 
diarrhoea in 3 patients.  14 (16%) required dose reduction (from starting doses of 
25mg) to 5-15mg primarily due to neutropenia.  One patient developed repeated 
thrombosis of a dialysis fistula which resulted in cessation of treatment but there were 
no other thrombotic complications (including in 8 patients with a prior personal history 
of thrombosis who received full intensity anticoagulation during their treatment). No 
significant change in the eGFR was evident following treatment (baseline median 51 
(range 10-100) mls/min to 47 (range 10-100) ml/min post therapy). No patients 
developed secondary malignancies during this follow up period. 
Discussion 
There has been significant evolution of treatment of AL amyloidosis during the last 
decade.  Although oral melphalan-dexamethasone remains widely considered as a 
standard of care, currently most patients receive a novel agent based regime, usually 
as induction chemotherapy and again frequently at relapse.  The optimal sequence for 
using novel agent based therapies and the outcomes of relapsed patients have been 
studied to a lesser degree. The current treatment of AL amyloidosis is directed against 
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the underlying clonal disorder; with the ultimate goal to achieve amyloid regression in 
the affected organs. Modern treatments are increasingly successful in achieving the 
former but the latter goal seems less tangible and also poorly studied and reported 
less in studies of patients treated by chemotherapy based approaches.  Ultimately it 
is the organ response that will impact on patient survival and quality of life.   
The present study reports the largest cohort of patients treated with lenalidomide-
dexamethasone (LD) currently, showing overall good haematological responses, in 
systemic AL amyloidosis specifically in the relapsed/refractory setting.  The overall 
haematological response rate of 58% (CR -20%) achieved is reflective similarly to 
earlier phase II studies of LD.104,105 The haematological response, particularly the 
dFLC response translated into a significant survival advantage (HR 0.25 (0.08-0.72); 
p=0.014)).  The dFLC-responses were rapid and the median time to respond was 3 
months – comparatively better than that reported in earlier LD studies 104, 105 and also 
similar to those reported for LD-alkylator combinations, often in those treatment naïve 
and previously treated 89, 106, 107 hence the benefit of an additional alkylator in treatment 
of patients with systemic AL.   
Data is limited data regarding the impact of prior Bortezomib or thalidomide based 
treatments on lenalidomide responses.  Myeloma studies analysis seems to suggest 
a poorer response in previously thalidomide treated patients.337  Although 
retrospective, this patient cohort had two thirds of all patients treated in a relatively 
uniform manner with oral cyclophosphamide-thalidomide-dexamethasone 85 as the 
standard first line therapy followed by Bortezomib at first clonal relapse and 
lenalidomide dexamethasone at second clonal relapse - a treatment line consequence 
as a result of treatment directed by funding availability clearly, in the UK, which is 
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regulated by the National Institute of Clinical Excellence (NICE). Italian colleagues in 
a study showed that a median 2 year OS following lenalidomide dexamethasone with 
Bortezomib pre-treatment was 47%.338  In the current study, treatment with 
thalidomide or Bortezomib did not impact on either the haematological response, 
overall or progression free survival (2 year OS was ~ 80% in those with and without 
previous exposure to either chemotherapeutic agent).  Our study showed that the 2 
year OS was 76%, which was better than that reported in the Italian study – very likely 
due to baseline disease characteristics which dominate survival outcomes in AL 
amyloidosis.  Typically cardiac involvement, specifically Mayo stage 3 carries a poorer 
prognosis. The OS in this study is very different in compared to the reported outcomes 
of newly diagnosed patient outcomes as reported for prospectively followed up 
patients in our Alchemy study cohort339 predominantly due to a very high proportion 
(29% early deaths in 714 patients (44% with Mayo stage 3)) in newly diagnosed 
patients with AL amyloidosis.  We performed a subgroup analysis determined by the 
dexamethasone dose which showed a trend for an improved OS and PFS in those 
having a higher dose but is difficult to interpret due to patient selection and the 
retrospective nature of the cohort.  This was also shown in the recent study illustrating 
better outcomes in patients administered higher dose dexamethasone in the upfront 
setting340 and may reflect rapid disease control in AL which may be different from 
myeloma.   Lack of impact of prior therapy on outcomes is encouraging and may be 
partly explained by the treatment strategy. It is important to consider that apparent 
poorer outcomes in patients who did not receive prior thalidomide may reflect patient 
selection with significant neuropathic disease in which case tolerance may be poorer.  
Due to significant risk of morbidity, it has become practice in the UK for patients to 
discontinue chemotherapy following one or two cycles following best haematological 
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response.  However, this may prevent selection of resistant plasma cell clones, and 
thus allowing for responsive disease at relapse.  There was a non-significant trend to 
poorer progression free and overall survival in patients in those who had not received 
prior thalidomide or prior Bortezomib, accounting for a third of the patients in the 
current series (mainly comprising of patients with significant peripheral and/or 
autonomic neuropathy); limiting tolerance and availability of therapies, likely, leading 
to poorer overall outcomes.  Therapeutic options for treatment of patients with 
relapsed disease are always changing.  Given the high upfront responses to 
Bortezomib, re-challenge may be useful but data is limited at this stage; trials 
incorporating drugs such as MLN9708 or Carfilzomib in this setting are currently 
ongoing.  
Organ response following chemotherapy treatment are generally fewer in number than 
haematological responses, and remain less well studied or explored.  Generally long 
term follow up of chemotherapy patients is scarce with most organ responses reported 
at six months – and likely to underestimate the true (delayed) advantages of these. 
Our colleagues from Italy recently reported the long term follow up of patients treated 
with oral Melphalan-dexamethasone with renal responses reported in 24% of 
patients.341 We have previously reported a renal response rate of 32.6% in 429 
patients seen from our centre until May 2008.342  The organ response rates in the 
current series at six months, seen in a fifth of the patients, is similar to the previous 
studies of patients treated with lenalidomide-dexamethasone (17% and 35% of 
patients from early phase II studies104, 105 respectively) and cyclophosphamide-
lenalidomide-dexamethasone (22% 89 and 31% 107). Assessment of cardiac response 
post chemotherapy using the standard NT-proBNP assay may not reflect the true 
benefit of lenalidomide in the current series due to potential for the paradoxical 
 CHAPTER EIGHT 
 
- 240 - 
increase as previously reported,136 with a rise in the median NT-proBNP 1881ng/L at 
6 months from baseline 1034ng/L in the current cohort.  The striking result was the 
fact that 55% of evaluable patients achieved a renal response by 18 months (with the 
median duration on lenalidomide - 11 months).  Interestingly, a select cohort of 
patients treated with long term lenalidomide (median duration - 9 months) reported by 
colleagues from Boston also showed an amyloidotic organ response in 44% of 
evaluable patients.343 The renal responses in both these series appear to be 
significantly higher than the previous reports of chemotherapy treated patients (25% 
in long term follow up of MDex treated patients in comparison to 55% in the current 
cohort) which appears to be similar to those treated with autologous stem cell 
transplantation.344  The amyloidotic organ responses are important and in LD treated 
patients are especially striking as the complete response rate is not particularly high 
(approximately 20%).  Lenalidomide is thought to increase the lymphoid immune 
function by increasing the natural killer (NK) cell numbers and antibody-dependent 
cell-mediated cytotoxicity and thus enhancing T-cell cytokine production.345  
Lenalidomide also induces NK cells to stimulate production of granulocyte-
macrophage colony-stimulating factor, TNF-α, and various other immune recruiting 
chemokines including RANTES, IL-8, MCP-1, and MIP-1α/β in response to antibody-
coated tumour cell lines, which contributes to a more effective cellular (including 
macrophage) immune response.346  Previous studies from our group have shown a 
natural slow clearance of amyloid from organs is affected by a macrophage type 
mediated mechanism, which can be substantially enhanced with therapeutic 
antibodies that target the deposits.15 Unexpectedly high percentage of renal 
responses raises the possibility that lenalidomide may directly enhance the natural 
regression of amyloid through its immunomodulatory effects. Supposing this was the 
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case, lenalidomide may play an adjuvant role in anti-amyloid immunotherapies which 
are currently in development, as seen in its similar use in myeloma immunotherapy 
with elotuzumab.  There are a number of caveats which remain in bearing in mind 
interpretations of these results: this is a retrospective series with limited patient 
numbers, the possible selection of patients who are long term survivors and have the 
resilience to tolerate long term therapy; with possible underestimation of organ 
responses in other studies due to the early assessment time points.   
Approximately a third of all patients in the current series developed grade 3 or greater 
toxicity.  Although worsening renal function347  or high incidence of skin toxicity has 
previously been reported with lenalidomide; not seen in the current cohort.  The major 
grade 3 toxicity experienced was cytopenias which consequently led to dose 
reductions. The grade 3 myelosuppression which developed improved following a 
reduction of the lenalidomide dose, with a lenalidomide dose of 15 mg better tolerated 
in our study, similar to previous reports,104, 106, 108 suggesting that this is an appropriate 
starting dose.  A few patients needed dose reduction after the first few cycles with the 
stable dose achieved with good tolerance and considered for longer term therapy.  
Although longer follow up is needed, there were no secondary malignancies in this 
patient series. The toxicity profile reported in this series appears to better than that of 
reported in prospective trials, very likely due to underestimation of toxicity due the 
retrospective nature of this study and should be interpreted with caution accordingly.  
Thus in summary, lenalidomide/dexamethasone is an effective regimen in treating 
patients with systemic AL amyloidosis with relapsed and/or refractory clonal disease 
with prior Bortezomib or thalidomide based regimens. Lower commencing doses 
compared to that routinely used in treatment of patients with myeloma should be 
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considered to allow better tolerance.  There was an encouragingly high rate of organ 
responses recorded in this study in those patients receiving long term lenalidomide is 
intriguing and needs further study in a larger patient cohort, with consideration of 
evaluating this concept in experimental models to evaluate the potential of 
lenalidomide in directly modulating the clearance of amyloid deposits. 
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Chapter Nine:  Use of targeted therapy for reducing circulating SAP 
in patients with hereditary fibrinogen amyloidosis and dialysis 
related amyloidosis 
 
Introduction 
Systemic amyloidosis can be a fatal condition which is either acquired or hereditary, 
leading to the accumulation of amyloid deposits within different tissues and organs, 
resulting in dysfunction in the latter, with a high risk of mortality depending on the organ 
involved.194 Hereditary fibrinogen amyloidosis was initially described in a Peruvian 
kindred in 1993.45 Fibrinogen related amyloidosis has predominant renal involvement 
with end stage renal failure within 5 years of presentation with proteinuria.47 There are 
4 novel mutations reported with the main mutation E526V variant.45 Currently there 
are no definitive therapeutic cures for this condition, with renal transplantation 
performed in a selected cohort with a median graft survival of 6.7 years, with a 
combined liver and renal transplantation considered only for very young, fit patients 
but also associated with a high mortality.47 
Beta-2-microglobulin (β2M) amyloidosis is a condition that arises in patients receiving 
long term haemodialysis or continuous ambulatory peritoneal dialysis (CAPD).348, 349 
Studies have shown that β2M is a major constituent of amyloid fibril formation, with 
deposition within the synovial membranes and osteo-articular sites and hence 
clinically destructive osteo-arthropathies, carpal tunnel syndrome, flexor tenosynovitis, 
subchondral bone cysts, erosions and fractures.350 
Serum amyloid P component (SAP) is a normal constituent plasma glycoprotein 
previously shown to bind calcium-dependently to amyloid fibrils.351, 352 and an earlier 
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study using ((R)-1-[6-[(R)-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2 
carboxylic acid (CPHPC)) to target SAP as a treatment for systemic amyloidosis1 with 
an excellent safety profile and variable SAP depletion in the various patient cohort. 
We therefore investigated the clinical, safety, biochemical results with the quality of 
life effects of CPHPC in patients with hereditary fibrinogen amyloidosis (n=10) and 
dialysis related amyloidosis (n=3) in a pilot study. 
Patients and methods 
Patients 
The primary cohort consisted of 10 patients diagnosed with hereditary fibrinogen A α-
chain amyloidosis (AFib) and 3 patients with dialysis related amyloid (Aβ2M) attending 
the National Amyloidosis Centre initially recruited from August 2012, with patient 
characteristics illustrated in table 9.1. We sought permission from the Royal Free 
Hospital’s Drugs and Therapeutics Committee and all patients consented for 
compassionate use of CPHPC, with written consent for retrospective publication of 
data obtained from all patients in accordance with the Declaration of Helsinki. 
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Table 9.1: Patient characteristics 
Number of patients 13 
Sex  
Male 10 
Female 3 
Age (years)  
Median 66.7  
Range 48.9-74.1 
Amyloid type  
Hereditary fibrinogen (AFib) 10 
Dialysis related (Aβ2M) 3 
ECOG  
0 11 
2 2 
Organ involvement  
Renal  13 
CKD stage 1-2 3 
CKD stage 3-4 7 
End stage renal failure (dialysis 
dependant) 
3 
Renal allograft 1 (with CKD stage 3-4) 
Baseline PET/CT involvement in (Aβ2M) 
patients 
3 
CKD – chronic kidney disease; PET/CT – positron emission tomography – computed 
tomography. 
 
 Study design and dosing 
We conducted a single centre study with compassionate use of CPHPC approved by 
Glaxo Group Ltd and the Royal Free Hospital in patients with hereditary fibrinogen A 
α-chain amyloidosis and dialysis related amyloidosis. The CPHPC administration was 
typically given as subcutaneous injections for patients with hereditary fibrinogen 
amyloidosis and via intravenous route for those with dialysis related amyloidosis.  The 
CPHPC dose was dependent upon the estimated glomerular filtration rate (eGFR). 
Patients with an eGFR greater than 25mls/min received 60mg subcutaneously three 
times a day, and those with an eGFR less than 25mls/min received 60mg 
subcutaneously twice a day. For those on haemodialysis patients (Aβ2M) a dose of 
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30mg CPHPC was given intravenously three times a week at the end of each dialysis 
session. The clinical status of the patients were assessed at baseline and serial 
monitoring performed with clinical assessment and investigations including 
haematological, biochemical renal parameters and urinary quantification of 
proteinuria, creatinine clearance, quality of life questionnaire 6 monthly, visual analog 
scale (VAS) scores for any joint pain and whole body 123I-labelled SAP scintigraphy 
(with a 4 week washout period to ensure no residual effect of the CPHPC effect). The 
VAS score is a continuous scale comprised of a horizontal (10cm) line with the 
extremes of pain 0; no pain and 10; maximum pain marked. It was self-completed by 
each patient. Patients with dialysis related amyloid had pre-treatment 2-deoxy-2-
[fluorine-18] fluoro–D-glucose positron emission tomography- computed tomography 
(18F FDG PET-CT) with reassessment of this imaging at 6 months post-treatment.  
Quality of life (QoL) questionnaire assessments 
The quality of life was assessed at 6 monthly intervals for all patients with the use of 
the validated Quality Metric SF36v2® Health survey. This is designed to measure 
functional health and well-being from the patient’s perspective. There are eight 
specified health domains (physical functioning, role physical, bodily pain, general 
health, social function, role emotional, mental health and vitality) which are assessed 
are scored individually.177 The result is expressed in comparison to the American 
norms. The average score for healthy controls in each measure is 50, with higher 
scores representing a better QoL. A change of 10 points or greater in any domain 
between administrations is considered clinically significant. This is explained in detail 
in the methods chapter.  
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Results 
Depletion of circulating SAP 
The median (range) SAP concentration in our patient cohort was 25 mg/L (range 8-
38), with the normal range 8-55 mg/L.353 The first follow up appointment was arranged 
for 6-8 weeks following the initial administration of CPHPC, showing the SAP 
concentration had fallen to undetectable limits, <4mg/L at the second visit and 
consequent visits, aside from visits which co-incided with an SAP scan; which the 
CPHPC had been stopped 2 weeks previously. The quantification of the visceral 
amyloid deposits by 123I labelled SAP scintigraphy performed yearly did not show any 
significant difference in the amyloid load. 
Clinical results 
Among the 10 patients administered with CPHPC, 3 patients progressed to dialysis 
(one patient post renal transplantation and renal function deteriorating secondary to a 
further renal insult). The median follow up for the whole cohort was 28.9 months (range 
9.1-38). The pre-treatment median eGFR was 31mls/minute (19-78) with pre-
treatment quantitative proteinuria 3g (range 1.1-18.6). Following treatment with 
CPHPC 7 patients have remained dialysis independent. Comparison was made with 
9 matched historical (eGFR matched) controls with reference made to the renal 
parameters as end points, table 9.2. Monitoring of the natural course of the 
biochemical parameters including the estimated glomerular filtration rate (eGFR) and 
creatinine are illustrated in figure 9.1A and figure 9.1B respectively, showing a more 
rapid decline in eGFR and corresponding rise in creatinine in the historical controls in 
comparison to patients treated with CPHPC.  
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Table 9.2: Comparison of clinical and laboratory features of AFib patients treated with 
CPHPC and historical controls 
 CPHPC No CPHPC 
Number of patients 10 9 
Baseline creatinine 
clearance (mls/minute) 
  
Median 39.8 41 
Range 8.2-144 28-138 
Age (years)   
Median 66.7 51.7 
Range 48.9-74.1 46.8-67.9 
Proteinuria (g of 
protein/24 hours) 
  
Pre 3 (1.1-18.6) 4.8 (0.2-8.2) 
Range 2.96 (1.6-10.8) 4.9 (0.2-7.6) 
Creatinine pre 177.5 (84-289) 173 (77-276) 
Creatinine post 257.5 (77-595) 452 (91-848) 
eGFR pre 31 (19-78) 28 (20-90) 
eGFR post 22 (9-71) 10 (10-59) 
Systolic blood pressure   
Median 132 140 
Range 98-186 129-170 
Diastolic blood pressure   
Median 73 89 
Range 56-97 70-105 
ACE inhibitor or ARB   
Number of patients taking 1 
agent 
7 6 
Number of patients taking 2 
agents 
2 0 
Dialysis dependant 3 7 
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Figure 9.1A: The natural history of estimated glomerular filtration rate (eGFR) in 
hereditary fibrinogen amyloidosis patients treated with CPHPC (solid lines) and CKD 
matched controls (dashed lines) 
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Figure 9.1B: Natural history of creatinine in hereditary fibrinogen amyloidosis patients 
treated with CPHPC (solid lines) and CKD matched controls (dashed lines) 
 
We assessed the time to dialysis as an end point showing a statistically significant 
difference between patients receiving CPHPC (n=10) and historical controls (n=9), 
with the median time to dialysis for the latter 60 months and not reached in those 
patients receiving CPHPC, figure 9.1D. Cox regression analysis also showed a HR of 
10.86 (2.17-54.45), p=0.004. 
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Figure 9.1D: Renal survival in patients receiving CPHPC (solid line) was significantly 
better (p<0.0001) than CKD matched controls (dashed line) 
 
 
We contacted the local doctors caring for these patients for prior renal function results 
to assess the natural history and time course of this disease, to assess the natural 
renal course in this disease, figure 9.1E. Unfortunately many patients had a limited 
history of serial biochemical monitoring, with the majority of patients presenting with 
renal impairment and proteinuria, and shortly followed by assessment at our Centre. 
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Fig 9.1E: Natural history of the creatinine pre CPHPC treatment in a select group of 
patients 
 
VAS scores in hereditary fibrinogen and dialysis related amyloidosis patients 
VAS scores were recorded at each visit for a follow up of 6-12 months, recorded in 
figure 9.2. Patients with hereditary fibrinogen amyloidosis recorded an improvement 
in their joint symptoms, with 1 patient not describing any joint pain. 
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Figure 9.2: Recordings of VAS scores in 9 patients treated with CPHPC showing a 
progressive decline in joint pain whilst patients were on treatment 
 
VAS scores were also recorded in the dialysis related amyloidosis patients, but 
multiple joints were described as painful at baseline, with the pictorial images in figure 
9.3 illustrating the chronological change in their symptoms following treatment. 
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Figure 9.3A: Patient 1 with (β2M) amyloidosis illustrating a pictorial image of the 
recorded VAS scores at baseline and following 12 months of treatment with CPHPC 
 
Figure 9.3B: Patient 2 with (β2M) amyloidosis illustrating a pictorial image of the 
recorded VAS scores at baseline and following 12 months of treatment with CPHPC 
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Figure 9.3C: Patient 3 with (β2M) amyloidosis illustrating a pictorial image of the 
recorded VAS scores at baseline and following 12 months of treatment with CPHPC 
 
 
18F FDG PET-CTs in DRA patients 
18F FDG PET-CTs were performed in the 3 patients with dialysis related amyloidosis, 
typically showing increased metabolic activity in the peri-articular soft tissue and 
bones. Clinically figure 9.3A, 9.3B and 9.3C illustrates the pattern of joint pain by each 
patient, with the typical joints showing uptake by 18F-FDG PET-CT the hip, shoulders 
and sacroiliac joints, figure 9.4A and 9.4B. Comparison of these images from baseline 
to 12 months following CPHPC treatment showed stable appearances, a result which 
is difficult to interpret particularly in light of not fully understanding why there is 
increased metabolic uptake in this disease. 
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Figure 9.4A and 9.4B: illustrate the coronal images of a PET/CT with increased 
metabolic activity in the thickened soft tissue surrounding both shoulders and hip joints 
at baseline (A) and 12 months post treatment respectively (B) 
Figure 9.4A Figure 9.4B 
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Safety and adverse side effects 
No serious adverse incidents occurred. All hereditary fibrinogen patients administered 
the CPHPC subcutaneously either twice or three times per day, governed by the 
underlying eGFR. Initially patients reported momentary local stinging at the injection 
site. The formulation was diluted slightly at 12 months post commencement of 
treatment resulting in less stinging. No patients withdrew from the study. During the 
winter months, a few patients reported crystallisation of the CPHPC which improved 
following warming the vial by placing it in a container containing warm water. All 3 DRA 
patients received CPHPC following each session of haemodialysis with no 
complications. 
Quality of life 
The SFv36 data was available in all patients recruited, with results subcategorised into 
AFib patients; good eGFR (eGFR>30mls/min) and low eGFR (eGFR<30mls/min), and 
DRA patients showing a declining trend of results from the former to latter groups, 
pictorially in figure 9.5. 
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Figure 9.5: Baseline QoL for AFib and DRA patients 
 
The QoL assessments were performed 6 monthly in DRA patients, with figure 9.6A 
and figure 9.6B showing 6 month and 12 month assessments from baseline. 
Interestingly, the QoL assessments showed an improvement in mental health, physical 
role activities and social function the latter by 12 months, despite no solid improvement 
in their joint symptoms. 
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Figure 9.6A and 9.6B: QoL at 6 and 12 months in DRA patients 
Figure 9.6A 
 
Figure 9.6B 
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The QoL at 6months, 12 months, and 24 months illustrate a slight overall decline in all 
parameters at 6 months, near baseline parameters by 12 months and general 
improvement at 24 months in physical function, physical role, bodily pain and general 
health, figure 9.7A, 9.7B and 9.7C. 
Figure 9.7A, 9.7B and 9.7C: QoL at 6, 12 and 24 months in AFib patients with a good 
eGFR 
Figure 9.7A 
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Figure 9.7B 
 
Figure 9.7C 
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Figure 9.8A, 9.8B and 9.8C illustrates the QoL at 6months, 12 months, 24 months 
illustrate a slight improvement in mental health, emotional role, and social function at 
6 months, with a slight decrease in all parameters by 12 months and general 
improvement in all parameters by 24 months. 
Figure 9.8A, 9.8B and 9.8C: QoL at 6, 12 and 24 months in AFib patients with a poor 
eGFR 
Figure 9.8A 
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Figure 9.8B 
 
Figure 9.8C 
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Discussion 
In systemic amyloidosis, amyloid deposits may occur in many tissues and hence result 
in impairment of the mechanical, structural and functional capacity of the tissue 
affected. Fibrinogen amyloidosis typically affects the renal function and beta-2-
microglobulin amyloidosis is recognised to affect the osteo-articular surfaces, bone 
and Carpal Tunnel Syndrome, with limited therapeutic options for both.160 Thus using 
this principle of reducing the serum amyloid P, and possible removal of the amyloid 
deposits, restoration of the organ function was the ultimate goal. Earlier studies have 
explored the use of CPHPC to deplete circulating CPHPC, and we wanted to analyse 
its use in these 2 groups of systemic amyloidosis.  
The predominant finding was that the regular administration of CPHPC resulted in 
sustained depletion of circulating serum amyloid P, and hence the most probable 
reason for a slower decline in the renal function in patients with fibrinogen related 
amyloidosis, in comparison to controls. This finding was variable with the various 
factors influencing the latter including the estimated glomerular filtration rate, degree 
of quantitative proteinuria and other incipient renal insults. The resulting improved 
renal survival was clearly apparent with the renal decline in controls described as 
13mls/min (6-21) per year, and previously described 25.8 (7.1-49.2) mls/min per 
year.160 In our study, the median renal decline of CPHPC treated patients was 
4.5mls/min per year (range 2.3-26.6), with 1 patient having an improvement of 
3.9mls/min per year. We also demonstrated a significantly improved renal survival in 
patients receiving CPHPC (p<0.0001) in comparison to CKD matched historical 
controls. 
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As in the earlier study by Gillmore et al, the current data supports the slowing of the 
natural decline in renal function seen in patients with fibrinogen amyloidosis, with early 
use of this drug likely to result in later need for dialysis. Studies with CPHPC and IgG 
antibody anti-SAP show promising results; with rapid clearance of the amyloid from 
the liver and other tissues.354 
During the study we recorded patients joint symptoms with a VAS score. Although 
these patients did not have confirmed osteoporosis or a diagnosis of joint disease, 
(with non-specific joint pain in a particular joint), they acknowledged that their pain 
score improved over the course of time, and can only describe this as a possible 
consequence secondary to CPHPC use with formal studies needed for its use in 
patients with a diagnosis of osteoporosis. There were minimal complications with an 
excellent safety profile.   
Given the profound joint symptoms that patients with beta-2-microglobulin amyloidosis 
have, a suitable hypothesis arises that CPHPC may deplete the circulating SAP and 
hence improvement in their joint symptoms. The latter finding was seen in patients on 
haemodialysis who then had a renal transplant, resulting in a marked reduction in their 
joint symptoms.355 In our study, all three patients did not report a noticeable difference 
in their joint symptoms; as evidence by no significant change in their VAS scores.  
Earlier studies have described multiple myeloma patients with arthropathy,356 with MRI 
imaging showing a homogenous low-to-intermediate signal intensity by both T1 and 
T2 weighted images. Peri-articular amyloid may demonstrate mild enhancement 
following gadolinium administration.357, 358 A case report of a patient with multiple 
myeloma and amyloid deposition within the peri-articular joints was also described359 
hence we thought to explore the utility of this investigation in this cohort of patients 
 CHAPTER NINE 
 
- 266 - 
and also in assessing their response following CPHPC treatment. 18F FDG PET-CT is 
a useful non-invasive imaging modality which demonstrates the amyloid arthropathy 
when other imaging such as x-rays do not delineate these changes. Our study also 
confirmed this finding and their potential use in diagnosing and assessing patients with 
dialysis related amyloidosis, or indeed in patients with systemic amyloidosis. 
The QoL serves as an important assessment in patients concerns and satisfaction 
with different facets affecting their lifestyle. In our study, we used this to assess 
whether this played an impact in their treatment. Given there were different groups, 
we subcategorised the groups into DRA, good and poor eGFR (the latter dependent 
upon the eGFR ≥30mls/min or <30mls/min respectively). The QoL showed a subtle 
improvement in different areas including mental health, physical role activities and 
social function but documented no overall improvement in their joint symptoms. All 
patients with AFib noticed an improving trend by 24 months, with a slight decline in 
parameters prior to this. Interestingly the decline in their parameters was earlier in the 
good eGFR group at 6 months compared to the poor eGFR group at 12 months. This 
may be partly due to the concern for the overall outcome of this treatment and the 
effectiveness over time.  
In summary, our pilot study shows the slower renal decline and hence effects of 
amyloid accumulation following commencement of CPHPC administration and clinical 
efficacy in patients with hereditary fibrinogen amyloidosis. Our study showed a 
significant improvement in the natural progression of renal decline with improved renal 
survival in the latter group with an excellent safety profile. There was some anecdotal 
improvement in joint symptoms, which will need further exploration in prospective 
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controlled studies for osteoporosis. The efficacy of this drug remains undetermined in 
patients with beta-2-microglobulin amyloidosis, with minimal clinical benefit seen. 
 
.
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Chapter Ten: General conclusions 
 
The studies undertaken in this thesis illustrate important unique findings in the 
diagnostic investigations, prognosis and management of systemic amyloidosis, and 
inform a greater understanding of localised amyloidosis and subtypes. 
Serum free light chain measurements have a crucial role in diagnosing and monitoring 
patients with systemic AL amyloidosis, now forming a standard part of the baseline 
and serial follow up clinical assessments.161, 162  Inclusion of free light chain 
concentration has lately been incorporated into the revised Mayo staging system and 
the international consensus criteria for assessment of disease response to treatment 
assessment.80,86,87 Our study is the largest study to date exploring the two 
commercially available free light chain assays and comparing the results in the clinical 
setting. The serum FreeliteTM assay measures immunoglobulin free light chains using 
polyclonal sheep antibodies directed against hidden epitopes on the light chain 
molecule producing an estimate of serum free kappa and lambda light chains. The N 
Latex assay uses a mixture to two kappa and two lambda monoclonal antibodies to 
the hidden epitopes of constant region of the immunoglobulin light chain molecules. 
We showed that there is an excellent correlation between the different assays for 
detecting the abnormal light chain subtype, but with the discordance in the absolute 
values of the FLC; crucially, this renders cross assay interpolation impossible. This is 
critically important as the newer N Latex assay becomes more widely adopted, with 
considerable potential for causing misinterpretation of patients’ responses to 
chemotherapy.  
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Coagulation abnormalities are often present in newly diagnosed systemic AL patients. 
There is a well described associated bleeding diathesis,164 which may range from 
small cutaneous bruising, pathgnomic “racoon eyes” or life threatening bleeds, with 
little known as to the underlying coagulation factor abnormalities aside from factor X 
deficiency and dysfibrinogenaemia. We described the novel finding of elevated factor 
VIII and vWF antigen levels in these patients, with normal ADAMTS13 results; thus 
excluding autoantibodies. This finding was not evident in normal controls. An albumin 
threshold less than 25g/L corresponded with a statistically significant rise in vWF:Ag, 
FVIII, FV and fibrinogen, with a fall in protein S and anti-thrombin III; the latter factors 
previously shown in prothrombotic states. Thus this finding emphasises the increasing 
importance of consideration of thromboprophylaxis or full anticoagulation in these 
patients. We also explored light chain toxicity using vWF Ag as a surrogate marker, 
with a FVIII and vWF Ag >280IU/L negatively impacting survival. Our study 
hypothesises that underlying vascular endothelial damage occurs in systemic AL, and 
possibly contributes to the light chain toxicity environment. The correlative fall in the 
vWF levels post chemotherapy may reflect the underlying vascular endothelial 
changes which occur.  Further studies to better understand the pathophysiology of 
these findings are needed to explore the endothelium by electron microscopy, and 
hence the utility of the prognostic findings as part of patient risk stratification. 
Fatigue is most universal in systemic amyloidosis and sleep disordered breathing 
patterns were shown to be frequent and a potential contributor to fatigue symptoms. 
Recurrent nocturnal oxygen desaturations are very common in patients with cardiac 
amyloidosis (both AL and ATTR type), and also in patients with soft tissue amyloid 
deposits affecting the oropharyngeal tract.  Sleep disordered breathing questionnaires 
such as STOPBANG and ESS questionnaires report a high proportion of patients 
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scoring ‘high risk’ for sleep disordered breathing.  Increased number and frequency of 
nocturnal desaturations may be associated with poorer survival in patients with cardiac 
AL amyloidosis.  Lack of heart rate variability (suggesting cardiac autonomic 
neuropathy) is a frequent occurrence in cardiac AL and also noted in those patients 
who died – findings which need further clarification. The role of hypoxia in precipitation 
of cardiac arrhythmias or sudden death in AL needs to be clarified.  Nocturnal hypoxia 
is a simple target for intervention in cardiac AL amyloidosis and could potentially help 
to reduce early mortality in AL which has remained an unmet medical need for over 
25 years.   
Localised amyloidosis is a very rare type of amyloidosis, with commonly reported sites 
including the urinary tract, respiratory tract, larynx, skin and eyelids.165 This has been 
poorly studied and our study describes the largest cohort of patients with localised AL 
amyloidosis with clinical features and natural disease course showing stark differences 
from systemic AL amyloidosis. Patients with obstructive/pressure symptoms or 
bleeding needed endoscopic or surgical resection.  Our results show that half of all 
patients needed one such procedure and a fifth of all patients required repeated 
procedures for symptom control highlighting the need for long term monitoring.  Four 
patients in the current study needed chemotherapy for localised amyloidosis.  
Radiotherapy (targeting the presumed clonal proliferation) appears to be a useful, and 
possibly underutilised, treatment modality in localised amyloidosis with all patients in 
the current series treated with radiotherapy showing lack of progression and over half 
achieving good symptomatic improvement following radiotherapy. Surprisingly, all 18 
patients who had a FDG-PET/CT study performed in the current series showed 
presence of FDG avidity at the site of amyloid deposition, in keeping with previous 
reports of high proportion of FDG-PET/CT positivity in localised amyloidosis.307 
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Progression to systemic AL amyloidosis is extremely rare except in  patients with 
lymph node involvement.  Patients with lymph node involvement and those with a 
isotypic specific circulating free light chains warrant closer follow up for development 
of systemic AL. The majority with localised AL have excellent long term outcomes. 
Most die with the disease rather than as a consequence of it.  
Laryngo-tracheobronchial amyloidosis is a rare type of localised amyloidosis, 
characterised by insoluble fibrillar proteins deposited within the upper and lower airway 
tract.311, 312 and we describe the largest series to date. In our study, we describe the 
laryngeal and tracheobronchial amyloid deposition was characterised further with 
laser capture and proteomic analysis. All 60 cases exhibited evidence of 3 amyloid 
protein signature proteins serum amyloid P (SAP), Apo E and Apo AIV in conjunction 
with Apo A1 and insulin-like growth factor binding protein complex. Proteomic analysis 
was also performed in a total of 60 patients with systemic AL amyloidosis (renal, 
cardiac and liver biopsies) or transthyretin based disease (cardiac, bone marrow) as 
a control, with none of these samples showing evidence insulin-like growth factor 
binding protein complex and a much lower peptide content of Apo A1. Excisional 
therapeutic options are the primary modality in managing these patients.321-323 
Radiotherapy has been described in some cases with LBTA309, 311, 318, 324 with the basis 
that plasma cells are radiosensitive, with the majority of patients being treated with 20 
Gy in 10 fractions.309 Similarly, in our series one patient with laryngeal involvement 
and three patients with tracheobronchial amyloidosis received radiotherapy, following 
failure with prior surgical resections and stent insertions to achieve local control. With 
a median follow up of 18.7 (6-47) months, these patients have had notable 
improvements in their quality of life, consistent with previously published literature. 
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Lenalidomide based treatment following prior novel agent based therapy has been 
little studied, which we endeavoured to do so in 84 systemic AL amyloidosis patients 
with relapsed/refractory clonal disease following prior treatment with thalidomide 
(76%) and/or Bortezomib (68%). On an intention to treat (ITT) basis, overall 
haematologic response rate was 61%, including 20% complete responses.  The 
median overall survival (OS) has not been reached; 2 year OS and progression free 
survival (PFS) was 84% and 73% respectively.  Achieving a free light chain (FLC) 
response was an independent good prognostic factor for OS in multivariate analysis. 
16% achieved an organ response at 6-months, with a marked improvement in organ 
responses in patients on long term therapy (median duration 11 months), 55% 
achieving renal responses by 18 months. Lower commencing doses compared to that 
routinely used in treatment of patients with myeloma should be considered to allow 
better tolerance. Lenalidomide/dexamethasone therapy achieves good 
haematological responses in patients with AL amyloidosis with relapsed/refractory 
clonal disease. The rate of renal responses among patients who received prolonged 
treatment was unexpectedly high, raising the possibility that immunomodulatory 
effects of lenalidomide therapy might enhance the otherwise slow natural regression 
of amyloid deposits. 
((R)-1-[6-[(R)-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2 carboxylic acid 
(CPHPC)) has emerged as a potential therapeutic target to deplete SAP as a 
treatment for systemic amyloidosis.1 We explored this treatment in patients with 
hereditary fibrinogen amyloidosis (AFib) and in patients with dialysis related 
amyloidosis. Our study showed a significant improvement in the natural progression 
of renal decline with improved renal survival in the latter group with an excellent safety 
profile. The resulting improved renal survival was clearly apparent with the renal 
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decline in controls described as 13mls/min (6-21) per year, and previously described 
25.8 (7.1-49.2) mls/min per year.160 In our study, the median renal decline of CPHPC 
treated patients was 4.5mls/min per year (range 2.3-26.6), with 1 patient having an 
improvement of 3.9mls/min per year. We also demonstrated a significantly improved 
renal survival in patients receiving CPHPC (p<0.0001) in comparison to CKD matched 
historical controls. There was some anecdotal improvement in joint symptoms, which 
will need further exploration in prospective controlled studies for osteoporosis. The 
QoL questionnaires were a useful adjunct in assessing patient’s treatment, showing a 
general improvement in several parameters from baseline. The efficacy of this drug 
remains undetermined in patients with beta-2-microglobulin amyloidosis, with minimal 
clinical benefit seen.  
Thus this thesis highlights the important techniques of FLC assays, coagulation 
assays, sleep disordered breathing important in the setting of diagnostic, monitoring 
and prognostic tests in systemic AL. Our knowledge of localised disease and a 
subtype – laryngeal and tracheobronchial amyloidosis are enriched following this 
study, showing this disease a separate entity to systemic AL, with the potential 
repeating peptide sequence in these patients a possible insight to this disease. 
Management is dependent on the type of systemic amyloidosis, with chemotherapy 
for systemic AL and treatments targeted against depletion of SAP for hereditary 
fibrinogen amyloidosis. 
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Future studies planned 
 
Results from chapter 4 describe endothelial dysfunction that occurs in systemic AL. 
Von Willebrand factor has been used in other diseases as a surrogate marker of 
endothelial dysfunction and preliminary results show likely light chain toxicity 
implications. There are ongoing plans to initiate a new study examining this 
relationship further by electron microscopy. 
The results from chapter 5 describe sleep disordered breathing and oxygen 
desaturations in systemic amyloidosis. This is a large study outlining the latter issues 
in patients with systemic amyloidosis, with the hypothesis that these oxygen 
desaturations may increase morbidity and mortality in this group. Initial plans are 
underway to study this prospectively including the use of supplemental oxygen in 
newly diagnosed systemic AL amyloidosis patients with Mayo stage 3 cardiac 
biomarkers.  
Chapter 6 outlines the largest detailed characteristics and natural history and survival 
features in localised amyloidosis. There are initial plans to form a collaborative group 
for this disease, enabling the patient details, treatment and outcome measures to be 
recorded prospectively. 
The results of chapter 7 describe a large series of patients diagnosed with laryngeal 
and tracheo-bronchial amyloidosis, elaborating on the clinical and proteomic analysis 
of these patients. The interesting finding of increased quantification of Apo A1 and 
presence of IGBF in these patients and not found in those diagnosed with systemic 
AL or transthyretin based disease, has initiated plans to study this further in another 
proteomic based study. 
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Chapter 8 outlines the use of lenalidomide based treatment in systemic AL. This was 
a large series of 84 patients, but retrospective in nature, and we are planning on 
confirming these results in a larger patient series treated with long term lenalidomide. 
We aim to also use a matched series of patients treated with other chemotherapy 
regimens.  There was an encouragingly but surprisingly high rate of organ responses 
recorded in this study for those patients receiving long term lenalidomide. This is 
intriguing and needs further study in a larger patient cohort, with plans for 
consideration of evaluating this concept in experimental models to evaluate the 
potential of lenalidomide in directly modulating the clearance of amyloid deposits. 
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Appendix 1 
 
Royal Free Hospital Bleeding Questionnaire v4 (Adapted) 
Name of Patient:     Date of Clinic: 
Hospital Number:     Name of Assessor: 
Date of Birth:      Bleeding Score: 
Grades of bleeding severity used to compute the bleeding score 
Symptom - 1 0 1 2 3 4 
Epistaxis - No or trivial 
(<5 episodes 
/ year ) 
>5 episodes or 
>10 min duration 
Consultation 
only 
Packing  or 
cauterisation 
or  TXA   
Blood products / 
DDAVP /  
concentrate  
Cutaneous - No or 
trivial  (<1 cm
) 
>1cm and no 
trauma 
Consultation 
only 
  
Bleeding from 
minor wounds 
- No or trivial 
(<5 episodes / 
year ) 
>5 episodes or > 
5 min  
Consultation 
only 
Surgical 
haemostasis 
Blood products / 
DDAVP /  
concentrate 
Oral cavity - None Referred at least 
once 
Consultation 
only 
Surgical 
haemostasis 
or TXA  
Blood products / 
DDAVP /  
concentrate 
Tooth extraction No bleeding in 
at least 2 
extractions 
No 
extractions or  
no bleeding 
in 1 
extraction 
Reported, no 
consultation 
Consultation 
only 
Resuturing  
or packing 
Blood products / 
DDAVP /  
concentrate 
Surgery No bleeding in 
at least 2 
surgeries 
None 
performed or 
no bleeding 
in one 
Surgery 
Reported, no 
consultation 
Consultation 
only 
Surgical 
haemostasis 
or 
TXA 
Blood products / 
DDAVP /  
concentrate 
Menorrhagia - No Consultation 
only 
TXA or pill use Dilatation & 
Curettage, iron 
therapy 
Blood products / 
DDAVP /  
concentrate / 
hysterectomy 
Postpartum 
haemorrhage 
No bleeding in 
at least 2 
deliveries  
No deliveries 
or no 
bleeding in 
one delivery 
Consultation 
only 
Dilatation & 
Curettage, iron 
therapy, TXA 
Blood products 
/ DDAVP /  
concentrate 
Hysterectomy 
Muscle 
Haematomas 
- Never Post-trauma no 
therapy 
Spontaneous, 
no therapy 
Spontaneous 
or traumatic, 
treated with 
DDAVP /  
concentrate 
Surgical 
intervention or 
blood transfusion 
Haemarthrosis - Never Consultation 
only 
Spontaneous, 
no therapy 
Spontaneous 
or traumatic, 
treated with 
DDAVP /  
concentrate 
Surgical 
intervention or 
blood transfusion 
CNS Bleeding - Never - - Subdural, any 
intervention 
Intra cerebral, 
any intervention 
GI Bleeding - No Associated with 
GI pathology 
e.g. ulcer, 
varices, 
haemorrhoids, 
angiodysplasia 
Spontaneous Surgical 
haemostasis 
Blood products 
/ DDAVP /  
concentrate/ 
TXA 
 
 
Duration of bleeding symptoms __________________ Aspirin Yes/No (please circle) 
Site__________________________________________  Warfarin Yes/No (please circle 
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Appendix 2 
 
 
 
  
To help understand whether your oxygen saturations fall while you sleep. 
Before you go to sleep, please place pulse oximeter on. 
Instructions for overnight pulse oximeter 
 
 
 
1. Place Velcro strap band on your 
wrist. 
2. Place this on your finger. 
It should fit snugly. 
5. When you awake: 
- switch power button off. 
- remove Velcro wrist strap and pulse 
oximeter. 
- give back to nurses at National Amyloidosis 
Centre for Shameem 
 
3. Press power switch 
on. Press firmly and 
display screen should 
light up. 
4. Sleep with pulse 
oximeter on. 
Please fill in the STOPBANG and EPWORTH questionnaire. 
Thank you. 
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EPWORTH SLEEPINESS SCORE 
 
How to work out your score 
 
How likely are you to doze off or fall asleep during the following situations, in contrast to just 
feeling tired? 
 
For each of the situations listed below, give yourself a score of 0 to 3 where: 
0 = would never doze 
1 = slight chance 
2 = moderate chance 
3 = high chance 
 
Work out your total score by adding up your individual scores for situations 1 to 8 
 
(If you have not been in the following situations recently, think about how you would have 
been affected). 
 
 
Situation 
 
 
Score (0 – 3) 
 
Sitting and reading 
 
 
 
Watching television 
 
 
 
Sitting inactive in a public place e.g. theatre, meeting 
 
 
 
As a passenger in a car for an hour without a break 
 
 
 
Laying down for a rest in the afternoon 
 
 
 
Sitting and talking to someone 
 
 
 
Sitting quietly after lunch (when you have had no alcohol) 
 
 
 
In a car, whilst stopped in traffic  
 
 
 
Total 
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STOP BANG QUESTIONAIRRE 
Height  inches/cm  Weight lb/kg 
Age    Male/Female   BMI 
Collar size of shirt: S, M, L or XL     Neck Circumference * cm 
1. Snoring. 
 Do you snore loudly (louder than talking or loud enough to be heard through closed doors)? 
 Yes No 
2. Tired. 
 Do you often feel tired, fatigued or sleepy during daytime? 
 Yes No 
3. Observed. 
 Has anyone observed you stop breathing during your sleep? 
 Yes No 
4. Blood pressure. 
 Do you have or are you being treated for high blood pressure? 
 Yes No 
5. BMI. 
 BMI more than 35 kg/m
2
? 
 Yes No 
6. Age 
 Age greater than 50? 
 Yes No 
7. Neck circumference. 
 Neck circumference greater than 40cm? 
 Yes No 
8. Gender. 
 Gender male? 
 Yes No 
* Neck circumference measured by staff 
High risk of OSA: answering yes to 3 or more items. 
Low risk of OSA: answering yes to less than 3 items 
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Supplemental Table 1: PET/CT in localised amyloidosis 
Patient Age/Sex Organ 
Involved 
Positive FDG 
PET/CT 
positive 
FDG uptake SUV 
1 74/F LN Yes Cervical and 
retroperitoneal LN, L 
ischium 
3.5 
3.9 
2 62/M LN Yes R paratracheal, 
Subcarinal, 
R supraclavicular 
10 
5.1 
9.4 
3 62/M LN Yes L supraclavicular, 
R lung base, 
Para-aortic, aortocaval and 
mesenteric LN 
2.3 
2.7 
3-6 
4 53/M LN Yes L hilum, R para-aortic LN 2.5 
5 77/F LN Yes Cervical, axillary, para-
aortic and inguinal 
lymphadenopathy 
2.5 
6 81/F LN Yes Mediastinal lymph nodes, 
soft tissue in the 
pericardiac region of left 
upper lobe 
3.8-4.2 
7 66/F Pulmonary Yes L upper lobe nodule 4.1 
8 74/F Pulmonary Yes Multiple lung nodules, 
peribronchial and 
subpleural 
6.3 
9 66/M Pulmonary Yes R upper lobe soft tissue 
mass 
2.5 
10 59/F Pulmonary Yes Right pulmonary nodule 2 
11 74/F Pulmonary Yes Right apical lung nodule NA 
12 77/M Pulmonary Yes Right pleural lesion in R 
upper lobe 
2.6 
13 79/M Pulmonary Yes R lower lobe lesion NA 
14 57/M Subcutaneous 
nodules 
Yes Soft tissue along iliac 
vessels, bilateral pleural 
masses. Calcification in 
both breasts 
2.5 
15 51/F Bone Yes T9 vertebral lesion NA 
16 72/F Skin nodules Yes Subcutaneous nodules 
within the legs 
2.7 
17 80/F Abdominal 
mass 
Yes Mass extending from 
anterior rectum, enveloping 
bladder anteriorly, and 
posteriorly encasing the 
uterus and ovaries 
NA 
18 67/M tongue Yes Right paramedian tongue 
base lesion 
4.5 
PET/CT – positron emission tomography; FDG – flurodeoxyglucose; SUV – standardised 
uptake values; F – female; M – male; R – right; L – left; LN – lymph node; NA – not available. 
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Supplemental Table 2: Characteristics of patients with disappearance of clonal 
markers following intervention 
Gender Site of 
Localised 
Amyloid 
Intervention Pre-
treatment 
Abnormal 
FLC or 
Paraprotein 
Post-
treatment 
FLC or 
Paraprotein 
Time 
duration 
post-
treatment 
F L 
ptygeropalatine 
fossa (bone) 
Radiotherapy IgGl 4g/L 0 4 months 
M R ileum Radiotherapy IgGk 5g/L 0 
 
6 months 
F T10 bone  
lesion 
Radiotherapy IgGk 2g/L 0 Not 
available 
M R axilla LN Radiotherapy IgGk 2g/L 0 4 months 
M R inguinal LN Surgery IgGl 2g/L 0 2 months 
M R eyelid lesion Surgery IgMl 1g/L 0 2 months 
M Cutaneous leg 
deposit 
Surgery IgGk 3g/L 0 2 months 
M Right 
supraclavicular 
LN 
Surgery Kappa 
200mg/L 
Kappa  
30mg/L 
6 months 
FLC - free light chain; F - female; M - male; LN  -lymph node; R – right; L – left; T – thoracic; 
k – kappa; l – lambda; mg/L – milligrams per litre; g/L; grams per litre 
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Supplemental Table 3: Characteristics of patients with localised amyloidosis 
progressing to systemic disease 
Gender Site of 
Localised 
Amyloid 
Site of 
progression 
to Systemic 
AL 
Time to 
progression 
(months) 
Abnormal 
FLC 
(mg/L) 
Paraprotein 
(g/L) 
Urine 
BJP 
M LN Renal 84 Lambda 
500 mg/L 
IgAl by IF Lambda 
M LN Macroglossia 20 Kappa  
610 mg/L 
IgMk by IF none 
M LN Splenic 
uptake by 
123SAP 
scintigraphy 
60 none none none 
F LN Bone 77 Lambda 
300 mg/L 
IgAl 5 none 
M LN Macroglossia 
and renal 
51 Lambda 
341 mg/L 
IgMl 13 Lambda 
F Eyelid Macroglossia 48 Kappa  
330 mg/L 
IgGk 18 none 
F Bone LN 51 Kappa  
124 mg/L 
none none 
AL – Light chain; FLC – free light chain; BJP – Bence Jones Protein; mg/L – milligrams per 
litre; g/L – grams per litre; M – male; F – female; LN – lymph node; SAP – Serum Amyloid P; 
IF - immunofixation 
 
 
